{
  "questions": [
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33594368"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Disruption of nuclear architecture as a cause of COVID-19 induced anosmia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33594368"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 1155,
          "text": "Here, using molecular evaluation of human olfactory epithelium (OE) from subjects succumbing to COVID-19 and a hamster model of SARS-CoV-2 infection, we discovered widespread downregulation of olfactory receptors (ORs) as well as key components of their signaling pathway. OR downregulation likely represents a non-cell autonomous effect, since SARS-CoV-2 detection in OSNs is extremely rare both in human and hamster OEs. A likely explanation for the reduction of OR transcription is the striking reorganization of nuclear architecture observed in the OSN lineage, which disrupts multi-chromosomal compartments regulating OR expression in humans and hamsters. Our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of COVID-19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33594368"
        }
      ],
      "body": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?",
      "type": "yesno",
      "id": "620155b6c9dfcb9c09000024",
      "ideal_answer": [
        "Yes. Disruption of nuclear architecture is a cause of COVID-19 induced anosmia."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34521188",
        "http://www.ncbi.nlm.nih.gov/pubmed/34532490",
        "http://www.ncbi.nlm.nih.gov/pubmed/34603452",
        "http://www.ncbi.nlm.nih.gov/pubmed/34504425",
        "http://www.ncbi.nlm.nih.gov/pubmed/32943323",
        "http://www.ncbi.nlm.nih.gov/pubmed/32406293",
        "http://www.ncbi.nlm.nih.gov/pubmed/30892132",
        "http://www.ncbi.nlm.nih.gov/pubmed/32487680",
        "http://www.ncbi.nlm.nih.gov/pubmed/33492986",
        "http://www.ncbi.nlm.nih.gov/pubmed/32224416",
        "http://www.ncbi.nlm.nih.gov/pubmed/31236579",
        "http://www.ncbi.nlm.nih.gov/pubmed/30805896",
        "http://www.ncbi.nlm.nih.gov/pubmed/32445174",
        "http://www.ncbi.nlm.nih.gov/pubmed/32589350",
        "http://www.ncbi.nlm.nih.gov/pubmed/34894461",
        "http://www.ncbi.nlm.nih.gov/pubmed/34632814",
        "http://www.ncbi.nlm.nih.gov/pubmed/32874831",
        "http://www.ncbi.nlm.nih.gov/pubmed/31403867",
        "http://www.ncbi.nlm.nih.gov/pubmed/34678907"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 783,
          "text": "METHODS: Patients with advanced non-small cell lung cancer who were hospitalized in The Affiliated Cancer Hospital of Nanjing Medical University from October 2018 to August 2019 were selected to receive anti-PD-1 (pembrolizumab, sintilimab or toripalimab) monotherapy or combination regimens. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521188"
        },
        {
          "offsetInBeginSection": 778,
          "offsetInEndSection": 990,
          "text": "Here, we have presented a case of refractory ACC with lung metastases that was reduced after combinatorial treatment using the immune checkpoint inhibitor (ICI) toripalimab and anti-angiogenesis agent anlotinib. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34532490"
        },
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 742,
          "text": "Toripalimab is a type of anti-PD-1 monoclonal antibody produced by Junshi Biosciences in China. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603452"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 826,
          "text": "Case summary: Herein, we described for the first time a case report of SBSR induced by anti-PD-1 therapy in a cervical cancer patient. In addition, we revised existing literature on anti-PD-1 induced cutaneous reactions. We reported a cervical cancer patient who was treated with four successive cycles of Sintilimab and Toripalimab injections and developed systemic rashes, bullae, and epidermal desquamation, which worsened and led to infection, eventually causing death after being unresponsive to aggressive treatments. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943323"
        },
        {
          "offsetInBeginSection": 399,
          "offsetInEndSection": 570,
          "text": "Toripalimab (JS001) is IgG4 monoclonal antibody targeting PD-1, which has been approved for treatment of patients with metastatic melanoma after previous systemic therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32943323"
        },
        {
          "offsetInBeginSection": 991,
          "offsetInEndSection": 1157,
          "text": "mber of studies have confirmed that PD-1 inhibitors, including toripalimab, are not as effective in mucosal and acral melanomas as in non-acral cutaneous subtype. Tor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293"
        },
        {
          "offsetInBeginSection": 593,
          "offsetInEndSection": 853,
          "text": "Our analysis reveals that toripalimab mainly binds to the FG loop of PD-1 with an unconventionally long complementarity-determining region 3 loop of the heavy chain, which is distinct from the known binding epitopes of anti-PD-1 mAbs with structural evidences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 592,
          "text": "Here, we report the complex structure of PD-1 with toripalimab, a mAb that is approved by China National Medical Products Administration as a second-line treatment for melanoma and is under multiple Phase 1-Phase 3 clinical trials in both China and the US.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32487680"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 315,
          "text": "NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "PURPOSE: This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard trea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 395,
          "text": "apy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30805896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "In this trial of programmed cell death-1 (PD-1) blockade with toripalimab in previously treated Chinese patients with melanoma, unique histologic and molecular features may explain why the objective response rate is lower than those defined in Western populations. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32487680"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 475,
          "text": "uentially. Toripalimab, a humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1), was approved by National Medical Product Administration in China in 2018 as second-line therapy for metastatic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32445174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30805896"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 217,
          "text": "Toripalimab is an anti-PD-1 monoclonal antibody used for the treatment of some cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34632814"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 729,
          "text": " with ICIs. Toripalimab is a type of anti-PD-1 monoclonal antibody produced by Junshi Bioscienc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34603452"
        },
        {
          "offsetInBeginSection": 1031,
          "offsetInEndSection": 1187,
          "text": "These findings benefit our understanding of the binding mechanisms of toripalimab to PD-1 and shed light for future development of biologics targeting PD-1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30892132"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 306,
          "text": "a (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chem",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492986"
        },
        {
          "offsetInBeginSection": 1690,
          "offsetInEndSection": 1858,
          "text": " first dose of toripalimab.CONCLUSIONS: Toripalimab is a promising anti-PD-1 antibody, which was well tolerated and demonstrated anti-tumor activity in treatment-refrac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350"
        },
        {
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1410,
          "text": "by immunohistochemistry. The patient was treated with toripalimab (a PD-1 inhibitor) concurrently with radiotherapy for bone metastases.OUTCOMES: Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Toripalimab, a humanized IgG4 monoclonal antibody (mAb) against programmed death receptor-1, is being extensively studied to treat various malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34894461"
        },
        {
          "offsetInBeginSection": 1723,
          "offsetInEndSection": 1903,
          "text": "SIONS: Toripalimab is a promising anti-PD-1 antibody, which was well tolerated and demonstrated anti-tumor activity in treatment-refractory advanced solitary malignant tumors. Furt",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "JS001 (toripalimab) is a humanized IgG monoclonal antibody which strongly inhibits programmed cell death protein 1 (PD1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32874831"
        },
        {
          "offsetInBeginSection": 252,
          "offsetInEndSection": 706,
          "text": "sequentially. Toripalimab, a humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1), was approved by National Medical Product Administration in China in 2018 as second-line therapy for metastatic melanoma.AREAS COVERED: This is a comprehensive review of the literature and studies of toripalimab in melanoma, including clinical trials and translational research.EXPERT OPINION: Toripalimab is not inferior to pembrolizumab as a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32406293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 426,
          "text": "PURPOSE: This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard treatment.PATIENTS AND METHODS: During dose escalation, patients received a single-dose intravenous infusion of toripalimab for 56 days followed by multi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224416"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589350"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 610,
          "text": "unotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1.PATIENTS AND METHODS: We reported on the AGC cohort of phase Ib/II trial evaluating the safety and activity of toripalimab in patients with AGC, oesophageal squamous cell carcinoma, nasopharyngeal carcinoma and head",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31236579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31403867"
        }
      ],
      "body": "What is the mechanism of action of Toripalimab?",
      "type": "summary",
      "id": "61f7d6db882a024a10000037",
      "ideal_answer": [
        "Toripalimab is IgG4 monoclonal antibody targeting PD-1, which has been approved for treatment of patients with metastatic melanoma after previous systemic therapy."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32377534",
        "http://www.ncbi.nlm.nih.gov/pubmed/28789367",
        "http://www.ncbi.nlm.nih.gov/pubmed/24091795",
        "http://www.ncbi.nlm.nih.gov/pubmed/21042709"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 770,
          "offsetInEndSection": 872,
          "text": "Αlpha-Taxilin (α-Taxilin) has been found as one of the novel, significantly up regulated protein in RA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32377534"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 238,
          "text": "Expression of α-taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28789367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "α-Taxilin, a binding partner of the syntaxin family, is a candidate tumor marker. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24091795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Expression of α-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21042709"
        }
      ],
      "body": "Is taxilin a cancer marker?",
      "type": "yesno",
      "id": "622dd1433a8413c6530000a5",
      "ideal_answer": [
        "Yes,\nα-Taxilin, a binding partner of the syntaxin family, is a candidate tumor marker."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10528385",
        "http://www.ncbi.nlm.nih.gov/pubmed/15260094"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 383,
          "text": "Incidental durotomy can cause postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528385"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Despite the frequency of dural tears in spinal surgery, meningitis is a rare complication reported to occur with a frequency of 0.18%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15260094"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 413,
          "text": "ATA: Incidental durotomy can cause postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. These symptoms are believed to",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10528385"
        }
      ],
      "body": "What are the symptoms of an incidental durotomy (ID).",
      "type": "list",
      "_body": "What are the symptoms of an incidental durotomy (ID)",
      "_type": "list",
      "id": "6238a32a3a8413c6530000b9",
      "ideal_answer": [
        "Incidental durotomy can cause postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo. Meningitis is a rare complication reported to occur with a frequency of 0.18%",
        "Incidental durotomy can cause postural headaches, nausea, vomiting, dizziness, photophobia, tinnitus, and vertigo."
      ],
      "exact_answer": [
        [
          "postural headaches"
        ],
        [
          "vomiting"
        ],
        [
          "dizziness"
        ],
        [
          "photophobia"
        ],
        [
          "tinnitus"
        ],
        [
          "vertigo"
        ],
        [
          "menningitis"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34620745"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 391,
          "text": "In this work, we investigated the role and regulatory mechanism of lncRNA prostate cancer-associated transcript 6 (PCAT6) in breast cancer progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620745"
        }
      ],
      "body": "Is PCAT6 a microRNA?",
      "type": "yesno",
      "id": "622668313a8413c653000087",
      "ideal_answer": [
        "No, PCAT6 is a long noncoding RNA."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34450641"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "HDAC1 is required for GATA-1 transcription activity, global chromatin occupancy and hematopoiesis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34450641"
        },
        {
          "offsetInBeginSection": 764,
          "offsetInEndSection": 1339,
          "text": "GATA-12RA knock-in (KI) mice suffer mild anemia and thrombocytopenia with accumulation of immature erythrocytes and megakaryocytes in bone marrow and spleen. Single cell RNA-seq analysis of Lin- cKit+ (LK) cells further reveal a profound change in cell subpopulations and signature gene expression patterns in HSC, myeloid progenitors, and erythroid/megakaryocyte clusters in KI mice. Thus, GATA-1 deacetylation and its interaction with HDAC1 modulates GATA-1 chromatin binding and transcriptional activity that control erythroid/megakaryocyte commitment and differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34450641"
        }
      ],
      "body": "Is HDAC1 required for GATA-1 transcriptional activity?",
      "type": "yesno",
      "id": "6201a4edc9dfcb9c09000028",
      "ideal_answer": [
        "Yes. HDAC1 is required for GATA-1 transcription activity, global chromatin occupancy and hematopoiesis."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
        "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
        "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
        "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
        "http://www.ncbi.nlm.nih.gov/pubmed/21044742",
        "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
        "http://www.ncbi.nlm.nih.gov/pubmed/31013363"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 354,
          "text": "Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 380,
          "text": "Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052"
        },
        {
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1965,
          "text": "Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600 mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 949,
          "text": "A number of phase 3 clinical trials are currently ongoing including Elafibranor, a dual PPAR α/δ agonist, Cenicriviroc, a CCR2/CCR5 chemokine antagonist, the nuclear bile acid receptor FXR agonist obeticholic acid, Aramchol, a fatty acid bile acid conjugate that modulates SCD-1, and Resmetrion, a liver-specific THR-β agonist. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 379,
          "text": "Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 353,
          "text": "Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 1104,
          "offsetInEndSection": 1255,
          "text": "Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid β-oxidation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325"
        },
        {
          "offsetInBeginSection": 1568,
          "offsetInEndSection": 1764,
          "text": "nclusions: Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. W",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112"
        },
        {
          "offsetInBeginSection": 205,
          "offsetInEndSection": 395,
          "text": "atherogenesis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atheroge",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatoh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 1127,
          "offsetInEndSection": 1279,
          "text": "stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid β-oxidation. Aramchol increased the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 337,
          "text": "epatitis (NASH). Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1473,
          "text": "d increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, reduci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 1474,
          "offsetInEndSection": 1666,
          "text": "g COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic genes a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "text": " hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052"
        },
        {
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "text": "atitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis wh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 365,
          "text": "sis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31013363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of stea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112"
        },
        {
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1663,
          "text": "cing COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1470,
          "text": "ich catalyses cholesterol synthesis. In phHeps, Aramchol also reduced SCD1 and increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, red",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
        }
      ],
      "body": "Which enzyme is inhibited by Aramchol?",
      "type": "factoid",
      "id": "61f7d683882a024a10000036",
      "ideal_answer": [
        "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression."
      ],
      "exact_answer": [
        [
          "hepatic stearoyl-CoA desaturase 1"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32620751",
        "http://www.ncbi.nlm.nih.gov/pubmed/32630050",
        "http://www.ncbi.nlm.nih.gov/pubmed/32643123"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620751"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "Diamond-Blackfan anemia is an autosomal dominant syndrome, characterized by anemia and a predisposition for malignancies. Ribosomal proteins are responsible for this syndrome, and the incidence of colorectal cancer in patients with this syndrome is higher than the general population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32643123"
        }
      ],
      "body": "What is the cause of the Diamond Blackfan Anemia?",
      "type": "factoid",
      "id": "622d17b83a8413c6530000a2",
      "ideal_answer": [
        "Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency."
      ],
      "exact_answer": [
        [
          "Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency."
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33021960",
        "http://www.ncbi.nlm.nih.gov/pubmed/34166611",
        "http://www.ncbi.nlm.nih.gov/pubmed/34162892",
        "http://www.ncbi.nlm.nih.gov/pubmed/34148284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34285374",
        "http://www.ncbi.nlm.nih.gov/pubmed/22376111",
        "http://www.ncbi.nlm.nih.gov/pubmed/22388183",
        "http://www.ncbi.nlm.nih.gov/pubmed/19330720",
        "http://www.ncbi.nlm.nih.gov/pubmed/26350216",
        "http://www.ncbi.nlm.nih.gov/pubmed/25207541",
        "http://www.ncbi.nlm.nih.gov/pubmed/32545267",
        "http://www.ncbi.nlm.nih.gov/pubmed/23458775",
        "http://www.ncbi.nlm.nih.gov/pubmed/32056246",
        "http://www.ncbi.nlm.nih.gov/pubmed/33733306",
        "http://www.ncbi.nlm.nih.gov/pubmed/22488917",
        "http://www.ncbi.nlm.nih.gov/pubmed/23012368",
        "http://www.ncbi.nlm.nih.gov/pubmed/29517770",
        "http://www.ncbi.nlm.nih.gov/pubmed/21416921"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 364,
          "text": "G-quadruplexes (G4s) was demonstrated. G4s are alternative nucleic acid structures, which influence many cellular pathways on a transcriptional and post-transcriptional level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33021960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Guanine quadruplexes (G4s) are non-canonical nucleic acid structures commonly found in regulatory genomic regions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166611"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 293,
          "text": "DNA G-quadruplex (G4)-folded regions in cells were reported to be associated with either increased or decreased transcriptional activity. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34162892"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "G-Quadruplex, a unique secondary structure in nucleic acids found throughout human genome, elicited widespread interest in the field of therapeutic research. Being present in key regulatory regions of oncogenes, RNAs and telomere, G-Quadruplex structure regulates transcription, translation, splicing, etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34148284"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "G-quadruplexes (G4s) are higher-order structures formed by guanine-rich sequences of nucleic acids, such as the telomeric 5\u0027-TTAGGG-3\u0027/5\u0027-UUAGGG-3\u0027 repeats and those in gene regulatory regions. G4s regulate various biological events, including replication, transcription, and translation. Imbalanced G4 dynamics is associated with diseases, such as cancer and neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34285374"
        },
        {
          "offsetInBeginSection": 791,
          "offsetInEndSection": 894,
          "text": "Further, the plausible functions of RNA G-quadruplexes such as translational suppression, splicing etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22376111"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 397,
          "text": "G-quadruplexes have various biological functions, including inhibition of telomerase and the regulation of gene transcription and translation, and have become an active target for drug development, particularly for novel anticancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19330720"
        },
        {
          "offsetInBeginSection": 822,
          "offsetInEndSection": 1029,
          "text": "Here we briefly discuss various aspects of reporter assays followed by a review of available studies using reporter assays to understand the role and functions of DNA and RNA quadruplexes in gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22388183"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 864,
          "text": " review, we summarize recent evidence for the in vivo presence and function of DNA and RNA G-quadruplexes in various cellular pathways including DNA replication, gene expression and telomere maintenance. We also highl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26350216"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 334,
          "text": "im was to investigate their interaction with DNA and RNA G-quadruplexes, their uptake in malignant and nonmalignant cells, and their capacity to modulate gene expression and inhibit cell growth. Flow ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23458775"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 472,
          "text": "particular, G-quadruplexes occupy strategic locations in genomic DNA and both coding and noncoding RNA molecules, being involved in many essential cellular and organismal functions. In ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32545267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Growing evidence indicates that RNA G-quadruplexes have important roles in various processes such as transcription, translation, regulation of telomere length, and formation of telomeric heterochromatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517770"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 484,
          "text": "RNA G-quadruplexes at these specific locations play important roles in key cellular functions, including telomere homeostasis and gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488917"
        },
        {
          "offsetInBeginSection": 799,
          "offsetInEndSection": 949,
          "text": " the plausible functions of RNA G-quadruplexes such as translational suppression, splicing etc. are discussed in brief, suggesting scope for an extens",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22376111"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 341,
          "text": "Accumulating evidence indicates that G-quadruplexes serve important regulatory roles in fundamental biological processes such as DNA replication, transcription, and translation, while aberrant G-quadruplex formation is linked to genome instability and cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33733306"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 643,
          "text": "Indeed, RNA G-quadruplexes appear as important regulators of pre-mRNA processing (splicing and polyadenylation), RNA turnover, mRNA targeting and translation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22488917"
        },
        {
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1084,
          "text": "We show that G-quadruplexes formed by both (G(4)C(2))(4) RNA and DNA not only complex tightly with heme but also enhance its intrinsic peroxidase and oxidase propensities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207541"
        },
        {
          "offsetInBeginSection": 802,
          "offsetInEndSection": 965,
          "text": "The formation of the DNA-RNA G-quadruplex causes a significant increase in the clonogenic capacity of cells and has an effect on inhibition of cellular senescence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23012368"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 473,
          "text": "Meanwhile, the different conformations of G-quadruplexes have certain influences on their biological functions, such as the inhibition of transcription, translation, and DNA replication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32056246"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 471,
          "text": "G-quadruplex has been implicated by a lot of studies as an important structure in many biological processes including gene stability, telomere synthesis, transcriptional or translational regulation of gene expression and recombination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416921"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "RNA and DNA G-quadruplexes bind to human dicer and inhibit its activity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33733306"
        }
      ],
      "body": "What are the functions of DNA and RNA G-quadruplexes?",
      "type": "list",
      "id": "6220ce4c3a8413c653000068",
      "ideal_answer": [
        "G-Quadruplex, a unique secondary structure in nucleic acids found throughout human genome, elicited widespread interest in the field of therapeutic research. Being present in key regulatory regions of oncogenes, RNAs and telomere, G-Quadruplex structure regulates transcription, translation, splicing, etc"
      ],
      "exact_answer": [
        [
          "transcription"
        ],
        [
          "translation"
        ],
        [
          "splicing"
        ],
        [
          "RNA regulation"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30738695"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Epiregulin (EREG) is a novel family member of EGF-like ligands and have elevated expression in a variety of human cancers. EREG expression promotes tumor progression and metastasis and reduces patient survival. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738695"
        },
        {
          "offsetInBeginSection": 625,
          "offsetInEndSection": 1003,
          "text": "We found that EREG expression was significantly higher in GC tissues than in matched adjacent noncancerous tissues. High EREG protein expression in GC was significantly associated with TNM stage including tumor size, lymph node metastases and distant metastases as well as poor overall survival. These finding demonstrate that EREG is an independent prognostic biomarker for GC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738695"
        }
      ],
      "body": "What is the effect of epiregulin expression in tumors?",
      "type": "summary",
      "id": "6237aa3c3a8413c6530000b5",
      "ideal_answer": [
        "Epiregulin has elevated expression in a variety of human cancers. Epiregulin expression promotes tumor progression and metastasis and reduces patient survival."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34512734",
        "http://www.ncbi.nlm.nih.gov/pubmed/34864884"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "SCDRHA: A scRNA-Seq Data Dimensionality Reduction Algorithm Based on Hierarchical Autoencoder.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512734"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 922,
          "text": "To address this issue, in this paper, we propose a scRNA-seq data dimensionality reduction algorithm based on a hierarchical autoencoder, termed SCDRHA. The proposed SCDRHA consists of two core modules, where the first module is a deep count autoencoder (DCA) that is used to denoise data, and the second module is a graph autoencoder that projects the data into a low-dimensional space. Experimental results demonstrate that SCDRHA has better performance than existing state-of-the-art algorithms on dimension reduction and noise reduction in five real scRNA-seq datasets. Besides, SCDRHA can also dramatically improve the performance of data visualization and cell clustering.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "CellVGAE: an unsupervised scRNA-seq analysis workflow with graph attention networks.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864884"
        },
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 934,
          "text": "With the help of several case studies, we show that our model, named CellVGAE, can be effectively used for exploratory analysis even on challenging datasets, by extracting meaningful features from the data and providing the means to visualise and interpret different aspects of the model.RESULTS: We show that CellVGAE is more interpretable than existing scRNA-seq variational architectures by analysing the graph attention coefficients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864884"
        }
      ],
      "body": "Name scRNA-seq workflows which harness graph attention networks",
      "type": "list",
      "id": "621e5cf53a8413c65300004e",
      "ideal_answer": [
        "SCDRHA and CellVGAE"
      ],
      "exact_answer": [
        [
          "CellVGAE"
        ],
        [
          "SCDRHA"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33689480",
        "http://www.ncbi.nlm.nih.gov/pubmed/33777941",
        "http://www.ncbi.nlm.nih.gov/pubmed/34042314",
        "http://www.ncbi.nlm.nih.gov/pubmed/33806595",
        "http://www.ncbi.nlm.nih.gov/pubmed/34750553",
        "http://www.ncbi.nlm.nih.gov/pubmed/31494233",
        "http://www.ncbi.nlm.nih.gov/pubmed/31371481",
        "http://www.ncbi.nlm.nih.gov/pubmed/32270926",
        "http://www.ncbi.nlm.nih.gov/pubmed/32832028",
        "http://www.ncbi.nlm.nih.gov/pubmed/31446134",
        "http://www.ncbi.nlm.nih.gov/pubmed/31907670"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 898,
          "text": "These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33689480"
        },
        {
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1103,
          "text": "However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton\u0027s tyrosine kinase (BTK).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 1013,
          "text": "In contrast, no bleeding has been reported in clinical trials of other BTKi. These include the brain-penetrant irreversible tolebrutinib and evobrutinib (against multiple sclerosis), the irreversible branebrutinib, the reversible BMS-986142 and fenebrutinib (targeting rheumatoid arthritis and lupus erythematodes), and the reversible covalent rilzabrutinib (against pemphigus and immune thrombocytopenia).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "Bruton\u0027s tyrosine kinase (BTK) is crucial for FcεRI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34750553"
        },
        {
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1311,
          "text": "New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton\u0027s tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Absence of Pharmacokinetic Interactions between the Bruton\u0027s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 560,
          "text": "In efforts to develop additional series of reversible Btk inhibitors for chronic immune diseases, we sought to differentiate from our clinical stage inhibitor fenebrutinib using cyclopropyl amide isosteres of the 2-aminopyridyl group to occupy the flat, lipophilic H2 pocket.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32832028"
        },
        {
          "offsetInBeginSection": 979,
          "offsetInEndSection": 1338,
          "text": "erapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264). We review the mechanisms of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233"
        },
        {
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1430,
          "text": "promising drugs that are currently under development for CU are a chemoattractant receptor-homologous molecule expressed on TH2 cell antagonist, a monoclonal antibody to Siglec-8 (AK002), Bruton tyrosine kinase inhibitors (fenebrutinib and Lou064), a spleen tyrosine kinase inhibitor, and dupilumab. Promising targets of future",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31446134"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 897,
          "text": "These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33689480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton\u0027s tyrosine kinase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton\u0027s tyrosine kinase (BTK), in patients with active rheumatoid arthrit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "PURPOSE: Fenebrutinib (GDC-0853), a Bruton\u0027s tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31907670"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton\u0027s tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX). T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31371481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton\u0027s tyrosine ki",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "PURPOSE: Fenebrutinib (GDC-0853), a Bruton\u0027s tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31907670"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton\u0027s tyrosine kinase (BTK), in patients with active rheumatoid arth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926"
        },
        {
          "offsetInBeginSection": 1370,
          "offsetInEndSection": 1610,
          "text": "utinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 level",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 375,
          "text": "OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton\u0027s tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).METHODS: Patients with RA and inadequate response to methotrexate (cohort 1, n\u003d480) were randomized to fenebrutinib (50 mg once daily, 150 mg once daily, 200 mg twice daily), 40 mg adalimumab every oth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32270926"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 289,
          "text": "Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34750553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u0027s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        },
        {
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1258,
          "text": "essants; however, additional treatments are needed. New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and top",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31494233"
        },
        {
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1758,
          "text": "brutinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 levels, all relative to placebo.CONCLUSION: While fenebrutinib had an acceptable safety profile, the primary end point, SRI-4 response, was not met despi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042314"
        }
      ],
      "body": "Which molecule is targeted by Fenebrutinib?",
      "type": "factoid",
      "id": "61f7d5a0882a024a10000035",
      "ideal_answer": [
        "Fenebrutinib is a noncovalent, oral, and highly selective inhibitor of Bruton\u0027s tyrosine kinase (BTK)."
      ],
      "exact_answer": [
        [
          "Bruton\u0027s tyrosine kinase"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34553266",
        "http://www.ncbi.nlm.nih.gov/pubmed/34489457",
        "http://www.ncbi.nlm.nih.gov/pubmed/34572892",
        "http://www.ncbi.nlm.nih.gov/pubmed/34588172"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Cereblon (CRBN) is a substrate recognition protein in the E3-ligase ubiquitin complex. The binding target of CRBN varies according to tissues and cells, and the protein regulates various biological functions by regulating tissue-specific targets. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34489457"
        },
        {
          "offsetInBeginSection": 591,
          "offsetInEndSection": 662,
          "text": "the cereblon (CRBN) protein was discovered as a direct target of IMiDs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572892"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572892"
        },
        {
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1062,
          "text": "cereblon, a substrate receptor of the cullin-4 RING E3 ligase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34588172"
        }
      ],
      "body": "What is Cereblon?",
      "type": "summary",
      "id": "622d04da3a8413c65300009f",
      "ideal_answer": [
        "Cereblon (CRBN) is a substrate recognition protein in the E3-ligase ubiquitin complex. The binding target of CRBN varies according to tissues and cells, and the protein regulates various biological functions by regulating tissue-specific targets."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17503572",
        "http://www.ncbi.nlm.nih.gov/pubmed/30624377",
        "http://www.ncbi.nlm.nih.gov/pubmed/29320211",
        "http://www.ncbi.nlm.nih.gov/pubmed/8861162",
        "http://www.ncbi.nlm.nih.gov/pubmed/11320737",
        "http://www.ncbi.nlm.nih.gov/pubmed/16060187",
        "http://www.ncbi.nlm.nih.gov/pubmed/20691038",
        "http://www.ncbi.nlm.nih.gov/pubmed/17092503",
        "http://www.ncbi.nlm.nih.gov/pubmed/3339667",
        "http://www.ncbi.nlm.nih.gov/pubmed/30663437",
        "http://www.ncbi.nlm.nih.gov/pubmed/34469860",
        "http://www.ncbi.nlm.nih.gov/pubmed/29137197",
        "http://www.ncbi.nlm.nih.gov/pubmed/20356359",
        "http://www.ncbi.nlm.nih.gov/pubmed/29930816",
        "http://www.ncbi.nlm.nih.gov/pubmed/20376615",
        "http://www.ncbi.nlm.nih.gov/pubmed/30841797",
        "http://www.ncbi.nlm.nih.gov/pubmed/10452467",
        "http://www.ncbi.nlm.nih.gov/pubmed/3925257",
        "http://www.ncbi.nlm.nih.gov/pubmed/7282320",
        "http://www.ncbi.nlm.nih.gov/pubmed/27586096"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 610,
          "text": "The authors report on their experience with the management of multiple trauma, through the study of 617 clinical cases. Patients were evaluated with the Revised Trauma Score (RTS), Injury Severity Score (ISS) and Abbreviated Injury Scale (AIS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16060187"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 318,
          "text": "Various trauma scoring systems were developed in order to assess injury severity and aid in decision making regarding further therapy and probable outcome.ANATOMIC INJURY SEVERITY SCALES: AIS--Abbreviated Injury Scale is a summary of all the values (from 1-9) for each organ or body part that is injured.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11320737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "One of the more often used measures of multiple injuries is the injury severity score (ISS). Determination of the ISS is based on the abbreviated injury scale (AIS). T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8861162"
        },
        {
          "offsetInBeginSection": 762,
          "offsetInEndSection": 1019,
          "text": "Mortality and morbidity of patients with chest injury depend on the actual combination of multiple body systems injury. The severity of total injury can be predicted using objective scoring systems (Abbreviated Injury Scale\u003dAIS; Injury Severity Score\u003dISS). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320211"
        },
        {
          "offsetInBeginSection": 495,
          "offsetInEndSection": 631,
          "text": "The injury and trauma severity was measured using the Abbreviated Injury Scale (AIS) and the Injury Severity Score (ISS), respectively. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30624377"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 280,
          "text": "There is no specific injury among fatally injured frontal car-occupants in frontal car collisions, used in forensic expertise. We tried to point out the usefulness of the Abbreviated Injury Scale (AIS) and Injury Severity Score (ISS) for the expertise in such cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17503572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "BACKGROUND: The purpose of Abbreviated Injury Scale (AIS) is to code various types of Traumatic Brain Injuries (TBI) based on their anatomical location and severity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691038"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Using Abbreviated Injury Scale (AIS) codes to classify Computed Tomography (CT) features in the Marshall System.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691038"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 523,
          "text": "The abbreviated injury scale (AIS) is the only dictionary specifically designed as a system to define the severity of injuries throughout the body.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17092503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Refinements in injury scaling of blunt trauma and expansion to include penetrating injuries have resulted in the publication of the 1985 revision of the Abbreviated Injury Scale (AIS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3339667"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 431,
          "text": "The Abbreviated Injury Scale (AIS) is a commonly used anatomical-based coding system created to classify and describe injury severity after initial presentation, once test results are able to better define the anatomical characteristics of the injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30663437"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "BACKGROUND: The Abbreviated Injury Scale (AIS) score is used widely to quantify injury severity by body region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34469860"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Background: The most widely used methods of describing traumatic brain injury (TBI) are the Glasgow Coma Scale (GCS) and the Abbreviated Injury Sca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137197"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "BACKGROUND: Injury severity measures are based either on the Abbreviated Injury Scale (AIS) or the International Classification of dise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356359"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "BACKGROUND: The purpose of Abbreviated Injury Scale (AIS) is to code various types of Traumatic Brain Injuries (TBI) based on their anatomical location and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691038"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 674,
          "text": "uries. Many facilities treating trauma patients perform duplicate coding for trauma diagnoses using two different classification systems, the ICD for administrative purposes and the Abbreviated Injury Scale (AIS) for trauma registry, because unambiguous conversion of codes between the ICD and AIS is not always possible due to structural differen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29930816"
        },
        {
          "offsetInBeginSection": 548,
          "offsetInEndSection": 642,
          "text": "8 in. on any site. The Abbreviated Injury Scale (AIS) was used to determine injury patterns fo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30841797"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "BACKGROUND: The Abbreviated Injury Scale (AIS) score is used widely to quantify injury severity by ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34469860"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "BACKGROUND: The purpose of Abbreviated Injury Scale (AIS) is to code various types of Traumatic Brain Injuries (TBI) based on their anatomical location a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20691038"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 166,
          "text": "sage and proven value of the Abbreviated Injury Scale (AIS) in rating severity of trauma, it is essential that certain reliability issues concerning i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3925257"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 421,
          "text": "universal scoring system in the field of trauma applicable in clinic and research. In engineering it is used as a classification system for vehicle safety. The AIS can therefore be considered as an international, interdisciplinary and universal code of injury severity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20376615"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 473,
          "text": "The Abbreviated Injury Scale (AIS) was used to ascertain injury severity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8859913"
        },
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 648,
          "text": "The Abbreviated Injury Scale is a system developed in the United States for ranking the severity of specific trauma lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7282320"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "BACKGROUND: The Abbreviated Injury Scale (AIS), developed by the Association for the Advancement of Automotive Medicine is the most widely used anatomic injury severity scale in the world (Association for the Advancement of Automoti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10452467"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "BACKGROUND: The Abbreviated Injury Scale (AIS) is an anatomical-based coding system created by the Association for the Advancement of Automotive Medicine, utilized to classify and code injuries resulting from trauma, in order ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27586096"
        }
      ],
      "body": "What is Abbreviated Injury Scale (AIS) used to determine?",
      "type": "summary",
      "id": "623648513a8413c6530000ae",
      "ideal_answer": [
        "The Abbreviated Injury Scale (AIS) is an objective anatomically-based injury severity scoring system that classifies each injury by body region on a 6 point scale. AIS is the system used to determine the Injury Severity Score (ISS) of the multiply injured trauma patient.\n\nAIS CLASSIFICATIONS\nThe AIS classifies individual injuries by body region as follows:\nAIS 1 – Minor\nAIS 2 – Moderate\nAIS 3 – Serious\nAIS 4 – Severe\nAIS 5 – Critical\nAIS 6 – Maximal (currently untreatable)"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32700456"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 225,
          "text": "EREG (epiregulin), a member of the epidermal growth factor (EGF) family, plays a role in inflammation, wound healing, normal physiology and malignancies. However, little is known about its function on hair growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32700456"
        }
      ],
      "body": "Which protein family is epiregulin a member of?",
      "type": "factoid",
      "id": "6237a8343a8413c6530000b2",
      "ideal_answer": [
        "EREG (epiregulin), a member of the epidermal growth factor (EGF) family."
      ],
      "exact_answer": [
        [
          "epidermal growth factor family"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34078885"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1255,
          "text": "Using the Cap Analysis of Gene Expression (CAGE) technology, the FANTOM5 consortium provided one of the most comprehensive maps of transcription start sites (TSSs) in several species. Strikingly, ~72% of them could not be assigned to a specific gene and initiate at unconventional regions, outside promoters or enhancers. Here, we probe these unassigned TSSs and show that, in all species studied, a significant fraction of CAGE peaks initiate at microsatellites, also called short tandem repeats (STRs). To confirm this transcription, we develop Cap Trap RNA-seq, a technology which combines cap trapping and long read MinION sequencing. We train sequence-based deep learning models able to predict CAGE signal at STRs with high accuracy. These models unveil the importance of STR surrounding sequences not only to distinguish STR classes, but also to predict the level of transcription initiation. Importantly, genetic variants linked to human diseases are preferentially found at STRs with high transcription initiation level, supporting the biological and clinical relevance of transcription initiation at STRs. Together, our results extend the repertoire of non-coding transcription associated with DNA tandem repeats and complexify STR polymorphism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078885"
        }
      ],
      "body": "Describe Cap Trap RNA-seq",
      "type": "summary",
      "id": "6202fa3cc9dfcb9c0900002c",
      "ideal_answer": [
        "Using the Cap Analysis of Gene Expression (CAGE) technology, the FANTOM5 consortium provided one of the most comprehensive maps of transcription start sites (TSSs) in several species. Strikingly, ~72% of them could not be assigned to a specific gene and initiate at unconventional regions, outside promoters or enhancers. Cap Trap RNA-seq is a technology which combines cap trapping and long read MinION sequencing."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34548412",
        "http://www.ncbi.nlm.nih.gov/pubmed/32965634",
        "http://www.ncbi.nlm.nih.gov/pubmed/34108196",
        "http://www.ncbi.nlm.nih.gov/pubmed/33987067",
        "http://www.ncbi.nlm.nih.gov/pubmed/32348267",
        "http://www.ncbi.nlm.nih.gov/pubmed/32373348",
        "http://www.ncbi.nlm.nih.gov/pubmed/32805098",
        "http://www.ncbi.nlm.nih.gov/pubmed/28844294",
        "http://www.ncbi.nlm.nih.gov/pubmed/17288613",
        "http://www.ncbi.nlm.nih.gov/pubmed/16730989",
        "http://www.ncbi.nlm.nih.gov/pubmed/19394111"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "PURPOSE: Although, Canadian C-spine rule and the National Emergency X-Radiography Utilization Study (NEXUS) criteria in ruling out clinically important cervical spine injuries have been validated using large prospective studies, no consensus exist as to which rule should be endorsed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32965634"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 282,
          "text": "OBJECTIVE: The Canadian C-Spine Rule (CCR) and the National Emergency X-Radiography Utilization Study (NEXUS) criteria are two commonly used clinical decision rules which use midline cervical spine (c-spine) tenderness on palpation as an indication for c-spine imaging post-trauma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548412"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "BACKGROUND: A consistent approach to cervical spine injury (CSI) clearance for patients 65 and older remains a challenge. Clinical clearance algorithms like the National Emergency X-Radiography Utilisation Study (NEXUS) criteria have variable accuracy and the Canadian C-spine rule excludes older patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34108196"
        },
        {
          "offsetInBeginSection": 725,
          "offsetInEndSection": 852,
          "text": ". Clinical decision rules such as the Canadian C-Spine Rule are frequently used to risk-stratify patients needing radiography. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Pragmatic Strategy Empowering Paramedics to Assess Low-Risk Trauma Patients With the Canadian C-Spine Rule and Selectively Transport Them Without Immobilization: Protocol for a Stepped-Wedge Cluster Randomized Trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348267"
        },
        {
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1329,
          "text": "The high sensitivity of the Canadian C-spine Rule (CCR) prevents missing C-spine injuries while limiting the amount of unnecessary radiologic examinations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32373348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "The Canadian C-spine rule clinically clears cervical spine fracture without imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32805098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "OBJECTIVE: The Canadian C-Spine Rule (CCR) and the National Emergency X-Radiography Utilization Study (NEXUS) criteria are two commonly used clinical decision rules which use midline cervical spine (c-spine) tenderness on palpation as an indication for c-spine imaging post-t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548412"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "INTRODUCTION: The Canadian C-Spine Rule (CCR) is a clinical decision aid to facilitate the safe removal of cervical collars in the alert, orientated, low-risk adult trau",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28844294"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 498,
          "text": "nt. The Canadian C-Spine Rule is designed to allow physicians to be more selective and accurate in ordering C-spine radiography, and to rapidly clear the C-spine without the need for radiography in many patie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17288613"
        },
        {
          "offsetInBeginSection": 735,
          "offsetInEndSection": 858,
          "text": " decision rules such as the Canadian C-Spine Rule are frequently used to risk-stratify patients needing radiography. The le",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The Canadian c-spine rule (CCR) allows safe, reproducible use of radiography in alert, stable patients with potential c-spine injury in the emergency setting [Stiell, I., Cle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730989"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "The Canadian C-spine rule clinically clears cervical spine fracture without imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32805098"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 490,
          "text": " efficient. The Canadian C-Spine Rule is designed to allow physicians to be more selective and accurate in ordering C-spine radiography, and to rapidly clear the C-spine without the need for radiography in ma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17288613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "STUDY OBJECTIVE: We designed the Canadian C-Spine Rule for the clinical clearance of the cervical spine, without need for diagnostic imaging, in alert and stable",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19394111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 392,
          "text": "The Canadian c-spine rule (CCR) allows safe, reproducible use of radiography in alert, stable patients with potential c-spine injury in the emergency setting [Stiell, I., Clement, C., McKnight, R., Brison, R., Schull, M., Lowe, B., Worthington, J., Eisenhauer, M., Cass, D., Greenberg, G., MacPhail, I., Dreyer, J., Lee, J., Bandiera, G., Reardon, M., Holroyd, B., Lesiuk, H., G. Wells, 2003.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730989"
        }
      ],
      "body": "What is the use of the Canadian C-Spine Rule?",
      "type": "summary",
      "id": "6200879ac9dfcb9c09000021",
      "ideal_answer": [
        "The Canadian C-spine rule clinically clears cervical spine fracture without imaging."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11731451",
        "http://www.ncbi.nlm.nih.gov/pubmed/8149916",
        "http://www.ncbi.nlm.nih.gov/pubmed/8217842"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "As the only class I helix-loop-helix transcription factor in Drosophila, Daughterless (Da) has generally been regarded as a ubiquitously expressed binding partner for other developmentally regulated bHLH transcription factors. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11731451"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8149916"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "The daughterless (da) gene in Drosophila functions in the regulation of at least three significant developmental pathways: sex determination, neurogenesis and oogenesis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8217842"
        }
      ],
      "body": "What is the Daughterless gene?",
      "type": "factoid",
      "id": "622d1ed13a8413c6530000a3",
      "ideal_answer": [
        "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined."
      ],
      "exact_answer": [
        [
          "The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined."
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11878947",
        "http://www.ncbi.nlm.nih.gov/pubmed/12917635",
        "http://www.ncbi.nlm.nih.gov/pubmed/15283144",
        "http://www.ncbi.nlm.nih.gov/pubmed/16652154",
        "http://www.ncbi.nlm.nih.gov/pubmed/23909929",
        "http://www.ncbi.nlm.nih.gov/pubmed/28611443"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11878947"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11878947"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917635"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 220,
          "text": " G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917635"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 509,
          "text": " We found that treatment with telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917635"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "A novel telomerase inhibitor, telomestatin, isolated from Streptomyces anulatus is the most potent telomerase inhibitor so far.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 93,
          "text": "Telomerase inhibitor, telomestatin, a specific mechanism to interact with telomere structure",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 232,
          "text": "Telomestatin specifically inhibited telomerase without affecting reverse transcriptases and polymerases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 379,
          "text": "In addition, telomestatin induced telomere shortening, but its ratio was extremely faster than that observed in physiological telomere shortening.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "A novel telomerase inhibitor, telomestatin, isolated from Streptomyces anulatus is the most potent telomerase inhibitor so far. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 530,
          "text": "ructure has been yet resolved for the complex with telomestatin, one of the most promising G-quadruplex-targeting anticancer drug candidates. Here",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23909929"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Telomestatin, a strong telomerase inhibitor with G-quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611443"
        },
        {
          "offsetInBeginSection": 871,
          "offsetInEndSection": 961,
          "text": "Thus, telomestatin provide the novel therapeutic molecular target for cancer chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15283144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16652154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917635"
        }
      ],
      "body": "Is telomestatin, a novel statin drug used to treat high cholesterol?",
      "type": "yesno",
      "id": "623a24d6f0baec9a1b000002",
      "ideal_answer": [
        "Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor and is used to treat cancer.",
        "Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34893673"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34893673"
        }
      ],
      "body": "What is amphiregulin a ligand of?",
      "type": "factoid",
      "id": "6237a8a33a8413c6530000b3",
      "ideal_answer": [
        "Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand."
      ],
      "exact_answer": [
        [
          "epidermal growth factor receptor"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34741163"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 643,
          "text": "We conducted a genome-wide association study with 53,400 cases and 433,201 controls and replicated significant associations in a 23andMe panel (205,252 cases and 1,384,055 controls). Our study identified and confirmed six genetic susceptibility loci for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741163"
        }
      ],
      "body": "Which genetic susceptibility loci are implicated in irritable bowel syndrome (IBS)?",
      "type": "list",
      "id": "6206743ac9dfcb9c09000037",
      "ideal_answer": [
        "There have been six genetic susceptibility loci identified and confirmed for IBS. Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6.",
        "Implicated genes included NCAM1, CADM2, PHF2/FAM120A, DOCK9, CKAP2/TPTE2P3 and BAG6."
      ],
      "exact_answer": [
        [
          "NCAM1"
        ],
        [
          "CADM2"
        ],
        [
          "PHF2",
          "FAM120A"
        ],
        [
          "DOCK9"
        ],
        [
          "CKAP2",
          "TPTE2P3"
        ],
        [
          "BAG6"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34560365",
        "http://www.ncbi.nlm.nih.gov/pubmed/34538679",
        "http://www.ncbi.nlm.nih.gov/pubmed/34548920",
        "http://www.ncbi.nlm.nih.gov/pubmed/34418708",
        "http://www.ncbi.nlm.nih.gov/pubmed/34330729",
        "http://www.ncbi.nlm.nih.gov/pubmed/34648420",
        "http://www.ncbi.nlm.nih.gov/pubmed/34649856",
        "http://www.ncbi.nlm.nih.gov/pubmed/34617967",
        "http://www.ncbi.nlm.nih.gov/pubmed/34187803",
        "http://www.ncbi.nlm.nih.gov/pubmed/33968610",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484780",
        "http://www.ncbi.nlm.nih.gov/pubmed/32896460",
        "http://www.ncbi.nlm.nih.gov/pubmed/34306190"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560365"
        },
        {
          "offsetInBeginSection": 518,
          "offsetInEndSection": 731,
          "text": "Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538679"
        },
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 639,
          "text": "CASE REPORT: We report a case of atypical GBS occurring after Coronavirus disease 2019 (COVID-19) vaccination in an otherwise healthy 38-year-old man.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538679"
        },
        {
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1489,
          "text": "It is critical for emergency physicians to be aware of the manifold presentations of GBS for early recognition and treatment. This may be of particular importance in the context of a worldwide vaccination campaign in response to the COVID-19 pandemic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34538679"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548920"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 326,
          "text": "We report three patients who developed Guillain-Barré syndrome following ChAdOx1 nCoV-19 vaccination, who did not have active or prior COVID-19 infection. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34418708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "We report a case of Guillain-Barré syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34330729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Guillain-​Barré Syndrome Associated with COVID-19 Vaccination",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34648420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Guillain-​Barré Syndrome Associated with COVID-19 Vaccination.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34648420"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 278,
          "text": "To date, cases of Guillain-Barré syndrome (GBS) following a COVID vaccine (Pfizer, Johnson \u0026 Johnson, Janssen, AstraZeneca) have been reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34649856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Case of Guillain-Barré syndrome following COVID-19 vaccine.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34187803"
        },
        {
          "offsetInBeginSection": 480,
          "offsetInEndSection": 630,
          "text": "We report a case of Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine and believe this is a temporal, rather than causal association.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33968610"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34617967"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Guillain-Barré syndrome associated with Covid-19: A close relationship or just a coincidence? (Review).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34306190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Relation between COVID-19 and Guillain-Barré syndrome in adults. Systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32896460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Guillain-Barré syndrome after COVID-19 vaccination.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34330729"
        }
      ],
      "body": "Is there an association between Guillain–Barré syndrome and covid vaccine?",
      "type": "yesno",
      "id": "61f7d4da882a024a10000033",
      "ideal_answer": [
        "Yes. There series reporting Guillain–Barré syndrome after COVID-19 vaccination."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34495528",
        "http://www.ncbi.nlm.nih.gov/pubmed/33360823",
        "http://www.ncbi.nlm.nih.gov/pubmed/34472223",
        "http://www.ncbi.nlm.nih.gov/pubmed/32733014"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 718,
          "offsetInEndSection": 938,
          "text": "Subsequently, the N-glycosylated nascent proteins enter the folding step, in which N-glycans contribute largely to attaining the correct protein fold by recruiting the lectin-like chaperones, calnexin, and calreticulin. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34495528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "The lectin chaperones calnexin (CNX) and calreticulin (CRT) localized in the endoplasmic reticulum play important roles in glycoprotein quality control. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33360823"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 155,
          "text": "Calreticulin (CRT), an endoplasmic reticulum-resident protein generally overexpressed in cancer cells, is associated with radiation resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34472223"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ buffer to assist correct protein folding within the ER.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32733014"
        }
      ],
      "body": "What is the function of the protein calreticulin?",
      "type": "factoid",
      "id": "623dfd2ef0baec9a1b000004",
      "ideal_answer": [
        "Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ buffer to assist correct protein folding within the ER."
      ],
      "exact_answer": [
        [
          "chaperone and Ca2+ buffer to assist correct protein folding within the ER"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32623537",
        "http://www.ncbi.nlm.nih.gov/pubmed/2645074",
        "http://www.ncbi.nlm.nih.gov/pubmed/11301365",
        "http://www.ncbi.nlm.nih.gov/pubmed/33763273",
        "http://www.ncbi.nlm.nih.gov/pubmed/2492542",
        "http://www.ncbi.nlm.nih.gov/pubmed/33850389",
        "http://www.ncbi.nlm.nih.gov/pubmed/16272271",
        "http://www.ncbi.nlm.nih.gov/pubmed/22665557",
        "http://www.ncbi.nlm.nih.gov/pubmed/16525818",
        "http://www.ncbi.nlm.nih.gov/pubmed/15776322",
        "http://www.ncbi.nlm.nih.gov/pubmed/6523080"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "Atlanto-axial instability (AAI) is common in the connective tissue disorders, such as rheumatoid arthritis, and increasingly recognized in the heritable disorders of Stickler, Loeys-Dietz, Marfan, Morquio, and Ehlers-Danlos (EDS) syndromes, where it typically presents as a rotary subluxation due to incompetence of the alar ligament.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32623537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Grisel\u0027s syndrome is a unilateral or bilateral subluxation of C1 on C2, associated with an infectious condition in the head or neck.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2645074"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 483,
          "text": "Compression of the spinal cord caused by atlanto-axial instability is a common, serious complication in SED patients, and causes severe spinal cord symptoms or occasionally sudden death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11301365"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 645,
          "text": "We present an SED patient who underwent a posterior fusion of the occiput to the cervical spine for severe spinal cord symptoms due to atlanto-axial instability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11301365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Atlantoaxial rotatory fixation (AARF) resulting from drug-induced cervical dystonia (DICD) represents an extremely rare complication of antipsychotic treatment, requiring a comprehensive assessment of pharmacologic therapy and timely radiologic workup. We ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33763273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "A relatively rare report of an 8-year-old girl with Maroteaux-Lamy syndrome that is Type VI mucopolysaccharidosis who presented with symptoms of spastic quadriparesis related to atlantoaxial instability is presented",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33850389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "We report a 15-year-old boy with mucopolysaccharidosis (MPS) Type VII (Sly disease) who was found to have atlantoaxial instability with quadriparesis. Su",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2492542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Atlanto-axial rotatory fixation (AARF) is a rare cause of childhood torticollis that may occur spontaneously or in association with trauma and upper respiratory infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15776322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Ankylosing spondylitis is one of the commonest inflammatory diseases of the axial skeleton and can be complicated by atlanto-axial instability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Atlantoaxial instability (AAI) affects 10-20% of individuals with Down syndrome (DS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16525818"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Atlanto-axial subluxation in rheumatoid arthritis. A study of 104 hospital patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6523080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The cervical spine often becomes involved early in the course of rheumatoid arthritis, leading to three different patterns of instability: atlantoaxial subluxation, atlantoaxial impaction, and subaxial subluxation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16272271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Arthritic affection of the upper cervical spine is relatively common in rheumatoid arthritis (RA). Atlanto-axial subluxations are also reported to occur frequently,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6523080"
        }
      ],
      "body": "Atlanto-axial rotary instability (Fielding type 1) is common to what diseases?",
      "type": "list",
      "id": "6235f0e93a8413c6530000ad",
      "ideal_answer": [
        "Atlanto-axial instability (AAI) is common in the connective tissue disorders, such as rheumatoid arthritis, and increasingly recognized in the heritable disorders of Stickler, Loeys-Dietz, Marfan, Morquio, and Ehlers-Danlos (EDS) syndromes as well as infectious disease.",
        "Atlanto-axial instability (AAI) is common in the connective tissue disorders, such as rheumatoid arthritis, and increasingly recognized in the heritable disorders of Stickler, Loeys-Dietz, Marfan, Morquio, and Ehlers-Danlos (EDS) syndromes, where it typically presents as a rotary subluxation due to incompetence of the alar ligament."
      ],
      "exact_answer": [
        [
          "rheumatoid arthritis"
        ],
        [
          "connective tissues disorders"
        ],
        [
          "infectious disease"
        ],
        [
          "Stickler syndrome"
        ],
        [
          "Loeys-Dietz syndrome"
        ],
        [
          "Marfan\u0027s syndrome"
        ],
        [
          "Morquio syndrome"
        ],
        [
          "Ehlers-Danlos (EDS) syndrome"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Epiregulin induces leptin secretion and energy expenditure in high-fat diet-fed mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
        },
        {
          "offsetInBeginSection": 723,
          "offsetInEndSection": 845,
          "text": " EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR/MAPK pathway. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
        },
        {
          "offsetInBeginSection": 1522,
          "offsetInEndSection": 1633,
          "text": "Our data revealed a new role of EREG in induction of leptin secretion leading to the energy expenditure state. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
        }
      ],
      "body": "What is the effect of epiregulin on leptin secretion?",
      "type": "factoid",
      "id": "6237ab873a8413c6530000b6",
      "ideal_answer": [
        "Epiregulin induces leptin secretion."
      ],
      "exact_answer": [
        [
          "induction",
          "increase"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34850907"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1313,
          "text": "JASPAR (http://jaspar.genereg.net/) is an open-access database containing manually curated, non-redundant transcription factor (TF) binding profiles for TFs across six taxonomic groups. In this 9th release, we expanded the CORE collection with 341 new profiles (148 for plants, 101 for vertebrates, 85 for urochordates, and 7 for insects), which corresponds to a 19% expansion over the previous release. We added 298 new profiles to the Unvalidated collection when no orthogonal evidence was found in the literature. All the profiles were clustered to provide familial binding profiles for each taxonomic group. Moreover, we revised the structural classification of DNA binding domains to consider plant-specific TFs. This release introduces word clouds to represent the scientific knowledge associated with each TF. We updated the genome tracks of TFBSs predicted with JASPAR profiles in eight organisms; the human and mouse TFBS predictions can be visualized as native tracks in the UCSC Genome Browser. Finally, we provide a new tool to perform JASPAR TFBS enrichment analysis in user-provided genomic regions. All the data is accessible through the JASPAR website, its associated RESTful API, the R/Bioconductor data package, and a new Python package, pyJASPAR, that facilitates serverless access to the data.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850907"
        }
      ],
      "body": "Which JASPAR release is JASPAR 2022?",
      "type": "factoid",
      "id": "6202f600c9dfcb9c0900002b",
      "ideal_answer": [
        "JASPAR (http://jaspar.genereg.net/) is an open-access database containing manually curated, non-redundant transcription factor (TF) binding profiles for TFs across six taxonomic groups. In JASPAR 2022, JASPAR\u0027s 9th release, the CORE collection was expanded with 341 new profiles (148 for plants, 101 for vertebrates, 85 for urochordates, and 7 for insects), which corresponds to a 19% expansion over the previous release."
      ],
      "exact_answer": [
        [
          "9th"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31940698",
        "http://www.ncbi.nlm.nih.gov/pubmed/34030616",
        "http://www.ncbi.nlm.nih.gov/pubmed/32961562"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "BACKGROUND: High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31940698"
        },
        {
          "offsetInBeginSection": 1448,
          "offsetInEndSection": 2232,
          "text": "There was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age (97 children [26%] vs. 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P \u003d 0.80). There were no significant differences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage, sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency of serious adverse events.CONCLUSIONS: High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31940698"
        },
        {
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1054,
          "text": "Based on existing evidence, it is still too early to recommend Epo as the standard treatment for preterm brain injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34030616"
        },
        {
          "offsetInBeginSection": 816,
          "offsetInEndSection": 1066,
          "text": "Erythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials; however, long-term follow-up of these infants is needed to come to definite conclusions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961562"
        }
      ],
      "body": "Is Erythropoietin effective for neuroprotection of Preterm Infants.",
      "type": "yesno",
      "id": "61fa904fc9dfcb9c09000004",
      "ideal_answer": [
        "No. High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34551432",
        "http://www.ncbi.nlm.nih.gov/pubmed/33348378",
        "http://www.ncbi.nlm.nih.gov/pubmed/33183910",
        "http://www.ncbi.nlm.nih.gov/pubmed/34189469"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 512,
          "text": "we explored the role of Spartan (SPRTN), a metalloprotease associated with DNA replication, which removes proteins forming DPCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551432"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Repair of covalent DNA-protein crosslinks (DPCs) by the metalloprotease SPRTN prevents genome instability, premature aging and carcinogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33348378"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "The protease SPRTN emerged as the essential enzyme for DNA-protein crosslink proteolysis repair",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33183910"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Covalent DNA-protein crosslinks (DPCs) have emerged as pervasive sources of genome instability. DPCs are targeted for repair by DNA-dependent proteases of the Wss1/SPRTN family.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34189469"
        }
      ],
      "body": "What is the SPRTN protein function?",
      "type": "factoid",
      "id": "622deabc3a8413c6530000a6",
      "ideal_answer": [
        "The protease SPRTN emerged as the essential enzyme for DNA-protein crosslink proteolysis repair."
      ],
      "exact_answer": [
        [
          "DNA-protein crosslink proteolysis repair"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33261250",
        "http://www.ncbi.nlm.nih.gov/pubmed/23101243",
        "http://www.ncbi.nlm.nih.gov/pubmed/22764663",
        "http://www.ncbi.nlm.nih.gov/pubmed/22996855",
        "http://www.ncbi.nlm.nih.gov/pubmed/3806684",
        "http://www.ncbi.nlm.nih.gov/pubmed/3356808",
        "http://www.ncbi.nlm.nih.gov/pubmed/25495513",
        "http://www.ncbi.nlm.nih.gov/pubmed/10797973",
        "http://www.ncbi.nlm.nih.gov/pubmed/27753733",
        "http://www.ncbi.nlm.nih.gov/pubmed/22254963",
        "http://www.ncbi.nlm.nih.gov/pubmed/32541159",
        "http://www.ncbi.nlm.nih.gov/pubmed/26442520",
        "http://www.ncbi.nlm.nih.gov/pubmed/34321945",
        "http://www.ncbi.nlm.nih.gov/pubmed/11311464",
        "http://www.ncbi.nlm.nih.gov/pubmed/18664636"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 346,
          "text": "the right pedicle of L4, moved inside the vertebral canal (bridging the cauda equina) stopping just in front of the body of S2. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33261250"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 124,
          "text": "Thermoesthesia-and-algesthesia status in the dermatomes of cauda equina roots in patients with lumbar spine osteochondrosis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101243"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Thermoesthesia-and-algesthesia disorders have been registered in the dermatomes of cauda equina roots of patients with lumbar spine osteochondrosis in all the cases. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101243"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 722,
          "text": " Magnetic resonance images of the lumbar spine showed an intradural cystic lesion displacing and compressing the lower cord and cauda equina.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22764663"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Cauda equina syndrome is a well described state of neurologic compromise due to lumbosacral root compression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996855"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Acute cauda equina syndrome secondary to a lumbar synovial cyst",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22996855"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "INTRODUCTION: Schwannoma is a relatively common benign spinal cord and/or cauda equina tumor; however, giant cauda equina schwannoma with extensive scalloping of the lumbar vertebral body is a rare pathology, and the treatment strategy, including the use of surgical procedures, is controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495513"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 509,
          "text": "In this report, we present a rare case of a giant lumbar schwannoma of the cauda equina with extremely large scalloping of the vertebral body, and we discuss the surgical strategy we used to treat this pathology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495513"
        },
        {
          "offsetInBeginSection": 532,
          "offsetInEndSection": 791,
          "text": "In contrast, the caudal cord of Rana is reduced to a filum terminale consisting of little more than an ependymal tube; spinal nerves to all caudal myotomes leave the cord in the sacral region and reach their motor targets via a cauda equina and caudal plexus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3356808"
        },
        {
          "offsetInBeginSection": 662,
          "offsetInEndSection": 791,
          "text": "The spinal cords of other teleosts, the sun-fish and angler, also are abbreviated and possess a filum terminale and cauda equina.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3806684"
        },
        {
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1126,
          "text": "Penetrating spinal cord injury with foreign body included or myelography stop or showing cauda equina syndrome should be operated on.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10797973"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Cauda Equina Conduction Time Determined by F-Waves in Normal Subjects and Patients With Neurogenic Intermittent Claudication Caused by Lumbar Spinal Stenosis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27753733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "After spinal cord injury, electrical stimulation of the roots inside the spinal column at the level of the cauda equina is a safe and effective way to regain some degree of control over lower body function, e.g. bladder and bowel management and leg movement. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22254963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Malignant spinal cord compression(MSCC)is defined as a compression of the spinal cord or cauda equina with neuropathy caused by tumor spreading to the vertebral body. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32541159"
        },
        {
          "offsetInBeginSection": 37,
          "offsetInEndSection": 187,
          "text": "nction of the cauda equina, the collection of ventral and dorsal lumbar, sacral and coccygeal nerve roots that surround the filum terminale. This most",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26442520"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "INTRODUCTION: Schwannoma is a relatively common benign spinal cord and/or cauda equina tumor; however, giant cauda equina schwannoma with extensive scalloping of the lumbar vertebral body is a rare pathology, and the treatment strategy, including the use of surgical procedures, is controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25495513"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Cauda equina syndrome is a relatively uncommon condition typically associated with a large, space-occupying lesion within the canal of the lumbosacral spine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18664636"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Cauda equina syndrome refers to dysfunction of the cauda equina, the collection of ventral and dorsal lumbar, sacral and coccygeal nerve roots that surround the filum terminale.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26442520"
        },
        {
          "offsetInBeginSection": 1320,
          "offsetInEndSection": 1510,
          "text": "The involvement of intrinsic spinal cord neurons in the compression-induced cauda equina syndrome includes anterograde, retrograde and transneuronal degeneration in the lumbosacral segments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11311464"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Single or double-level compression of the lumbosacral nerve roots located in the dural sac results in a polyradicular symptomatology clinically diagnosed as cauda equina syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11311464"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 470,
          "text": "The cauda equina is an anatomic structure located in the lower part of the spinal canal consisting of multiple lumbar and sacral nerve roots.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34321945"
        }
      ],
      "body": "What part of the body is associated with Cauda equina",
      "type": "factoid",
      "id": "6238a0033a8413c6530000b8",
      "ideal_answer": [
        "The cauda equina is the sack of nerve roots (nerves that leave the spinal cord between spaces in the bones of the spine to connect to other parts of the body) at the lower end of the spinal cord."
      ],
      "exact_answer": [
        [
          "spine"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32589708"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 96,
          "text": "Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32589708"
        }
      ],
      "body": "What does RUNX1T1 stand for?",
      "type": "factoid",
      "id": "62265b4a3a8413c653000083",
      "ideal_answer": [
        "RUNX1T1 stands for runt-related transcription factor 1."
      ],
      "exact_answer": [
        [
          "runt-related transcription factor 1"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34864868"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 643,
          "text": "In this work, we introduce a new R package InteractiveComplexHeatmap that brings interactivity to the widely used ComplexHeatmap package. InteractiveComplexHeatmap is designed with an easy-to-use interface where static complex heatmaps can be directly exported to an interactive Shiny web application only with one additional line of code. InteractiveComplexHeatmap also provides flexible functionalities for integrating interactive heatmap widgets to build more complex and customized Shiny web applications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864868"
        }
      ],
      "body": "Describe InteractiveComplexHeatmap",
      "type": "summary",
      "id": "621e5dcf3a8413c65300004f",
      "ideal_answer": [
        "InteractiveComplexHeatmap is an R package that brings interactivity to the widely used ComplexHeatmap package. InteractiveComplexHeatmap is designed with an easy-to-use interface where static complex heatmaps can be directly exported to an interactive Shiny web application only with one additional line of code. InteractiveComplexHeatmap also provides flexible functionalities for integrating interactive heatmap widgets to build more complex and customized Shiny web applications.",
        "InteractiveComplexHeatmap is designed with an easy-to-use interface where static complex heatmaps can be directly exported to an interactive Shiny web application only with one additional line of code."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29740743",
        "http://www.ncbi.nlm.nih.gov/pubmed/33817641",
        "http://www.ncbi.nlm.nih.gov/pubmed/34775780",
        "http://www.ncbi.nlm.nih.gov/pubmed/29464141",
        "http://www.ncbi.nlm.nih.gov/pubmed/31526671",
        "http://www.ncbi.nlm.nih.gov/pubmed/28586952",
        "http://www.ncbi.nlm.nih.gov/pubmed/30524969"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "PURPOSE/OBJECTIVE(S): Brain metastasis velocity (BMV) is a metric that describes the rate of development of new brain metastases (BM) after initial stereotactic radiosurgery (SRS). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29740743"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Background: Brain metastasis velocity (BMV) predicts outcomes after initial distant brain failure (DBF) following upfront stereotactic radiosurgery (SRS). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641"
        },
        {
          "offsetInBeginSection": 787,
          "offsetInEndSection": 972,
          "text": "lso tells the history of the derivation and validation of BMV, a recently identified biomarker for survival and neurologic death in the brain metastasis population treated with SRS.CONC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "OBJECTIVE: To provide a review of the current status of predictive nomograms and brain metastasis velocity (BMV) in the prognostication of brain metastasis outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "INTRODUCTION: Brain metastasis velocity (BMV) is a prognostic metric that describes the recurrence rate of new brain metastases after initial treatment with radiosurgery (SRS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31526671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Background: Brain metastasis velocity (BMV) predicts outcomes after initial distant brain failure (DBF) following upfront stereotactic radiosurgery (SRS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 398,
          "text": "We introduce a novel clinical metric, brain metastasis velocity (BMV), for predicting clinical outcomes after initial DBF following upfront SRS alone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "PURPOSE/OBJECTIVE(S): Brain metastasis velocity (BMV) is a metric that describes the rate of development of new brain metastases (BM) after initial stereotactic radiosurgery (SRS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29740743"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 397,
          "text": "e. We introduce a novel clinical metric, brain metastasis velocity (BMV), for predicting clinical outcomes after initial DBF following upfront SRS alone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28586952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "INTRODUCTION: Brain metastasis velocity (BMV) is a prognostic metric that describes the recurrence rate of new brain metastases after initial treatment with radios",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31526671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "OBJECTIVE: To provide a review of the current status of predictive nomograms and brain metastasis velocity (BMV) in the prognostication of brain metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34775780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "PURPOSE/OBJECTIVE(S): Brain metastasis velocity (BMV) is a metric that describes the rate of development of new brain metastases (BM) after initial stereotactic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29740743"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 351,
          "text": "SRS). We developed an integrated model of clinical predictors and pre-SRS MRI-derived radiomic scores (R-scores) to identify high-BMV (BMV-H) patients upon initial identification of brain metastases (BM",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "PURPOSE/OBJECTIVE(S): Brain metastasis velocity (BMV) is a metric that describes the rate of development of new brain metastases (BM) after initial stereotact",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29740743"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "INTRODUCTION: Brain metastasis velocity (BMV) is a prognostic metric that describes the recurrence rate of new brain metastases after initial treatment with radio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31526671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Background: Brain metastasis velocity (BMV) predicts outcomes after initial distant brain failure (DBF) following upfront stereotactic radiosu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33817641"
        },
        {
          "offsetInBeginSection": 810,
          "offsetInEndSection": 1001,
          "text": "Besides clinical and treatment related factors, brain metastasis velocity (BMV) as a newly described clinical prognostic metric was included and calculated between first and second treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30524969"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 537,
          "text": "stasis velocity (vBMV) was defined as the volume of new intracranial disease at the time of distant brain failure (DBF) for the first DBF (DBF1) and s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29464141"
        }
      ],
      "body": "What is the use of Brain Metastasis Velocity (BMV) Model?",
      "type": "summary",
      "id": "620086aac9dfcb9c09000020",
      "ideal_answer": [
        "Brain metastasis velocity (BMV) is a metric that describes the rate of development of new brain metastases (BM) after initial stereotactic radiosurgery."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34500336",
        "http://www.ncbi.nlm.nih.gov/pubmed/34485872",
        "http://www.ncbi.nlm.nih.gov/pubmed/33357449",
        "http://www.ncbi.nlm.nih.gov/pubmed/33508854"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 329,
          "text": "Cell competition involves a conserved fitness-sensing process during which fitter cells eliminate neighbouring less-fit but viable cells1. Cell competition has been proposed as a surveillance mechanism to ensure normal development and tissue homeostasis, and has also been suggested to act as a barrier to interspecies chimerism2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33508854"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Cell competition is a social cellular phenomenon in which unfit cells are selectively eliminated to maintain tissue homeostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33357449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "At the initial stage of carcinogenesis, cell competition often occurs between newly emerging transformed cells and the neighboring normal cells, leading to the elimination of transformed cells from the epithelial layer. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34485872"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 355,
          "text": "Cell competition represents one of the operating arms of such quality control mechanisms and relies on fitness comparison among individual cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34500336"
        }
      ],
      "body": "What is \"cell competition\"?",
      "type": "summary",
      "id": "622df6663a8413c6530000a7",
      "ideal_answer": [
        "Cell competition is a social cellular phenomenon in which unfit cells are selectively eliminated to maintain tissue homeostasis.\nAt the initial stage of carcinogenesis, cell competition often occurs between newly emerging transformed cells and the neighboring normal cells, leading to the elimination of transformed cells from the epithelial layer."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32633023",
        "http://www.ncbi.nlm.nih.gov/pubmed/28030433",
        "http://www.ncbi.nlm.nih.gov/pubmed/28027062"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 173,
          "text": "Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 358,
          "text": "Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32633023"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 345,
          "text": " organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "PURPOSE OF REVIEW: Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 340,
          "text": "ent organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062"
        },
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "text": ": Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "PURPOSE OF REVIEW: Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28030433"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 437,
          "text": "ent organ discard. Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death.RECENT FINDINGS: A protocol for IDD was developed at Rhode Island Hospital and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027062"
        }
      ],
      "body": "What is IDD in relation to organ transplantation?",
      "type": "summary",
      "id": "623648723a8413c6530000af",
      "ideal_answer": [
        "Imminent death donation (IDD) is described as living organ donation prior to a planned withdrawal of life-sustaining care in an imminently dying patient.",
        "Imminent death donation (IDD) is a proposal to procure organs from patients prior to the withdrawal of life support, which is anticipated to lead to death",
        "Imminent death donation (IDD) has been proposed as a separate category of organ donation: distinct from living donation and donation after cardiac death"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34535671"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 401,
          "text": "Here we report decreased expression of the m6A \"writer\" METTL3 in tumor-infiltrating NK cells, and a positive correlation between protein expression levels of METTL3 and effector molecules in NK cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535671"
        }
      ],
      "body": "Is METTL3 an m6A writer, reader or eraser?",
      "type": "factoid",
      "id": "62265c953a8413c653000084",
      "ideal_answer": [
        "The methyltransferase METTL3 is an m6A writer."
      ],
      "exact_answer": [
        [
          "Writer"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28905911"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 692,
          "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions. The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions. Validated experimental technologies will be combined with biophysical approaches to generate quantitative models of spatial genome organization in different biological states, both in cell populations and in single cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905911"
        }
      ],
      "body": "What is the 4D nucleome project?",
      "type": "summary",
      "id": "6201a06fc9dfcb9c09000026",
      "ideal_answer": [
        "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions. The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions. Validated experimental technologies will be combined with biophysical approaches to generate quantitative models of spatial genome organization in different biological states, both in cell populations and in single cells.",
        "The 4D Nucleome Network aims to develop and apply approaches to map the structure and dynamics of the human and mouse genomes in space and time with the goal of gaining deeper mechanistic insights into how the nucleus is organized and functions.",
        "The project will develop and benchmark experimental and computational approaches for measuring genome conformation and nuclear organization, and investigate how these contribute to gene regulation and other genome functions."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30342297"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 856,
          "text": "METHODS: TIPS-3 is a 2x2x2 factorial randomized controlled trial that will examine the effect of a FDC polypill on major CV outcomes in a primary prevention population. This study aims to determine whether the Polycap (comprised of atenolol, ramipril, hydrochlorothiazide, and a statin) reduces CV events in persons without a history of CVD, but who are at least at intermediate CVD risk. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30342297"
        }
      ],
      "body": "Which drugs were included in the polypill that was tested in TIPS-3 trial?",
      "type": "list",
      "id": "61f7d017882a024a1000002f",
      "ideal_answer": [
        "Polypill tested in the TIPS-3 trial was comprised of atenolol, ramipril, hydrochlorothiazide, and a statin."
      ],
      "exact_answer": [
        [
          "atenolol"
        ],
        [
          "ramipril"
        ],
        [
          "hydrochlorothiazide"
        ],
        [
          "statin"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33336218",
        "http://www.ncbi.nlm.nih.gov/pubmed/34198582",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155411"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1183,
          "text": "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155411"
        },
        {
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1327,
          "text": "The late-stage agents with positive clinical or biomarker data include four antibodies that engage Aβ oligomers (aducanumab, lecanemab, gantenerumab, and donanemab) and ALZ-801, an oral agent that fully blocks the formation of Aβ oligomers at the clinical dose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34198582"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 136,
          "text": "Reduction in Amyloid Burden with Subcutaneous Gantenerumab.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336218"
        },
        {
          "offsetInBeginSection": 770,
          "offsetInEndSection": 929,
          "text": "These results demonstrate that prolonged gantenerumab treatment, at doses up to 1200 mg, reduces amyloid plaque levels below the amyloid positivity threshold. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336218"
        }
      ],
      "body": "What is the drug  gantenerumab targeting?",
      "type": "factoid",
      "id": "622dfb133a8413c6530000a8",
      "ideal_answer": [
        "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain."
      ],
      "exact_answer": [
        [
          "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain."
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32659412",
        "http://www.ncbi.nlm.nih.gov/pubmed/34510060",
        "http://www.ncbi.nlm.nih.gov/pubmed/34599642",
        "http://www.ncbi.nlm.nih.gov/pubmed/34594553",
        "http://www.ncbi.nlm.nih.gov/pubmed/34511355",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484411",
        "http://www.ncbi.nlm.nih.gov/pubmed/28191811",
        "http://www.ncbi.nlm.nih.gov/pubmed/25206141",
        "http://www.ncbi.nlm.nih.gov/pubmed/26925653",
        "http://www.ncbi.nlm.nih.gov/pubmed/25298718",
        "http://www.ncbi.nlm.nih.gov/pubmed/32698263",
        "http://www.ncbi.nlm.nih.gov/pubmed/27721617",
        "http://www.ncbi.nlm.nih.gov/pubmed/26261564",
        "http://www.ncbi.nlm.nih.gov/pubmed/30126803",
        "http://www.ncbi.nlm.nih.gov/pubmed/23986011",
        "http://www.ncbi.nlm.nih.gov/pubmed/33394372",
        "http://www.ncbi.nlm.nih.gov/pubmed/27099699",
        "http://www.ncbi.nlm.nih.gov/pubmed/31674718",
        "http://www.ncbi.nlm.nih.gov/pubmed/1569364",
        "http://www.ncbi.nlm.nih.gov/pubmed/29747056",
        "http://www.ncbi.nlm.nih.gov/pubmed/10895162",
        "http://www.ncbi.nlm.nih.gov/pubmed/34508164",
        "http://www.ncbi.nlm.nih.gov/pubmed/21717310",
        "http://www.ncbi.nlm.nih.gov/pubmed/31990904",
        "http://www.ncbi.nlm.nih.gov/pubmed/20051072",
        "http://www.ncbi.nlm.nih.gov/pubmed/30196986",
        "http://www.ncbi.nlm.nih.gov/pubmed/14970780",
        "http://www.ncbi.nlm.nih.gov/pubmed/17170964",
        "http://www.ncbi.nlm.nih.gov/pubmed/25567699",
        "http://www.ncbi.nlm.nih.gov/pubmed/30420932",
        "http://www.ncbi.nlm.nih.gov/pubmed/28187692",
        "http://www.ncbi.nlm.nih.gov/pubmed/27435007",
        "http://www.ncbi.nlm.nih.gov/pubmed/29274152",
        "http://www.ncbi.nlm.nih.gov/pubmed/26015700",
        "http://www.ncbi.nlm.nih.gov/pubmed/28212886"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Ameloblastoma is a benign odontogenic tumor which undergoes malignant transformation to ameloblastic carcinoma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32659412"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 86,
          "text": "Ameloblastomas are benign tumors that most commonly affecting the mandible. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34510060"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Ameloblastoma is a neoplasm arising in the craniofacial skeleton.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34599642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Ameloblastoma is an invasive odontogenic tumor, and for reconstruction, i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34594553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Ameloblastoma is a locally aggressive, benign epithelial odontogenic neoplasm currently classified to include conventional, unicystic, and extraosseous/peripheral subtypes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511355"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Ameloblastoma (AM) is a slow growing and aggressive benign tumor with an odontogenic epithelial origin arising from the mandible or maxilla.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484411"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "The ameloblastoma is a benign but aggressive neoplasm of odontogenic origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206141"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Ameloblastoma is a rare odontogenic tumor of the jaw.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28191811"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Ameloblastoma is the most common epithelial odontogenic tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26925653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Ameloblastoma or adamantinoma is the rarest of the three forms of tumor of the odontogenic type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25298718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Ameloblastoma is a benign locally invasive odontogenic tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32698263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Ameloblastoma is the second most common benign epithelial odontogenic tumor and though it is of a benign nature, it is locally invasive, has a high recurrence rate and could potentially become malignant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-facial region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Ameloblastoma is the most common odontogenic tumor of epithelial origin, and though it is of a benign nature, it frequently infiltrates the bone, has a high rate of recurrence and could potentially become malignant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23986011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "OBJECTIVES: Ameloblastoma is a benign, slow-growing, locally invasive epithelial tumor of odontogenic origin, with unlimited growth capacity and a strong tendency to recur.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30126803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Ameloblastoma, a benign but locally aggressive odontogenic tumor, often demonstrates metastasis despite benign histological features and this variant is termed as metastasizing ameloblastoma (METAM). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33394372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification. AC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-fac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Peripheral ameloblastoma is a benign odontogenic tumor with the same histological characteristics as the centrally located ameloblastoma, but appearing in the gingiva and mucosa of the tooth-bearing area of the jaws.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1569364"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "BACKGROUND Ameloblastoma (AB) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31990904"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Ameloblastoma(AB) is an aggressive and slow-growing tumor with high recurrence rate, which arises from odontogenic epithelium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30196986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Ameloblastoma (AB) is the most common benign epithelial odontogenic tumor occurring in the jawbone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34508164"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 351,
          "text": "or growth. Ameloblastoma (AB) is a relatively common odontogenic epithelial neoplasm that manifests local infiltrative intraosse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14970780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 236,
          "text": "Ameloblastoma is a benign epithelial odontogenic tumor that typically arises in the mandible or maxilla or, rarely, in the immediate adjacent soft tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567699"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "text": "nic epithelial components with a mature fibrous stroma. It is the second most common odontogenic neoplasm following odontome. Acanthomatous ameloblast",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30420932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "OBJECTIVE AND IMPORTANCE: Ameloblastoma is a locally aggressive benign tumor, commonly occurring in the mandible",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28187692"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "BACKGROUND AND OVERVIEW: Ameloblastoma is an odontogenic tumor predominantly occurring in patients who are in their 20s and 30s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-facial region",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261564"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "BACKGROUND: Ameloblastoma is a neoplasm classified as a benign epithelial odontogenic tumor of the jaws, grow slowly and are locally invasive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29274152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "BACKGROUND: Ameloblastoma is a frequent odontogenic benign tumor characterized by local invasiveness, high risk of recurrence and occasional metastasis and malignant transformation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19995435"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "BACKGROUND: Ameloblastoma is a rare benign odontogenic tumor with locally aggressive behavior and a high recurrence rate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21968082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: Ameloblastoma is a benign odontogenic tumor, exhibiting local invasiveness and high rate of recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21371124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 653,
          "text": "BACKGROUND: Ameloblastoma is a rare benign odontogenic tumor with a metastasis rate estimated at 2% of cases, mainly involving the lung (80%) and lymph nodes (20%).METHODS: We hereby present the case of a 26 year old patient with a history of locally recurrent mandibular ameloblastoma who developed a temporal intracranial ameloblastoma tumor requiring a collaborative neurosurgical and maxillo-facial radical surgical approach.CONCLUSION: Although ameloblastomas are histologically benign, the temporal topography questions the dissemination pathophysiology of the tumor (metastasis or local extension through temporal muscle fibers), mainly relevant ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29747056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Ameloblastoma is a histologically benign tumor derived from odontogenic apparatus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10895162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: Ameloblastoma is a benign odontogenic tumour that may exhibit aggressive biological behaviour with local recurrence and metastasis following initial surgica",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27099699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Ameloblastomas are histologically benign tumors derived from the odontogenic apparatus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17170964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Ameloblastoma is a benign odontogenic tumor generally present in the jaw bone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26015700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Ameloblastoma is a locally aggressive tumor derived from odontogenic epithelium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28212886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Ameloblastoma is the most common clinically significant epithelial odontogenic tumor, and is considered a benign but locally aggressive tumor of the craniofacial region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20051072"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Ameloblastoma (AB), which is the most common odontogenic tumor, may originate from the dental lamina remnants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21717310"
        }
      ],
      "body": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?",
      "type": "yesno",
      "id": "6226317a3a8413c653000080",
      "ideal_answer": [
        "Ameloblastoma (AB) is the most common benign epithelial odontogenic tumor occurring in the mandible",
        "Ameloblastoma (AM) is a slow growing and aggressive benign tumor with an odontogenic epithelial origin arising from the mandible or maxilla.",
        "Ameloblastoma is a neoplasm arising in the craniofacial skeleton."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34515345"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 932,
          "text": "Here, we summarize the current state of m6 A methylation researches, focusing on how these modifications modulate the fate decisions of innate and adaptive immune cells and regulate immune responses in immune-associated diseases, including viral infections and cancer. These studies showed that m6 A modifications and m6 A modifying proteins play a critical role in pathogen recognition, immune cell activation, immune cell fate decisions, and immune reactions. m6 A is a novel regulator of immune system homeostasis and activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34515345"
        }
      ],
      "body": "In which aspects of the immune response is m6A methylation implicated?",
      "type": "list",
      "id": "622664fa3a8413c653000086",
      "ideal_answer": [
        "m6A is a novel regulator of immune system homeostasis and activation.  m6A modifications and m6A modifying proteins play a critical role in pathogen recognition, immune cell activation, immune cell fate decisions, and immune reactions. These modifications modulate the fate decisions of innate and adaptive immune cells and regulate immune responses in immune-associated diseases, including viral infections and cancer."
      ],
      "exact_answer": [
        [
          "pathogen recognition"
        ],
        [
          "immune cell activation"
        ],
        [
          "immune cell fate decisions"
        ],
        [
          "immune reactions"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34788790"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "nextNEOpi: a comprehensive pipeline for computational neoantigen prediction.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790"
        },
        {
          "offsetInBeginSection": 451,
          "offsetInEndSection": 748,
          "text": "Here, we present nextNEOpi, a comprehensive and fully-automated bioinformatic pipeline to predict tumor neoantigens from raw DNA and RNA sequencing data. In addition, nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790"
        }
      ],
      "body": "Describe nextNEOpi",
      "type": "summary",
      "id": "621e991a3a8413c653000052",
      "ideal_answer": [
        "NextNEOpi is a comprehensive and fully-automated bioinformatic pipeline to predict tumor neoantigens from raw DNA and RNA sequencing data. In addition, nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33550837",
        "http://www.ncbi.nlm.nih.gov/pubmed/29274754",
        "http://www.ncbi.nlm.nih.gov/pubmed/29030869",
        "http://www.ncbi.nlm.nih.gov/pubmed/28363682",
        "http://www.ncbi.nlm.nih.gov/pubmed/29560065",
        "http://www.ncbi.nlm.nih.gov/pubmed/24991318",
        "http://www.ncbi.nlm.nih.gov/pubmed/31800901"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "Many parameters included in the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex category) scores also predict coronary artery disease (CAD). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33550837"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29274754"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 932,
          "text": "METHODS: Using the Danish registries, we evaluated and compared the risk classification properties of the Hypertension, Age, Stroke, Bleeding tendency/predisposition, Labile international normalized ratios, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs or alcohol excess (HAS-BLED), Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA), and Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) scores for predicting major bleeding in 57,930 atrial fibrillation patients (44.6% female; mean age 73.5 years, standard deviation 11.4 years; mean CHA2DS2-VASc score 3.2, standard deviation 1.8).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29274754"
        },
        {
          "offsetInBeginSection": 1608,
          "offsetInEndSection": 1900,
          "text": "All the BRSs show a satisfactory calibration for major and CRB events. Among these BRSs, only HEMORR2 HAGES (C-statistic \u003d 0.71, 95% CI 0.60-0.82, P \u003c .001) and ATRIA score (C-statistic \u003d 0.70, 95% CI 0.58-0.82, P \u003c .001) show acceptable discrimination performance for major bleeding events. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29030869"
        },
        {
          "offsetInBeginSection": 705,
          "offsetInEndSection": 923,
          "text": "Patients were then sorted into two groups at non-low and low risk of bleeding, as defined by an ATRIA score \u003e3 and ≤3 respectively, and compared regarding major adverse cardiac and vascular events (MACVE) and bleeding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363682"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 544,
          "text": "Methods: This prospective study included non-anticoagulated adults at high risk for ischemic stroke (ATRIA score ≥7) who received emergency AF/FL care and were discharged home from seven community EDs between May 2011 and August 2012. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29560065"
        },
        {
          "offsetInBeginSection": 773,
          "offsetInEndSection": 1089,
          "text": "viduals with moderate-to-high stroke risk per CHADS2 but not at high bleeding risk per ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) bleeding risk score were evaluated for warfarin use, as identified by the presence of ≥1 warfarin prescription claims within 12 months after the index diagnosis. War",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991318"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 325,
          "text": "BACKGROUND: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) risk score used to detect the thromboembolic and hemorrhagic risk in atrial fibrillation patients has been shown recently to predict poor clinical outcomes in patients with acute myocardial infarction (ACS), regardless of having atrial fibrillat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31800901"
        }
      ],
      "body": "What is the use of the ATRIA score?",
      "type": "summary",
      "id": "62008577c9dfcb9c0900001f",
      "ideal_answer": [
        "ATRIA score determines bleeding risk for patients on warfarin."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34532642",
        "http://www.ncbi.nlm.nih.gov/pubmed/33468562"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 347,
          "text": "HER2-targeting agents such as Herceptin®, Kadcyla® and ENHERTU® have been approved by the FDA for the treatment of breast cancer,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34532642"
        },
        {
          "offsetInBeginSection": 799,
          "offsetInEndSection": 851,
          "text": " Herceptin toward ErbB2-positive breast cancer cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33468562"
        }
      ],
      "body": "Which protein is targeted by Herceptin?",
      "type": "factoid",
      "id": "622b99f73a8413c653000093",
      "ideal_answer": [
        "Her2 is targeted by Herceptin."
      ],
      "exact_answer": [
        [
          "Her2"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32312535",
        "http://www.ncbi.nlm.nih.gov/pubmed/32648194",
        "http://www.ncbi.nlm.nih.gov/pubmed/32524528",
        "http://www.ncbi.nlm.nih.gov/pubmed/33273410",
        "http://www.ncbi.nlm.nih.gov/pubmed/31456011",
        "http://www.ncbi.nlm.nih.gov/pubmed/20724258",
        "http://www.ncbi.nlm.nih.gov/pubmed/32667440",
        "http://www.ncbi.nlm.nih.gov/pubmed/18514082",
        "http://www.ncbi.nlm.nih.gov/pubmed/21604079",
        "http://www.ncbi.nlm.nih.gov/pubmed/22522447"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 979,
          "offsetInEndSection": 1348,
          "text": "A total of 157 ancillary tests were performed, including electroencephalogram (62%), computed tomography angiography (22%), transcranial Doppler ultrasound (6%), cerebral blood flow nuclear study (5%), cerebral angiography (4%), and other (1%). Forty-seven patients (53% of patients with AT) with confirmatory AT still underwent additional ancillary for BD confirmation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312535"
        },
        {
          "offsetInBeginSection": 1349,
          "offsetInEndSection": 1469,
          "text": " Only 21 patients (12% of all patients) were declared brain-dead using confirmatory ATs alone without ancillary testing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312535"
        },
        {
          "offsetInBeginSection": 1588,
          "offsetInEndSection": 1724,
          "text": "Our study highlights the variability in practice in regard to the AT and supports the use of ancillary tests to determine BD in patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312535"
        },
        {
          "offsetInBeginSection": 407,
          "offsetInEndSection": 1047,
          "text": "Details provided on the performance and interpretation of ancillary tests for determination of BD/DNC were variably provided and inconsistent. Approximately half of all protocols that included each ancillary test provided details about study performance: 63% of protocols that included conventional cerebral angiography, 55% of protocols that included electroencephalography, 50% of protocols that included somatosensory evoked potentials, 48% of protocols that included transcranial Doppler ultrasonography, 43% of protocols that included nuclear medicine flow study and 41% of protocols that included brainstem auditory evoked potentials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648194"
        },
        {
          "offsetInBeginSection": 1566,
          "offsetInEndSection": 1660,
          "text": " Diagnostic requirements for ancillary testing in BD/DNC determination vary around the world. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648194"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Apnea is one of the three cardinal findings in brain death (BD). Apnea testing (AT) is physiologically and practically complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Apnea Testing for the Determination of Brain Death:",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524528"
        },
        {
          "offsetInBeginSection": 1584,
          "offsetInEndSection": 1750,
          "text": " When conducting the neurologic examination and apnea test required for death by neurologic criteria determination in patients with suspected or confirmed coronavirus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33273410"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 196,
          "text": "To discuss the challenges of conducting a death by neurologic criteria or brain death evaluation in the coronavirus disease 2019 era and provide guidance to mitigate viral transmission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33273410"
        },
        {
          "offsetInBeginSection": 1847,
          "offsetInEndSection": 1996,
          "text": "he final exam, negative brain flow was demonstrated 12 of 15 patients with craniectomy (80%) and 111 of 123 patients without craniectomy (90.2%). The",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31456011"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Use of CPAP as an alternative to the apnea test during the determination of brain death in hypoxemic patients",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32667440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "The apnea test, which involves disconnection from the mechanical ventilator, presents risks during the determination of brain death, especially in hypoxemic patients. W",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32667440"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 770,
          "text": "The 2 main radionuclidic techniques used in evaluation of brain death are radionuclide angiography with nonlipophilic radiopharmaceuticals and parenchymal imaging with lipophilic agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18514082"
        },
        {
          "offsetInBeginSection": 2143,
          "offsetInEndSection": 2552,
          "text": "are not a substitute for the neurologic examination. Ancillary studies may be used to assist the clinician in making the diagnosis of brain death (a) when components of the examination or apnea testing cannot be completed safely due to the underlying medical condition of the patient; (b) if there is uncertainty about the results of the neurologic examination; (c) if a medication effect may be present; or (",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 538,
          "text": "BACKGROUND: Although the new Practice Parameters for brain death support a single examination, there is paucity of data comparing its impact to dual brain death (DBD) examinations.METHODS: We reviewed all brain deaths in our hospital over a 39-month period and compared the optional single brain death (SBD) exam requiring an apnea and a mandatory confirmatory blood flow test to the DBD for organ function at the time of death, rate of donation, and cost.RESULTS: Thirty-six patients had a SBD and 59 DBD exams, without any of them regai",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21604079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "BACKGROUND: In Canada, ancillary tests, such as selective four vessels angiography (S4VA), are sometimes necessary for brain death (BD) diagnosis when the clinical exam cannot be completed or confounding factors ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20724258"
        },
        {
          "offsetInBeginSection": 1237,
          "offsetInEndSection": 1571,
          "text": "We hypothesize that the existence of these apparent contradictions is related to differences in sensitivity of the physical examination and the confirmatory examinations, differences in localization of the physical examination and confirmatory tests, and differences between blood flow and cerebral function as markers of brain death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18514082"
        },
        {
          "offsetInBeginSection": 984,
          "offsetInEndSection": 1127,
          "text": "Nonetheless, on occasion patients clinically diagnosed with brain death will exhibit persistent intracranial blood flow or electrical activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18514082"
        }
      ],
      "body": "What are the main clinical components of the brain death exam?",
      "type": "list",
      "id": "6235ee453a8413c6530000ac",
      "ideal_answer": [
        "The three essential findings in brain death are coma, absence of brain stem reflexes by neurologic exam including ancillary testing, and apnea. Studies can highlight the variability in practice in regard to the AT and supports the use of ancillary tests to determine BD in patients. Coma and brain stem reflexes can be determined by several ancillary tests  Ancillary tests include electroencephalography,  brainstem auditory evoked potentials, included somatosensory evoked potentials, transcranial Doppler ultrasonography, conventional cerebral angiography, and  nuclear medicine flow study"
      ],
      "exact_answer": [
        [
          "coma"
        ],
        [
          "neurologic exam",
          "neurologic criteria"
        ],
        [
          "Apnea test"
        ],
        [
          "Ancillary test"
        ],
        [
          "somatosensory evoked potentials"
        ],
        [
          "electroencephalography"
        ],
        [
          "transcranial Doppler ultrasonography"
        ],
        [
          "nuclear medicine flow study"
        ],
        [
          "conventional cerebral angiography"
        ],
        [
          "brainstem auditory evoked potentials"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34893673"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 837,
          "offsetInEndSection": 1059,
          "text": "In SNU-C4 and Caco-2 cells which were relatively sensitive to cetuximab among the seven CRC cell lines tested, AREG significantly decreased the anti-proliferative effect of cetuximab (p \u003c 0.05) via AKT and ERK activation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34893673"
        }
      ],
      "body": "How does amphiregulin decrease the anti-proliferative effect of cetuximab?",
      "type": "summary",
      "id": "6237a94f3a8413c6530000b4",
      "ideal_answer": [
        "In SNU-C4 and Caco-2 cells which were relatively sensitive to cetuximab among the seven CRC cell lines tested, AREG significantly decreased the anti-proliferative effect of cetuximab (p \u003c 0.05) via AKT and ERK activation."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34864895"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "RCandy: an R package for visualising homologous recombinations in bacterial genomes.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 568,
          "text": "Here, we present RCandy, a platform-independent R package for rapid, simple, and flexible visualisation of recombination events in bacterial genomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864895"
        }
      ],
      "body": "Describe RCandy",
      "type": "summary",
      "id": "621e5aa53a8413c65300004d",
      "ideal_answer": [
        "RCandy is a platform-independent R package for rapid, simple, and flexible visualisation of recombination events in bacterial genomes."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32860431",
        "http://www.ncbi.nlm.nih.gov/pubmed/33573696",
        "http://www.ncbi.nlm.nih.gov/pubmed/33729130",
        "http://www.ncbi.nlm.nih.gov/pubmed/32923449"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 456,
          "offsetInEndSection": 734,
          "text": "Patients were assessed according to HScore, SOFA (Sequential Organ Failure Assessment Score \u003d SOFA), MuLBSTA Score (multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hyper-tension, and age), Brescia-COVID respiratory severity scale (BCRSS). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32860431"
        },
        {
          "offsetInBeginSection": 2619,
          "offsetInEndSection": 2814,
          "text": "MuLBSTA score for viral pneumonia (multinodular infiltration, hypo-lymphocytosis, bacterial co infection, Total Leucocyte Count (TLC ≤ 0.8 x 109/L), smoking history, hyper-tension and age) score.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33573696"
        },
        {
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1994,
          "text": "There were significantly differences in ages (years old: 43±13 vs. 57±13), the proportion of patients with one chronic disease (17.7% vs. 55.6%), C-reactive protein [CRP (mg/L): 7.3 (2.3, 21.0) vs. 40.1 (18.8, 62.6)], lymphocyte count [LYM (×109/L): 1.3 (1.0, 1.8) vs. 0.8 (0.7, 1.1)], the neutrophil/lymphocyte ratio [NLR: 2.1 (1.6, 3.0) vs. 3.1 (2.2, 8.8)] and multilobularinltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hyper-tension and age [MuLBSTA score: 5.0 (3.0, 5.0) vs. 5.0 (5.0, 7.0)] between mild/common group and severe/critical group (all P \u003c 0.05). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33729130"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 812,
          "text": "g admission. The Multi-lobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age (MuLBSTA) Score and Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65) score were used to assess the death and intensive care unit (ICU) risks in all patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923449"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 673,
          "text": "The Multi-lobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age (MuLBSTA) Score and Confusion, Urea,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923449"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 812,
          "text": "The Multi-lobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age (MuLBSTA) Score and Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65) score were used to assess the death and intensive care unit (ICU) risks in all patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923449"
        }
      ],
      "body": "What variables are included in the MuLBSTA score?",
      "type": "list",
      "id": "61fbca4bc9dfcb9c09000011",
      "ideal_answer": [
        "MuLBSTA score includes Multilobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age."
      ],
      "exact_answer": [
        [
          "Multilobular infiltration"
        ],
        [
          "hypo-Lymphocytosis"
        ],
        [
          "Bacterial coinfection"
        ],
        [
          "Smoking history"
        ],
        [
          "hyper-Tension"
        ],
        [
          "Age"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31552661",
        "http://www.ncbi.nlm.nih.gov/pubmed/31642470",
        "http://www.ncbi.nlm.nih.gov/pubmed/32185395",
        "http://www.ncbi.nlm.nih.gov/pubmed/29069413",
        "http://www.ncbi.nlm.nih.gov/pubmed/29761466"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "The nematode C. elegans is a useful model organism for studying neuronal development and function due to its extremely simple, well-defined nervous system, translucence, short life cycle, and abundance of genetic tools (WormBase. http://wormbase.org , 2018; WormBook.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31552661"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "WormBase (https://wormbase.org/) is a mature Model Organism Information Resource supporting researchers using the nematode Caenorhabditis elegans as a model system for studies across a broad range of basic biological processes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31642470"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 593,
          "text": "WormBase (WB), the authoritative repository for research data on Caenorhabditis elegans and other nematodes, uses text mining (TM) to semi-automate its curation pipeline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32185395"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 423,
          "text": "WormBase continues to advance its practices on data acquisition, curation and retrieval to most effectively deliver comprehensive knowledge about Caenorhabditis elegans, and genomic information about other nematodes and parasitic flatworms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "WormBase ( www.wormbase.org ) provides the nematode research community with a centralized database for information pertaining to nematode genes and genomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29761466"
        }
      ],
      "body": "Which organisms are the focus of the Wormbase?",
      "type": "list",
      "id": "622cebe13a8413c65300009d",
      "ideal_answer": [
        "WormBase continues to advance its practices on data acquisition, curation and retrieval to most effectively deliver comprehensive knowledge about Caenorhabditis elegans, and genomic information about other nematodes and parasitic flatworms."
      ],
      "exact_answer": [
        [
          "Caenorhabditis elegans"
        ],
        [
          "nematodes"
        ],
        [
          "parasitic flatworms"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31674718",
        "http://www.ncbi.nlm.nih.gov/pubmed/32712102",
        "http://www.ncbi.nlm.nih.gov/pubmed/21558899",
        "http://www.ncbi.nlm.nih.gov/pubmed/18230377",
        "http://www.ncbi.nlm.nih.gov/pubmed/28944145",
        "http://www.ncbi.nlm.nih.gov/pubmed/6575436",
        "http://www.ncbi.nlm.nih.gov/pubmed/23775022",
        "http://www.ncbi.nlm.nih.gov/pubmed/24374844"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 313,
          "text": "AC develops pulmonary metastasis in about one third of the patients and reveals a poor prognosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31674718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Ameloblastomas are benign but locally invasive neoplasms which may grow to massive proportions and cause significant morbidity. Although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32712102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Ameloblastoma of the maxilla is a rare odontogenic tumor that rarely metastasizes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21558899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Ameloblastoma is an odontogenic tumor, usually benign, which rarely metastasizes to distant organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18230377"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 218,
          "text": "Although ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374844"
        },
        {
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "text": "The World Health Organization (WHO) has defined malignant ameloblastoma (MA) as a histologically benign-appearing ameloblastoma that has metastasized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944145"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 250,
          "text": "Distant metastasis is a very rare condition and is designated as metastasizing (malignant) ameloblastoma despite its benign histological appearance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23775022"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Ameloblastoma is a locally invasive, histologically nonmalignant tumor that may on very rare occasions give rise to metastases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6575436"
        }
      ],
      "type": "yesno",
      "body": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?",
      "id": "622901d23a8413c65300008c",
      "ideal_answer": [
        "Ameloblastomas are benign but locally invasive neoplasms which can be metastatic"
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34620745"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 391,
          "text": "In this work, we investigated the role and regulatory mechanism of lncRNA prostate cancer-associated transcript 6 (PCAT6) in breast cancer progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620745"
        }
      ],
      "body": "What does PCAT6 stand for?",
      "type": "factoid",
      "id": "622668b13a8413c653000088",
      "ideal_answer": [
        "PCAT6 stands for prostate cancer-associated transcript 6."
      ],
      "exact_answer": [
        [
          "rostate cancer-associated transcript 6"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30626972"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 1269,
          "text": "Chromatin conformation capture using in situ Hi-C on fluorescence-activated cell-sorted olfactory sensory neurons and their progenitors shows that olfactory receptor gene clusters from 18 chromosomes make specific and robust interchromosomal contacts that increase with differentiation of the cells. These contacts are orchestrated by intergenic olfactory receptor enhancers, the \u0027Greek islands\u0027, which first contribute to the formation of olfactory receptor compartments and then form a multi-chromosomal super-enhancer that associates with the single active olfactory receptor gene. The Greek-island-bound transcription factor LHX2 and adaptor protein LDB1 regulate the assembly and maintenance of olfactory receptor compartments, Greek island hubs and olfactory receptor transcription, providing mechanistic insights into and functional support for the role of trans interactions in gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30626972"
        }
      ],
      "body": "Is there any role of the \u0027Greek islands\u0027 in olfactory receptor choice?",
      "type": "yesno",
      "id": "620157bec9dfcb9c09000025",
      "ideal_answer": [
        "Yes. \u0027Greek islands\u0027 first contribute to the formation of olfactory receptor compartments and then form a multi-chromosomal super-enhancer that associates with the single active olfactory receptor gene. The Greek-island-bound transcription factor LHX2 and adaptor protein LDB1 regulate the assembly and maintenance of olfactory receptor compartments, Greek island hubs and olfactory receptor transcription, providing mechanistic insights into and functional support for the role of trans interactions in gene expression."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34431455",
        "http://www.ncbi.nlm.nih.gov/pubmed/31706753",
        "http://www.ncbi.nlm.nih.gov/pubmed/32208843",
        "http://www.ncbi.nlm.nih.gov/pubmed/30077603",
        "http://www.ncbi.nlm.nih.gov/pubmed/28236594",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649218",
        "http://www.ncbi.nlm.nih.gov/pubmed/23559264",
        "http://www.ncbi.nlm.nih.gov/pubmed/23493731",
        "http://www.ncbi.nlm.nih.gov/pubmed/29994736"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 724,
          "offsetInEndSection": 870,
          "text": "RESULTS: : Among all the scales, the ASTRAL score had the best accuracy for predicting 2-year prognosis in Chinese patients with ischemic stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431455"
        },
        {
          "offsetInBeginSection": 1356,
          "offsetInEndSection": 1628,
          "text": "CONCLUSION: : The ASTRAL score had higher efficacy than the SPAN-100 and THRIVE scores in predicting 2-year adverse outcomes among Chinese patients with ischemic stroke, suggesting that it could be a valuable risk assessment tool for the 2-year prognosis of such patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431455"
        },
        {
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1307,
          "text": "CONCLUSIONS: The ASTRAL score was an independent predictor of 3-month functional outcome and showed high predictive accuracy in patients with ESUS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31706753"
        },
        {
          "offsetInBeginSection": 501,
          "offsetInEndSection": 1060,
          "text": "We first validated point-based stroke prognostic scores (preadmission comorbidities, level of consciousness, age, and neurological deficit [PLAN] score, ischemic stroke predictive risk score [IScore], and acute stroke registry and analysis of Lausanne [ASTRAL] score in all patients; Houston intraarterial recanalization therapy [HIAT] score, totaled health risks in vascular events [THRIVE] score, and stroke prognostication using age and National Institutes of Health Stroke Scale-100 [SPAN-100] in patients who received reperfusion therapy) in our cohort. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32208843"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "The Prognostic Value of the THRIVE Score, the iScore Score and the ASTRAL Score in Chinese Patients With Acute Ischemic Stroke.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077603"
        },
        {
          "offsetInBeginSection": 83,
          "offsetInEndSection": 251,
          "text": "Many prediction tools have been developed to predict the risk of poor outcomes in patients after AIS, such as the THRIVE score, the iScore score, and the ASTRAL score. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077603"
        },
        {
          "offsetInBeginSection": 1786,
          "offsetInEndSection": 2012,
          "text": "CONCLUSIONS: The iScore score and the ASTRAL score reliably predict 1-year poor outcomes in Chinese patients with AIS, and the iScore score can accurately predict 1-year mortality and severe disability in Chinese AIS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "The Prognostic Value of the iScore, the PLAN Score, and the ASTRAL Score in Acute Ischemic Stroke.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28236594"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 467,
          "text": "In this study, we evaluated the ability of 3 prognostic models including the iScore, the PLAN score, and the ASTRAL score in predicting clinical poor outcomes or mortality at 6 months in patients with acute ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28236594"
        },
        {
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1351,
          "text": "CONCLUSIONS: The results of this study suggest that the iScore, the PLAN score, and the ASTRAL score were equal in predicting 6-month poor prognosis and mortality in patients with acute ischemic stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28236594"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 450,
          "text": "THODS: Logistic regression was performed in the derivation cohort of previously independent patients with AIS (Acute Stroke Registry and Analysis of Lausanne [ASTRAL]) to identify predictors of unfavorable outcome (3-month modified Rankin Scale score \u003e2). A",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND AND PURPOSE: The ASTRAL score was recently introduced as a prognostic tool for acute ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23493731"
        },
        {
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1265,
          "text": "SIONS: ASTRAL score is a reliable tool to predict unfavorable outcome at 3 and 12 months after acute ischemic stroke in the Chinese population. It is",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23493731"
        },
        {
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1188,
          "text": "C-statistic of the ASTRAL score for the 2-year primary outcome was 0.79 (95% confidence interval [CI]: 0.78-0.80), and the Hosmer-Lemeshow goodness-of-fit test showed that the ASTRAL score fitted Chinese patients with ischemic stroke well (χ2 \u003d 9.83, P \u003d 0.277). The incidences of the primary outcome in the \u003c5%, 5",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431455"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559264"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 389,
          "text": "n the last five years, several scores such as the ASTRAL, DRAGON, and THRIVE have been proposed as tools to help physicians predict the patient functional outcome after a stroke. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29994736"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 548,
          "text": " So, this study aimed to determine the ability of the THRIVE score, the iScore score, and the ASTRAL score in predicting clinical poor outcomes in Chinese patients with AIS at 1 year",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077603"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 249,
          "text": " Many prediction tools have been developed to predict the risk of poor outcomes in patients after AIS, such as the THRIVE score, the iScore score, and the ASTRAL score",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "ASTRAL score predicts 5-year dependence and mortality in acute ischemic stroke.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559264"
        }
      ],
      "body": "What is ASTRAL Score?",
      "type": "summary",
      "id": "62008456c9dfcb9c0900001e",
      "ideal_answer": [
        "ASTRAL Score is used to predict prognosis of stroke patients."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32193744",
        "http://www.ncbi.nlm.nih.gov/pubmed/30609675",
        "http://www.ncbi.nlm.nih.gov/pubmed/22807029"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 899,
          "offsetInEndSection": 1329,
          "text": "Western blotting assays presented upregulated expressions of TNF receptor-activating factor 6 (TRAF6) and integrin β3 induced by gingipains and RANKL compared to RANKL alone. Enhanced integrin-related signaling was also demonstrated by elevated phosphorylations of FAK and paxillin compared to control. Moreover, the pit resorption assays showed that gingipains augmented bone resorptive function of osteoclasts induced by RANKL. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32193744"
        },
        {
          "offsetInBeginSection": 1192,
          "offsetInEndSection": 1253,
          "text": "paxillin levels induced by RANKL in murine bone marrow cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30609675"
        },
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 776,
          "text": "RANKL promotes paxillin serine and tyrosine phosphorylation,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22807029"
        }
      ],
      "body": "Is paxillin affected by RANKL?",
      "type": "yesno",
      "id": "622dc4b63a8413c6530000a4",
      "ideal_answer": [
        "Yes,\nRANKL promotes paxillin serine and tyrosine phosphorylation."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32350585",
        "http://www.ncbi.nlm.nih.gov/pubmed/32686748",
        "http://www.ncbi.nlm.nih.gov/pubmed/12385930",
        "http://www.ncbi.nlm.nih.gov/pubmed/14562287",
        "http://www.ncbi.nlm.nih.gov/pubmed/26439747",
        "http://www.ncbi.nlm.nih.gov/pubmed/25189638",
        "http://www.ncbi.nlm.nih.gov/pubmed/25228336",
        "http://www.ncbi.nlm.nih.gov/pubmed/17277764",
        "http://www.ncbi.nlm.nih.gov/pubmed/30363387",
        "http://www.ncbi.nlm.nih.gov/pubmed/22367295",
        "http://www.ncbi.nlm.nih.gov/pubmed/15475927",
        "http://www.ncbi.nlm.nih.gov/pubmed/10652560",
        "http://www.ncbi.nlm.nih.gov/pubmed/21862072"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "The Gleason score is an important parameter for clinical outcome in prostate cancer patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32686748"
        },
        {
          "offsetInBeginSection": 83,
          "offsetInEndSection": 124,
          "text": "Gleason score 8 prostate cancer patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32686748"
        },
        {
          "offsetInBeginSection": 348,
          "offsetInEndSection": 390,
          "text": "Gleason score 8 prostate cancer patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32686748"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 114,
          "text": "Men with Gleason score 9-10 prostate cancer have worse outcomes compared to those with Gleason 8 disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32350585"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "OBJECTIVES: Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a high risk of progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26439747"
        },
        {
          "offsetInBeginSection": 571,
          "offsetInEndSection": 730,
          "text": "eason score (GS) and predominant Gleason pattern were determined in prostate biopsies and in prostate tissue specimens, crosschecked by two uro-pathologists.RE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26439747"
        },
        {
          "offsetInBeginSection": 1712,
          "offsetInEndSection": 1918,
          "text": "In conclusion, cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer at radical prostatectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Accurate recognition of Gleason pattern 5 (GP5) prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst clinical outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25228336"
        },
        {
          "offsetInBeginSection": 1255,
          "offsetInEndSection": 1498,
          "text": " the first time that reelin is expressed in prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns. This suggests reelin may b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17277764"
        },
        {
          "offsetInBeginSection": 89,
          "offsetInEndSection": 426,
          "text": "ne of the recent important modifications in the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30363387"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22367295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "The Gleason score of prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15475927"
        },
        {
          "offsetInBeginSection": 935,
          "offsetInEndSection": 1093,
          "text": " frequently found in high Gleason score prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 patt",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17277764"
        },
        {
          "offsetInBeginSection": 2843,
          "offsetInEndSection": 3036,
          "text": " of prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our study is based upon a very li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10652560"
        },
        {
          "offsetInBeginSection": 713,
          "offsetInEndSection": 934,
          "text": "3 + 4 \u003d 7 and Gleason score 4 + 3 \u003d 7. Gleason score 4 + 3 \u003d 7 showed an overall correlation with pathological stage (organ confined, focal extraprostatic extension, nonfocal extraprostatic extension, seminal vesicle inva",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21862072"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 490,
          "text": "We compared the Gleason scores found on needle biopsy with the grade and stage (organ-confined, extra-prostatic extension, positive seminal vesicles or lymph nodes) at radical prostatectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14562287"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "OBJECTIVES: Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a high risk of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22367295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189638"
        },
        {
          "offsetInBeginSection": 1697,
          "offsetInEndSection": 1893,
          "text": "A were similar in normal prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations showed ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10652560"
        }
      ],
      "body": "What organ is associated with a Gleason pattern or Gleason Score?",
      "type": "factoid",
      "id": "622b9d593a8413c653000095",
      "ideal_answer": [
        "The Gleason score is an important parameter for clinical outcome in prostate cancer patients.",
        "The Gleason score is an important parameter for clinical outcome in prostate cancer patients"
      ],
      "exact_answer": [
        [
          "prostate"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34484859"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "m6A demethylase FTO suppresses pancreatic cancer tumorigenesis by demethylating PJA2 and inhibiting Wnt signaling.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484859"
        },
        {
          "offsetInBeginSection": 759,
          "offsetInEndSection": 1185,
          "text": "Reduced expression of the m6A demethylase, fat mass and obesity-associated protein (FTO), was responsible for the high levels of m6A RNA modification in pancreatic cancer. Moreover, FTO demethylated the m6A modification of praja ring finger ubiquitin ligase 2 (PJA2), thereby reducing its mRNA decay, suppressing Wnt signaling, and ultimately restraining the proliferation, invasion, and metastasis of pancreatic cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484859"
        }
      ],
      "body": "How does FTO suppress pancreatic tumorigenesis?",
      "type": "summary",
      "id": "62262b353a8413c65300007f",
      "ideal_answer": [
        "Reduced expression of the m6A demethylase, fat mass and obesity-associated protein (FTO), was responsible for the high levels of m6A RNA modification in pancreatic cancer. Moreover, FTO demethylated the m6A modification of praja ring finger ubiquitin ligase 2 (PJA2), thereby reducing its mRNA decay, suppressing Wnt signaling, and ultimately restraining the proliferation, invasion, and metastasis of pancreatic cancer cells."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34864901"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "GLYCO: a tool to quantify glycan shielding of glycosylated proteins.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864901"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 910,
          "text": "Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface. The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface. GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34864901"
        }
      ],
      "body": "Which tool has been developed to identify the glycan shielding of glycosylated proteins?",
      "type": "factoid",
      "id": "621e59ce3a8413c65300004c",
      "ideal_answer": [
        "GLYCO (GLYcan COverage) is an in silico approach to quantify the glycan shielding of a protein surface. The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface. GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.",
        "GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics."
      ],
      "exact_answer": [
        [
          "GLYCO"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33567191",
        "http://www.ncbi.nlm.nih.gov/pubmed/33713299",
        "http://www.ncbi.nlm.nih.gov/pubmed/34783452",
        "http://www.ncbi.nlm.nih.gov/pubmed/34349652",
        "http://www.ncbi.nlm.nih.gov/pubmed/33196758"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "BACKGROUND: The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33567191"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "Tirbanibulin (Klisyri®) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Tirbanibulin is a novel tubulin polymerization and Src kinase signaling inhibitor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34783452"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34349652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Tirbanibulin (Klisyri®) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis. Based on the data fro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 391,
          "text": "Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33196758"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34349652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Tirbanibulin is a novel tubulin polymerization and Src kinase signaling inhibitor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34783452"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 386,
          "text": "atment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic kerat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33196758"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Tirbanibulin (Klisyri®) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "BACKGROUND: The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinoma.METHODS: In two identically designed double-blind trials, we randomly assigned, in a 1:1 ratio, adults with actinic keratoses on the face or scalp to receive either topical tirbanibulin or vehicl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33567191"
        }
      ],
      "body": "What are the targets of Tirbanibulin?",
      "type": "list",
      "id": "61f7ceeb882a024a1000002e",
      "ideal_answer": [
        "Tirbanibulin is Src kinase signaling inhibitor and tubulin polymerisation inhibitor that is being developed for the topical treatment of actinic keratosis, and psoriasis."
      ],
      "exact_answer": [
        [
          "Src kinase signaling"
        ],
        [
          "tubulin polymerisation"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33484131",
        "http://www.ncbi.nlm.nih.gov/pubmed/33199363",
        "http://www.ncbi.nlm.nih.gov/pubmed/34575030"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Systematic Quantification of Neurotrophic Adipokines RBP4, PEDF, and Clusterin in Human Cerebrospinal Fluid and Serum.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33484131"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 150,
          "text": "Retinol-binding protein 4 (RBP4) is a prominent adipokine i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33199363"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 105,
          "text": "Fetuin-A and retinol-binding protein 4 (RBP4) are secreted as both hepatokine and adipokine. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34575030"
        }
      ],
      "body": "Is retinol binding protein 4 an adipokine?",
      "type": "yesno",
      "id": "622b95dc3a8413c653000092",
      "ideal_answer": [
        "Yes,\nRetinol-binding protein 4 (RBP4) is a prominent adipokine."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34482423",
        "http://www.ncbi.nlm.nih.gov/pubmed/34605540",
        "http://www.ncbi.nlm.nih.gov/pubmed/33373621",
        "http://www.ncbi.nlm.nih.gov/pubmed/33503260",
        "http://www.ncbi.nlm.nih.gov/pubmed/8887638",
        "http://www.ncbi.nlm.nih.gov/pubmed/17701549",
        "http://www.ncbi.nlm.nih.gov/pubmed/31939443",
        "http://www.ncbi.nlm.nih.gov/pubmed/22348305",
        "http://www.ncbi.nlm.nih.gov/pubmed/18325350",
        "http://www.ncbi.nlm.nih.gov/pubmed/22107958",
        "http://www.ncbi.nlm.nih.gov/pubmed/23181164",
        "http://www.ncbi.nlm.nih.gov/pubmed/27959382",
        "http://www.ncbi.nlm.nih.gov/pubmed/21473739",
        "http://www.ncbi.nlm.nih.gov/pubmed/19439223",
        "http://www.ncbi.nlm.nih.gov/pubmed/34339740",
        "http://www.ncbi.nlm.nih.gov/pubmed/16462773",
        "http://www.ncbi.nlm.nih.gov/pubmed/21873975",
        "http://www.ncbi.nlm.nih.gov/pubmed/26377036",
        "http://www.ncbi.nlm.nih.gov/pubmed/34322202",
        "http://www.ncbi.nlm.nih.gov/pubmed/20501657",
        "http://www.ncbi.nlm.nih.gov/pubmed/19119918",
        "http://www.ncbi.nlm.nih.gov/pubmed/15809329",
        "http://www.ncbi.nlm.nih.gov/pubmed/12511571",
        "http://www.ncbi.nlm.nih.gov/pubmed/15743416",
        "http://www.ncbi.nlm.nih.gov/pubmed/18555605",
        "http://www.ncbi.nlm.nih.gov/pubmed/30370001",
        "http://www.ncbi.nlm.nih.gov/pubmed/11301010",
        "http://www.ncbi.nlm.nih.gov/pubmed/15855052",
        "http://www.ncbi.nlm.nih.gov/pubmed/18550526",
        "http://www.ncbi.nlm.nih.gov/pubmed/21812759"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 54,
          "text": "Regulatory mechanisms of heme regulatory protein BACH1",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482423"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 306,
          "text": "(BACH1) is the first mammalian heme-binding transcription factor that belongs to the basic region leucine zipper (bZIP) family and a member of CNC (cap \u0027n\u0027 collar)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482423"
        },
        {
          "offsetInBeginSection": 530,
          "offsetInEndSection": 613,
          "text": "BACH1 is a ubiquitous master regulator of the cellular response to oxidative stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34605540"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Bach1 is a known transcriptional repressor of the heme oxygenase-1 (HO-1) gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33373621"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 345,
          "text": "Here, we report a transcription factor BACH1,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33503260"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8887638"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 436,
          "text": "we have identified two novel bZip transcription factors, Bach1 and Bach2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8887638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Bach1, a heme-dependent transcription factor, reveals presence of multiple heme binding sites with distinct coordination structure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701549"
        },
        {
          "offsetInBeginSection": 324,
          "offsetInEndSection": 507,
          "text": "Proteomics analysis of Bach1 complex revealed its interaction with p19(ARF), a tumor suppressor that competitively inhibited the Bach1-p53 interaction when overexpressed within cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22348305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Bach1 is a transcriptional repressor which modulates several critical transcriptional responses, such as the expression of the heme oxygenase-1 (HO-1) gene in response to oxidative stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 141,
          "text": "Bach1 is a mammalian transcriptional repressor of HO-1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325350"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 238,
          "text": "Bach1 is an important transcriptional repressor that acts by modulating oxidative stress and represents a potential target in the treatment of pulmonary fibrosis (PF).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27959382"
        },
        {
          "offsetInBeginSection": 801,
          "offsetInEndSection": 1019,
          "text": "Overexpression of Bach1, together with MafK, represses basal and UVA-mediated HO-1 protein expression, whereas silencing of the Bach1 gene by Bach1-specific siRNAs causes robust enhancement of constitutive HO-1 levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107958"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "BTB and CNC homologue 1 (Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473739"
        },
        {
          "offsetInBeginSection": 447,
          "offsetInEndSection": 680,
          "text": "tly, BTB and CNC homology 1 (BACH1), a heme-regulated transcription factor that represses genes involved in iron and heme metabolism in normal cells, was shown to shape the metabolism and metastatic potential of cancer cells. The gro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34339740"
        },
        {
          "offsetInBeginSection": 569,
          "offsetInEndSection": 724,
          "text": "reveal BACH1 as a novel let-7-regulated transcription factor that induces matrix metalloproteinase1 (MMP1) expression and promotes metastasis. An RKIP path",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21873975"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 529,
          "text": "tory. The BTB and CNC homology 1 (BACH1) protein is known to regulate α- and β-globin gene transcriptions during the terminal differentiation of erythroid ce",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26377036"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "BACH1 recruits NANOG and histone H3 lysine 4 methyltransferase MLL/SET1 complexes to regulate enhancer-promoter activity and maintains pluripotency",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33503260"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Bach1 functions as a transcriptional repressor of heme oxygenase-1 (HO-1) and the beta-globin genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15809329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12511571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Bach1 is a transcriptional repressor of the cytoprotective enzyme heme oxygenase-1 (HO-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15743416"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 538,
          "text": "Bach1 is a transcriptional repressor of the HO-1 gene, and plays a critical role in tissue protection from oxidative stress by reperfusion injury of the myocardium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555605"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 291,
          "text": "Bach1 is a transcriptional repressor of the HO-1 gene (Hmox-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Bach1 as a regulator of mitosis, beyond its transcriptional function.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Bach1 is a transcriptional repressor of the heme oxygenase (HO)-1 gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19439223"
        },
        {
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1303,
          "text": "Thus, Bach1 plays an important role in regulating the constitutive and inducible expression levels of HO-1 in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555605"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 492,
          "text": "BACH1 plays important roles both in phosphorylated as well as dephosphorylated state and functions in coordination with multiple signaling molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322202"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "text": "he Maf recognition element (MARE). Because Bach1 is a repressor of the oxidative stress response, we examined the function(s) of Bach1 in keratinocyte",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "The transcription factor BTB and CNC homology 1 (Bach1) is widely expressed in most mammalian tissues and functions primarily as a transcriptional suppressor by heterodimerizing with small Maf proteins and binding to Maf recognition elements in the promoters of targeted genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370001"
        },
        {
          "offsetInBeginSection": 1205,
          "offsetInEndSection": 1357,
          "text": "Therefore, Bach1 functions as a hypoxia-inducible repressor for the HO-1 gene, thereby contributing to fine-tuning of oxygen homeostasis in human cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12511571"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 436,
          "text": "Thus, BACH1 is a likely candidate for mediating BRCA1 DNA repair and tumor suppression functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11301010"
        },
        {
          "offsetInBeginSection": 715,
          "offsetInEndSection": 990,
          "text": "Transcription factor BACH1 [BTB (broad-complex, tramtrack and bric-a-brac) and CNC (cap\u0027n\u0027collar protein) homology 1] binds to ARE-like sequences, functioning as a transcriptional repressor in a subset of ARE-regulated genes, thus antagonizing the activator function of Nrf2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759"
        },
        {
          "offsetInBeginSection": 1145,
          "offsetInEndSection": 1336,
          "text": "The loss of BACH1 function in human keratinocytes results almost exclusively in HMOX1 induction, suggesting that BACH1 may function as a rheostat regulating levels of intracellular free heme.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550526"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "BACH1 is a DNA repair protein supporting BRCA1 damage response.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16462773"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 205,
          "text": "The N-terminus of BACH1 functions in DNA metabolism as DNA-dependent ATPase and helicase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Bach1 is a transcriptional repressor of heme oxygenase-1, one of the most inducible phase 2 proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15855052"
        },
        {
          "offsetInBeginSection": 750,
          "offsetInEndSection": 870,
          "text": "Our findings suggest that Bach1 might mediate the regulation of mitotic chromosomes under conditions of cellular stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 302,
          "text": "In our recent study, we found that Bach1 possesses a novel role in mitotic chromosome alignment during metaphase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181164"
        },
        {
          "offsetInBeginSection": 6,
          "offsetInEndSection": 290,
          "text": "The purpose of this study was to investigate the potential correlation between metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and the transcription factor BTB and CNC homology 1 (BACH1) and their clinicopathological significance in triple-negative breast cancer (TNBC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31939443"
        }
      ],
      "body": "What is the function of BACH1",
      "type": "summary",
      "id": "622cbb4e3a8413c65300009a",
      "ideal_answer": [
        "BACH1) is the first mammalian heme-binding transcription factor that belongs to the basic region leucine zipper (bZIP) family and a member of CNC (cap \u0027n\u0027 collar"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34667080"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 569,
          "text": "We found that epidermal growth factor (EGF)-deficient cells exhibited lower basal ERK activity than the cells deficient in heparin-binding EGF (HBEGF), transforming growth factor alpha (TGFα) or epiregulin (EREG), but all cell lines deficient in a single EGFR ligand retained the ERK activation waves.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34667080"
        }
      ],
      "body": "What does the gene symbol EREG stand for?",
      "type": "factoid",
      "_body": "epiregulin",
      "_type": "factoid",
      "id": "6237a5513a8413c6530000b0",
      "ideal_answer": [
        "The gene symbol EREG stands for the gene epiregulin."
      ],
      "exact_answer": [
        [
          "epiregulin"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27048983"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048983"
        },
        {
          "offsetInBeginSection": 355,
          "offsetInEndSection": 1018,
          "text": "Here we report a profile Hidden Markov Model based method capable of detecting Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have been described to date, and further classifies these proteins based on their position in respect to the membrane, either as peripheral or transmembrane. MBPpred is available online at http://bioinformatics.biol.uoa.gr/MBPpred. This method was applied in selected eukaryotic proteomes, in order to examine the characteristics they exhibit in various eukaryotic kingdoms and phyla.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048983"
        }
      ],
      "body": "Which tool has been developed for proteome-wide detection of membrane lipid-binding proteins?",
      "type": "factoid",
      "id": "62005e02c9dfcb9c09000018",
      "ideal_answer": [
        "MBPpred is a profile Hidden Markov Model based method capable of detecting Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence."
      ],
      "exact_answer": [
        [
          "MBPpred"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34473462",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484454",
        "http://www.ncbi.nlm.nih.gov/pubmed/34553355",
        "http://www.ncbi.nlm.nih.gov/pubmed/33164993",
        "http://www.ncbi.nlm.nih.gov/pubmed/34224265",
        "http://www.ncbi.nlm.nih.gov/pubmed/33596356",
        "http://www.ncbi.nlm.nih.gov/pubmed/29718732",
        "http://www.ncbi.nlm.nih.gov/pubmed/32088663",
        "http://www.ncbi.nlm.nih.gov/pubmed/28400446",
        "http://www.ncbi.nlm.nih.gov/pubmed/33128347",
        "http://www.ncbi.nlm.nih.gov/pubmed/33625803",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826105",
        "http://www.ncbi.nlm.nih.gov/pubmed/34006155"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1397,
          "text": "Current therapies are often effective in inducing and maintaining remission but are associated with a range of toxicities. Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial and may play a role in reducing the cumulative glucocorticoid dose. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34473462"
        },
        {
          "offsetInBeginSection": 846,
          "offsetInEndSection": 973,
          "text": "New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a minimized steroid treatment in the future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "GPA/MPA INDUCTION OF REMISSION:  As demonstrated in the ADVOCATE-trial avacopan allows for a substantial reduction of glucocorticoid (GC) use during induction of remission. A future role of avacopan in the treatment of GPA and MPA is likely.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553355"
        },
        {
          "offsetInBeginSection": 1058,
          "offsetInEndSection": 1216,
          "text": "Avacopan has shown significant promise in ANCA-associated vasculitis as part of a glucocorticoid-free induction regimen in a recently completed phase 3 trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33164993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "SOURCE CITATION: Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609. 33596356.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 57,
          "text": "Avacopan for the Treatment of ANCA-Associated Vasculitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 1886,
          "offsetInEndSection": 2149,
          "text": "CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28400446"
        },
        {
          "offsetInBeginSection": 431,
          "offsetInEndSection": 592,
          "text": "tly, new molecules are being developed and some of them have already demonstrated clinical efficacy, such as avacopan (C5aR blocker) in ANCA vasculitis. As for k",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33625803"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 769,
          "text": "ber 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma. In October 20",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Avacopan for the treatment of ANCA-associated vasculitis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34006155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Avacopan for the Treatment of ANCA-Associated Vasculitis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 55,
          "text": "Avacopan in the treatment of ANCA-associated vasculitis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29718732"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224265"
        },
        {
          "offsetInBeginSection": 772,
          "offsetInEndSection": 1045,
          "text": " avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use). Avacopan has rece",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Avacopan (TAVNEOS™) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 938,
          "text": "al will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088663"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 57,
          "text": "Avacopan for the treatment of ANCA-associated vasculitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34006155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Avacopan in the treatment of ANCA-associated vasculitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29718732"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128347"
        },
        {
          "offsetInBeginSection": 1876,
          "offsetInEndSection": 2024,
          "text": "rednisone.CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone tap",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Avacopan (TAVNEOS™) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 439,
          "offsetInEndSection": 755,
          "text": "In September 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 756,
          "offsetInEndSection": 1027,
          "text": "In October 2021, avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 343,
          "text": "BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 470,
          "text": "OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab.METHODS: In this randomized 12-week study, twice daily avacopan (10 mg or 30 mg) plus SOC was assessed versus SOC only in patients with newly diagnosed/relapsing ANCA-as",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33128347"
        },
        {
          "offsetInBeginSection": 789,
          "offsetInEndSection": 1505,
          "text": "onephritis. This trial will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTIVE: The aim of this study is to determine the proportions of patients in remission at week 26 and with sustained remission at week 52, defined as Birmingham Vasculitis Activity Score\u003d0, and not taking glucocorticoids within the 4 weeks before week 26 and week 52, respectively.METHODS: The Avacopan Development in Vasculitis to Obtain Corticosteroid elimination and Therapeutic Efficacy study is a randomized, double-blind, active-comparator (prednisone), 2-arm study evaluating the safety and efficacy of avacopan versus prednisone, administered in combination with ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088663"
        }
      ],
      "body": "What disease can be treated with Avacopan?",
      "type": "factoid",
      "id": "61f7c883882a024a10000026",
      "ideal_answer": [
        "Avacopan is effective for ANCA-associated vasculitis."
      ],
      "exact_answer": [
        [
          "ANCA-associated vasculitis"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17683645",
        "http://www.ncbi.nlm.nih.gov/pubmed/17296793"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 292,
          "text": "Hydin was recently identified as an axonemal protein; however, its function is as yet unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17683645"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 891,
          "text": "precise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17296793"
        }
      ],
      "body": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?",
      "type": "yesno",
      "id": "622ce21d3a8413c65300009c",
      "ideal_answer": [
        "Yes,\nHYDIN is a axonemal protein."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29101454",
        "http://www.ncbi.nlm.nih.gov/pubmed/22085520",
        "http://www.ncbi.nlm.nih.gov/pubmed/11803718",
        "http://www.ncbi.nlm.nih.gov/pubmed/6983935",
        "http://www.ncbi.nlm.nih.gov/pubmed/25050151",
        "http://www.ncbi.nlm.nih.gov/pubmed/18650743",
        "http://www.ncbi.nlm.nih.gov/pubmed/6461592",
        "http://www.ncbi.nlm.nih.gov/pubmed/22744304",
        "http://www.ncbi.nlm.nih.gov/pubmed/2233790",
        "http://www.ncbi.nlm.nih.gov/pubmed/3923615",
        "http://www.ncbi.nlm.nih.gov/pubmed/32349490"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 373,
          "text": "Ankylosing spondylitis (Bechterew\u0027s disease) is the most typical form of axial SpA whereby sacroiliitis can be found on X-rays of the SI joints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22085520"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "[Special considerations in therapy of injuries of the cervical spine in ankylosing spondylitis (Bechterew disease)]",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11803718"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Ankylosing spondylitis (AS) or Bechterew disease is a chronic, usually progressive, systemic inflammatory joint disease, which predominantly affects the spine and sacroiliac joints. In ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050151"
        },
        {
          "offsetInBeginSection": 2,
          "offsetInEndSection": 106,
          "text": "iagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew\u0027s disease)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22744304"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Hyperplasia of the coronoid process in patients with ankylosing spondylitis (Bechterew disease)",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18650743"
        },
        {
          "offsetInBeginSection": 2,
          "offsetInEndSection": 115,
          "text": "pecial considerations in therapy of injuries of the cervical spine in ankylosing spondylitis (Bechterew disease)]",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11803718"
        },
        {
          "offsetInBeginSection": 2,
          "offsetInEndSection": 113,
          "text": "irected cloning of the HLA-B27 gene isolated from a patient with ankylosing spondylitis (Bechterew\u0027s disease)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2233790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 46,
          "text": "Bechterew\u0027s syndrome (ankylosing spondylitis).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3923615"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Ankylosing spondylitis (AS) or Bechterew disease is a chronic, usually progressive, systemic inflammatory joint disease, which predominantly affects the spine and sacroiliac joints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050151"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "[Ankylosing spondylitis (Bechterew\u0027s disease)--a current review (author\u0027s transl)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6461592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "The distribution of clinical findings in Bechterew\u0027s syndrome (ankylosing spondylitis) suggests distinct genetic subgroups.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6983935"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Hyperplasia of the coronoid process in patients with ankylosing spondylitis (Bechterew disease).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18650743"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "[Surgical management of ankylosing spondylitis (Bechterew\u0027s disease)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29101454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "[Diagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew\u0027s disease)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22744304"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Ankylosing spondylitis (AS) or else Bechterews or Marie-Strümpells disease is a chronic inflammatory autoimmune disease affecting preferentially the spine in the form of sacroileitis and spondylitis [1,2].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32349490"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Although involvement of the temporomandibular joint in patients with ankylosing spondylitis (AS, Bechterew disease) has been described previously",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18650743"
        }
      ],
      "body": "What disease is also known as Bechterew\u0027s Disease?",
      "type": "factoid",
      "id": "622b9e743a8413c653000097",
      "ideal_answer": [
        "Ankylosing spondylitis (Bechterew\u0027s disease) is the most typical form of axial SpA whereby sacroiliitis can be found on X-rays of the SI joints."
      ],
      "exact_answer": [
        [
          "Ankylosing spondylitis"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 724,
          "offsetInEndSection": 845,
          "text": "EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR/MAPK pathway. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30400011"
        }
      ],
      "body": "Through which pathway does epiregulin promote leptin secretion?",
      "type": "factoid",
      "id": "6237ac143a8413c6530000b7",
      "ideal_answer": [
        "EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR/MAPK pathway."
      ],
      "exact_answer": [
        [
          "EGFR/MAPK pathway"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34849585"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "spiralize: an R package for Visualizing Data on Spirals.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849585"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 584,
          "text": "Spiral layout has two major advantages for data visualization. First, it is able to visualize data with long axes, which greatly improves the resolution of visualization. Second, it is efficient for time series data to reveal periodic patterns. Here we present the R package spiralize that provides a general solution for visualizing data on spirals. spiralize implements numerous graphics functions so that self-defined high-level graphics can be easily implemented by users. The flexibility and power of spiralize are demonstrated by five examples from real-world datasets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34849585"
        }
      ],
      "body": "Are there any R packages that help with visualizing data on spirals?",
      "type": "yesno",
      "id": "621e62c33a8413c653000050",
      "ideal_answer": [
        "Yes. Spiralize is an R package for visualizing data on spirals."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33761206",
        "http://www.ncbi.nlm.nih.gov/pubmed/34029515",
        "http://www.ncbi.nlm.nih.gov/pubmed/32554928"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1662,
          "text": "During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P \u003d 0.84).CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33761206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 433,
          "text": "The advanced-phase HIV prevention vaccine trials done in South Africa (HVTN 702) and in Thailand (RV144), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results. The South African trial did not find vaccine efficacy, whereas the Thai trial had modest, but statistically significant, success with the modified intention-to-treat analysis prespecified in the protocols of both studies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34029515"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 450,
          "text": "However, with the recent failure of the HVTN 702 clinical trial, comprehensive profiling of humoral immune responses may provide insight for these disappointing results. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32554928"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 238,
          "text": "A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33761206"
        },
        {
          "offsetInBeginSection": 1228,
          "offsetInEndSection": 1567,
          "text": "e vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P \u003d 0.84).CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33761206"
        }
      ],
      "body": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?",
      "type": "yesno",
      "id": "61faa3bac9dfcb9c0900000b",
      "ideal_answer": [
        "No. The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity"
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33409873",
        "http://www.ncbi.nlm.nih.gov/pubmed/29587878",
        "http://www.ncbi.nlm.nih.gov/pubmed/30220025",
        "http://www.ncbi.nlm.nih.gov/pubmed/30247793",
        "http://www.ncbi.nlm.nih.gov/pubmed/28877915"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "The plasma glycoprotein afamin has been previously identified as an alternative carrier protein for vitamin E in extravascular fluids such as plasma and cerebrospinal, ovarian follicular, and seminal fluids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33409873"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 179,
          "text": "afamin, a vitamin E-binding protein in human plasma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29587878"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 172,
          "text": "the human vitamin E-binding protein afamin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30220025"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 61,
          "text": "Afamin is a plasma vitamin E-binding glycoprotein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30247793"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 165,
          "text": "The human vitamin E-binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877915"
        }
      ],
      "body": "Do Afamin bind Vitamin E?",
      "type": "yesno",
      "id": "622baf3f3a8413c653000099",
      "ideal_answer": [
        "Yes,\nAfamin is a plasma vitamin E-binding glycoprotein."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34412079",
        "http://www.ncbi.nlm.nih.gov/pubmed/31608721",
        "http://www.ncbi.nlm.nih.gov/pubmed/32573856",
        "http://www.ncbi.nlm.nih.gov/pubmed/34509865",
        "http://www.ncbi.nlm.nih.gov/pubmed/34599631",
        "http://www.ncbi.nlm.nih.gov/pubmed/34576285",
        "http://www.ncbi.nlm.nih.gov/pubmed/32161574",
        "http://www.ncbi.nlm.nih.gov/pubmed/34847253",
        "http://www.ncbi.nlm.nih.gov/pubmed/24520479",
        "http://www.ncbi.nlm.nih.gov/pubmed/29756666",
        "http://www.ncbi.nlm.nih.gov/pubmed/21498785",
        "http://www.ncbi.nlm.nih.gov/pubmed/30079067",
        "http://www.ncbi.nlm.nih.gov/pubmed/9272206",
        "http://www.ncbi.nlm.nih.gov/pubmed/19683334",
        "http://www.ncbi.nlm.nih.gov/pubmed/27108670",
        "http://www.ncbi.nlm.nih.gov/pubmed/34191338",
        "http://www.ncbi.nlm.nih.gov/pubmed/30058156"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 244,
          "text": " Maternal systemic and placental inflammatory responses participate in the pathogenesis of hypertensive disorders of pregnancy including preeclampsia, a pregnancy-specific syndrome, although the role of inflammation remains unclear. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34412079"
        },
        {
          "offsetInBeginSection": 588,
          "offsetInEndSection": 718,
          "text": "Our results indicate these proteins are new factors that play important roles in the immunological pathomechanism of preeclampsia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31608721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Inflammation and oxidative stress at the maternal-fetal interface characterize the placental dysfunction that underlies the pregnancy disorder preeclampsia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32573856"
        },
        {
          "offsetInBeginSection": 1119,
          "offsetInEndSection": 1265,
          "text": "The abnormal expression of Tim-3 on MDSC might be involved in the pathogenesis of PE, and could be a marker to evaluate the immune function in PE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34509865"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 408,
          "text": "Maternal immune tolerance is important for maintaining pregnancy, and researchers have increasingly focused on the critical roles of cytokines in the pathogenesis of PE in recent years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34599631"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 289,
          "text": "Disruption of well-controlled immune functions leads to infertility, placental inflammation, and numerous pregnancy complications, including preeclampsia (PE).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32161574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Effect of Endogenic and Exogenic Oxidative Stress Triggers on Adverse Pregnancy Outcomes: Preeclampsia, Fetal Growth Restriction, Gestational Diabetes Mellitus and Preterm Birth.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34576285"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 330,
          "text": "Disruption of complex immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (PE).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34847253"
        },
        {
          "offsetInBeginSection": 1203,
          "offsetInEndSection": 1427,
          "text": "In addition, it has been demonstrated that immune disturbance may be responsible for some adverse pregnancy outcomes such as preeclampsia (PE), recurrent spontaneous abortion (RSA) and intrauterine growth restriction (IUGR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24520479"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 265,
          "text": "esponse. In previous models of preeclampsia (PE), defective immune function caused by disruption of lymphangiogenesis was shown to be involved in the disease pathophy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29756666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "OBJECTIVE: Increased oxidative stress and immune dysfunction are implicated in preeclampsia (PE) and may contribute to the two- to fourfold increase in PE prevalence among women with type 1 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498785"
        },
        {
          "offsetInBeginSection": 433,
          "offsetInEndSection": 655,
          "text": "r, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differentiation of T-helper cell subsets creating a cytotoxic environment in uter",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 1654,
          "offsetInEndSection": 1808,
          "text": "a disrupted immune system might be a predisposing factor or result of placental oxidative stress or excessive inflammation in preeclampsia. Preeclampsia c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 1247,
          "offsetInEndSection": 1448,
          "text": "clude insufficient control of inflammation, failure of tolerance toward paternal antigens at the fetal-maternal interface, and subsequent over- or insufficient activation of immune mediators. It is als",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of pre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272206"
        },
        {
          "offsetInBeginSection": 1091,
          "offsetInEndSection": 1244,
          "text": "s review, we focus on the role of excessive systemic inflammation as the result of a dysregulated immune system in the development of preeclampsia. These",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of pree",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272206"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 657,
          "text": "However, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differentiation of T-helper cell subsets creating a cytotoxic environment in utero.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 1639,
          "offsetInEndSection": 1793,
          "text": "In conclusion, a disrupted immune system might be a predisposing factor or result of placental oxidative stress or excessive inflammation in preeclampsia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 264,
          "text": "esponse. In previous models of preeclampsia (PE), defective immune function caused by disruption of lymphangiogenesis was shown to be involved in the disease pathoph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29756666"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 385,
          "text": "Disruption of this immune balance and/or inadequate placental perfusion is believed to be associated with a lot of pregnancy-related complications, such as recurrent spontaneous abortion, pre-eclampsia, and fetal intrauterine growth restriction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34191338"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 530,
          "text": "Therefore, a delicate immune balance is critical for the maintenance of a successful pregnancy, while disruption of this balance can induce complications such as implantation failure, miscarriage, preterm birth/labor, preeclampsia and fetal growth restriction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30058156"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 327,
          "text": "antigens during pregnancy. Disruption of complex immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (P",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34847253"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 381,
          "text": "ccessful pregnancy. It has been demonstrated that innate immune disturbances may be responsible for some adverse pregnancy outcomes such as preeclamps",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108670"
        },
        {
          "offsetInBeginSection": 430,
          "offsetInEndSection": 580,
          "text": "ever, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of preeclampsia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272206"
        },
        {
          "offsetInBeginSection": 1079,
          "offsetInEndSection": 1323,
          "text": "However, immune maladaptation and hemostatic imbalance have been suggested to be responsible for adverse pregnant outcomes, such as preeclampsia (PE), miscarriage, recurrent spontaneous abortion (RSA) and intrauterine growth restriction (IUGR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19683334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 856,
          "text": "PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of preeclampsia.METHOD OF STUDY: The serum concentrations of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) were determined by using enzyme-linked immunoadsorbent assay (ELISA) in the first trimester of pregnancy in women who had preeclampsia develop after 28 weeks of pregnancy (preeclamptic group) and in women who completed pregnancy uneventfully (control group).RESULTS: Serum concentrations of both IL-2 and TNF-alpha in the first trimester of the preeclamptic group were significantly higher than those of the control group.CONCLUSIONS: That the perturbation of feto-maternal immune regulation may precede the clinical manifestations of preeclampsia, which may be of relevance i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272206"
        },
        {
          "offsetInBeginSection": 1794,
          "offsetInEndSection": 2009,
          "text": "Preeclampsia can thus be considered a hyperinflammatory state associated with defective regulation of the immune system proposed as a key element in the pathological events of the placental subtype of this disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079067"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 538,
          "text": "It has been demonstrated that innate immune disturbances may be responsible for some adverse pregnancy outcomes such as preeclampsia (PE); hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome; intrauterine growth restriction (IUGR); and recurrent spontaneous abortion (RSA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108670"
        }
      ],
      "body": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?",
      "type": "yesno",
      "id": "622632483a8413c653000081",
      "ideal_answer": [
        "Disruption of complex immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (PE)",
        "Inflammation and oxidative stress at the maternal-fetal interface characterize the placental dysfunction that underlies the pregnancy disorder preeclampsia."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34692467"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "A Novel Prognostic Prediction Model for Colorectal Cancer Based on Nine Autophagy-Related Long Noncoding RNAs",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34692467"
        },
        {
          "offsetInBeginSection": 1347,
          "offsetInEndSection": 1882,
          "text": "A prognostic prediction model of CRC was built based on nine ARlncRNAs (NKILA, LINC00174, AC008760.1, LINC02041, PCAT6, AC156455.1, LINC01503, LINC00957, and CD27-AS1). The 5-year overall survival rate was significantly lower in the high-risk group than in the low-risk group among train set, validation set, and all patients (all p \u003c 0.001). The model had high sensitivity and accuracy in predicting the 1-year overall survival rate (area under the curve \u003d 0.717). The prediction model risk score was an independent predictor of CRC. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34692467"
        },
        {
          "offsetInBeginSection": 2284,
          "offsetInEndSection": 2518,
          "text": "The new ARlncRNA-based model predicts CRC patient prognosis and provides new research ideas regarding potential mechanisms regulating the biological behavior of CRC. ARlncRNAs may play important roles in personalized cancer treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34692467"
        }
      ],
      "body": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?",
      "type": "yesno",
      "id": "62266c353a8413c65300008a",
      "ideal_answer": [
        "Yes, a prognostic prediction model of CRC was built based on nine ARlncRNAs (NKILA, LINC00174, AC008760.1, LINC02041, PCAT6, AC156455.1, LINC01503, LINC00957, and CD27-AS1). The 5-year overall survival rate was significantly lower in the high-risk group than in the low-risk group among train set, validation set, and all patients (all p \u003c 0.001). The model had high sensitivity and accuracy in predicting the 1-year overall survival rate (area under the curve \u003d 0.717). The prediction model risk score was an independent predictor of CRC."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31552185"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 1336,
          "text": "Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31552185"
        }
      ],
      "body": "Are there roles for cohesin mutations in AML?",
      "type": "yesno",
      "id": "621e9aa13a8413c653000053",
      "ideal_answer": [
        "Yes. Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34520956",
        "http://www.ncbi.nlm.nih.gov/pubmed/34504076",
        "http://www.ncbi.nlm.nih.gov/pubmed/34558391",
        "http://www.ncbi.nlm.nih.gov/pubmed/34553354",
        "http://www.ncbi.nlm.nih.gov/pubmed/34607583",
        "http://www.ncbi.nlm.nih.gov/pubmed/34607832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34158284",
        "http://www.ncbi.nlm.nih.gov/pubmed/34800654",
        "http://www.ncbi.nlm.nih.gov/pubmed/33547148",
        "http://www.ncbi.nlm.nih.gov/pubmed/33004338",
        "http://www.ncbi.nlm.nih.gov/pubmed/33466360",
        "http://www.ncbi.nlm.nih.gov/pubmed/33097477",
        "http://www.ncbi.nlm.nih.gov/pubmed/34776511",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590053",
        "http://www.ncbi.nlm.nih.gov/pubmed/34004237",
        "http://www.ncbi.nlm.nih.gov/pubmed/32955176",
        "http://www.ncbi.nlm.nih.gov/pubmed/34715449",
        "http://www.ncbi.nlm.nih.gov/pubmed/33971321",
        "http://www.ncbi.nlm.nih.gov/pubmed/34838325",
        "http://www.ncbi.nlm.nih.gov/pubmed/34137282",
        "http://www.ncbi.nlm.nih.gov/pubmed/34200676",
        "http://www.ncbi.nlm.nih.gov/pubmed/34675734"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 622,
          "text": "Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956"
        },
        {
          "offsetInBeginSection": 705,
          "offsetInEndSection": 881,
          "text": "Finally, we show that a selective PI4KA inhibitor augments the antineoplastic activity of the KRASG12C inhibitor sotorasib, suggesting a clinical path to exploit this pathway. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504076"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 811,
          "text": "However, clinical candidates targeting the KRAS G12C protein have recently been developed. MRTX849 and recently approved Sotorasib are covalent binders targeting the mutated cysteine 12, occupying Switch II pocket.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558391"
        },
        {
          "offsetInBeginSection": 682,
          "offsetInEndSection": 736,
          "text": "Sotorasib with efficacy in kRAS-G12C mutation of NSCLC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34553354"
        },
        {
          "offsetInBeginSection": 725,
          "offsetInEndSection": 954,
          "text": "Two such inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), were recently evaluated in phase I-III trials for the treatment of non-small cell lung cancer with KRAS-G12C mutations, heralding a new era of precision oncology. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34607583"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 616,
          "text": "The findings, along with data on the KRASG12C inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34607832"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158284"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 549,
          "text": "In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced or metastatic NSCLC, following at least one prior systemic therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34800654"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these result",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33547148"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590053"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. In the nonclinical to",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 247,
          "text": "Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33971321"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 509,
          "text": "We evaluated the clinical validity of Guardant360 CDx as a companion diagnostic for sotorasib for detection of KRAS p.G12C, an important oncogenic NSCLC driver mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34838325"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 379,
          "text": "Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34715449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KR",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mut",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 397,
          "text": "t efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. L",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33466360"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590053"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 290,
          "text": "phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097477"
        },
        {
          "offsetInBeginSection": 533,
          "offsetInEndSection": 658,
          "text": "seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34200676"
        },
        {
          "offsetInBeginSection": 560,
          "offsetInEndSection": 800,
          "text": "re have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776511"
        },
        {
          "offsetInBeginSection": 435,
          "offsetInEndSection": 629,
          "text": "gly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. To bett",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 367,
          "text": "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176"
        },
        {
          "offsetInBeginSection": 1642,
          "offsetInEndSection": 1792,
          "text": "esults of the nonclinical safety program support a high benefit/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 166,
          "text": "oved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34158284"
        },
        {
          "offsetInBeginSection": 49,
          "offsetInEndSection": 199,
          "text": "ered an \"undruggable\" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicite",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33004338"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 404,
          "text": "er cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34004237"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 621,
          "text": "Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34520956"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 513,
          "text": "Based on promising results in both preclinical and clinical trials, sotorasib, a novel KRASG12C inhibitor, was given conditional approval by the FDA in May 2021.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34675734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 290,
          "text": "In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33097477"
        },
        {
          "offsetInBeginSection": 1628,
          "offsetInEndSection": 1792,
          "text": "Overall, the results of the nonclinical safety program support a high benefit/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34137282"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32955176"
        }
      ],
      "body": "What is the target of Sotorasib?",
      "type": "factoid",
      "id": "61f7c60c882a024a10000025",
      "ideal_answer": [
        "Sotorasib is a KRASG12C inhibitor."
      ],
      "exact_answer": [
        [
          "KRASG12C"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24598821",
        "http://www.ncbi.nlm.nih.gov/pubmed/32755577",
        "http://www.ncbi.nlm.nih.gov/pubmed/23946870",
        "http://www.ncbi.nlm.nih.gov/pubmed/23869254",
        "http://www.ncbi.nlm.nih.gov/pubmed/20222959"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 231,
          "text": "Asf1, a key histone H3-H4 chaperone required for this process, is phosphorylated by Tousled-like kinases (TLKs). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "The Tousled-like kinases 1 and 2 (TLK1/2) control histone deposition through the ASF1 histone chaperone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32755577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "The Tousled-like kinases (TLKs) are involved in chromatin assembly, DNA repair, and transcription. Two TLK genes exist in humans, and their expression is often dysregulated in cancer. TLKs phosphorylate Asf1 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946870"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 264,
          "text": "TLKs interact specifically (and phosphorylate) with the chromatin assembly factor Asf1, a histone H3-H4 chaperone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23869254"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 269,
          "text": "TLK1 substrates were identified as the histone H3 and Asf1 (a histone H3/H4 chaperone)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20222959"
        }
      ],
      "body": "Is ASF1 phopshorylated by  the Tousled-like kinases?",
      "type": "yesno",
      "id": "622d0aa63a8413c6530000a0",
      "ideal_answer": [
        "Yes,\nAsf1, a key histone H3-H4 chaperone required for this process, is phosphorylated by Tousled-like kinases (TLKs)."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34717250",
        "http://www.ncbi.nlm.nih.gov/pubmed/32081041",
        "http://www.ncbi.nlm.nih.gov/pubmed/32694396",
        "http://www.ncbi.nlm.nih.gov/pubmed/34460026",
        "http://www.ncbi.nlm.nih.gov/pubmed/30280574",
        "http://www.ncbi.nlm.nih.gov/pubmed/27170112",
        "http://www.ncbi.nlm.nih.gov/pubmed/24477342",
        "http://www.ncbi.nlm.nih.gov/pubmed/33469821",
        "http://www.ncbi.nlm.nih.gov/pubmed/30119240",
        "http://www.ncbi.nlm.nih.gov/pubmed/20074346",
        "http://www.ncbi.nlm.nih.gov/pubmed/29928143",
        "http://www.ncbi.nlm.nih.gov/pubmed/31994822",
        "http://www.ncbi.nlm.nih.gov/pubmed/32407927",
        "http://www.ncbi.nlm.nih.gov/pubmed/16140950",
        "http://www.ncbi.nlm.nih.gov/pubmed/18991571",
        "http://www.ncbi.nlm.nih.gov/pubmed/27016074",
        "http://www.ncbi.nlm.nih.gov/pubmed/29207088",
        "http://www.ncbi.nlm.nih.gov/pubmed/23317200",
        "http://www.ncbi.nlm.nih.gov/pubmed/22203870",
        "http://www.ncbi.nlm.nih.gov/pubmed/22269172",
        "http://www.ncbi.nlm.nih.gov/pubmed/18937165",
        "http://www.ncbi.nlm.nih.gov/pubmed/31019613",
        "http://www.ncbi.nlm.nih.gov/pubmed/26020516",
        "http://www.ncbi.nlm.nih.gov/pubmed/27185356",
        "http://www.ncbi.nlm.nih.gov/pubmed/21881237",
        "http://www.ncbi.nlm.nih.gov/pubmed/12027807",
        "http://www.ncbi.nlm.nih.gov/pubmed/26246742",
        "http://www.ncbi.nlm.nih.gov/pubmed/10972088",
        "http://www.ncbi.nlm.nih.gov/pubmed/24353826"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Recently, many studies have reported the anticancer properties of flavonoid luteolin against a variety of tumors, but there is still a lack in the description of its mechanism of action",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32081041"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 319,
          "text": "Luteolin, a polyphenolic flavonoid, has potent anti-inflammatory properties. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32694396"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 265,
          "text": "Luteolin is a falconoid compound that has an antioxidant effect, but its mechanism in I/R injury in vivo and in vitro is still under explored.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34460026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Luteolin is a naturally occurring flavone that reportedly has anti-inflammatory effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27170112"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Luteolin is a flavonoid present in plants in the form of aglycone or glucosides.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30280574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "Luteolin, a naturally occurring flavonoid, possesses anti-cancer activities against several human cancers, but the exact molecular and biochemical mechanisms of above findings are not very clear, and its activity against head and neck squamous cell carcinoma (HNSCC) is seldom mentioned. In thi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24477342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Luteolin is a flavonoid with antioxidant properties already demonstrated in studies related to inflammation, tumor, and cardiovascular processes; however, there are no available information regarding its antioxidant effects at the venous endothelial site. We ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33469821"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 258,
          "text": "Luteolin (3\u0027,4\u0027,5,7-tetrahydroxyflavone) is a phytochemical found frequently in medicinal herbs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32407927"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 228,
          "text": "Luteolin is a dietary flavonoid commonly found in some medicinal plants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140950"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 393,
          "text": "Luteolin (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone), is a naturally occurring flavonoid found in fruits and vegetables that exhibits many anticancer properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29928143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Luteolin, 3\u0027,4\u0027,5,7-tetrahydroxyflavone, is a common flavonoid that exists in many types of plants including fruits, vegetables, and medicinal herbs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Luteolin is a common dietary flavonoid present in Chinese herbal medicines that has been reported to have important anti-inflammatory properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27016074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Luteolin is a falconoid compound that is present in various types of plants and possesses remarkable potential as a chemopreventive agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29207088"
        },
        {
          "offsetInBeginSection": 75,
          "offsetInEndSection": 166,
          "text": "Luteolin is a natural flavonoid widely distributed in plants with anti-inflammatory effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30119240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Luteolin is a plant flavonoid which exhibits anti-oxidative, anti-inflammatory and anti-tumor effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23317200"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 229,
          "text": "Luteolin is an anti-inflammatory flavonoid and widely distributed in the plants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22203870"
        },
        {
          "offsetInBeginSection": 34,
          "offsetInEndSection": 184,
          "text": "ucial in the pathogenesis of numerous brain disorders. Luteolin, a flavonoid compound, inhibits glutamate release, however, its ability to affect glut",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27185356"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 249,
          "text": "depression and endoplasmic reticulum stress. Luteolin is a flavonoid contained in many plants and with a variety of known pharmacological properties s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881237"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 171,
          "text": " common multiple infection disease under 2 years old. Luteolin is a natural flavonoid widely distributed in plants with anti-inflammatory effect. This",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30119240"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 360,
          "text": "Luteolin is a naturally occurring flavonoid with diverse pharmacological properties such as anti-inflammatory, antioxidant and anticancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "BACKGROUND: Luteolin is a 3\u0027,4\u0027,5,7-tetrahydroxyflavone found in various fruits and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22269172"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Luteolin is a bioflavonoid that attenuates adipocyte-derived inflammatory responses via suppression of nuclear factor-κB/mitogen-activated protein kinases pathway.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Background: Luteolin (3\u0027,4\u0027,5,7-tetrahydroxyflavone) is a flavone with a yellow crystalline appearance present in numerous plants such as broccoli, green chili,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31019613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Luteolin is a flavone which occurs in medicinal plants as well as in some vegetables and spices.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18937165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Luteolin, a flavonoid with potential for cancer prevention and therapy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18991571"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 563,
          "text": "I diabetes. Luteolin is a bioflavonoid with many beneficial properties such as antioxidant, antiproliferative, and anti-cancer.OBJECTIVES: To elucidate the potential anti-inflammatory response and the underlying mechanism of luteolin in 3T3-L1 adipocytes.MATERIALS AND METHODS: We stimulated 3T3-L1 adipocytes with the mixture of tumor necrosis factor-α, lipopolysaccharide, and interferon-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12027807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10972088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Luteolin is a natural flavonoid with strong anti-oxidative properties that is reported to have an anti-cancer effect in several malignancies other than bladder cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31994822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Luteolin is a flavonoid found in abundance in celery, green pepper, and dandelions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24353826"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND: Luteolin, a plant derived flavonoid, exerts a variety of pharmacological activities and anti-oxidant properties associated with its capacity to scavenge oxygen and nitro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20074346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12027807"
        },
        {
          "offsetInBeginSection": 714,
          "offsetInEndSection": 809,
          "text": "The flavonoid luteolin shows therapeutic potential with low incidence of unwanted side effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26020516"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 370,
          "text": "Luteolin is a flavonoid contained in many plants and with a variety of known pharmacological properties such as anti-inflammatory, anti-anxiety, and memory-improving effects, suggesting that luteolin penetrates into the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881237"
        }
      ],
      "body": "What is Luteolin?",
      "type": "factoid",
      "id": "6226335d3a8413c653000082",
      "ideal_answer": [
        "Luteolin has been reviewed as a flavonoid possessing potential cardioprotective, anti-inflammatory, anti-cancer activities.",
        "Luteolin, a polyphenolic flavonoid, has potent anti-inflammatory properties."
      ],
      "exact_answer": [
        [
          "flavonoid"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33189864"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1971,
          "offsetInEndSection": 2128,
          "text": "S1P-induced FOXO1 and EREG gene expression suggests that the activation of S1P-S1PR axis may cooperate with gonadotropins in modulating follicle development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33189864"
        },
        {
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1627,
          "text": "S1P-dependent CREB phosphorylation induced FOXO1 and the EGF-like epiregulin-encoding gene (EREG), confirming the exclusive role of gonadotropins and interleukins in this process, but did not affect steroidogenesis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33189864"
        }
      ],
      "body": "Does sphingosine-1 phosphoate suppress epiregulin?",
      "type": "yesno",
      "id": "6237a6e93a8413c6530000b1",
      "ideal_answer": [
        "Sphingosine-1 phosphate induces epiregulin (EREG) gene expression."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34788791"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "PheneBank: a literature-based database of phenotypes.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788791"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 772,
          "text": "PheneBank is a Web-portal for retrieving human phenotype-disease associations that have been text-mined from the whole of Medline. Our approach exploits state-of-the-art machine learning for concept identification by utilising an expert annotated rare disease corpus from the PMC Text Mining subset. Evaluation of the system for entities is conducted on a gold-standard corpus of rare disease sentences and for associations against the Monarch initiative data.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788791"
        }
      ],
      "body": "Which is the literature-based database of phenotypes?",
      "type": "factoid",
      "id": "621e63a43a8413c653000051",
      "ideal_answer": [
        "PheneBank is a Web-portal for retrieving human phenotype-disease associations that have been text-mined from the whole of Medline. This approach exploits state-of-the-art machine learning for concept identification by utilising an expert annotated rare disease corpus from the PMC Text Mining subset. Evaluation of the system for entities is conducted on a gold-standard corpus of rare disease sentences and for associations against the Monarch initiative data.",
        "PheneBank is a Web-portal for retrieving human phenotype-disease associations that have been text-mined from the whole of Medline."
      ],
      "exact_answer": [
        [
          "PheneBank"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34461271",
        "http://www.ncbi.nlm.nih.gov/pubmed/34527606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34256668",
        "http://www.ncbi.nlm.nih.gov/pubmed/34145225",
        "http://www.ncbi.nlm.nih.gov/pubmed/33626253",
        "http://www.ncbi.nlm.nih.gov/pubmed/34104374",
        "http://www.ncbi.nlm.nih.gov/pubmed/33598857",
        "http://www.ncbi.nlm.nih.gov/pubmed/33896344",
        "http://www.ncbi.nlm.nih.gov/pubmed/34854741",
        "http://www.ncbi.nlm.nih.gov/pubmed/34625232"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 342,
          "text": "B-cell maturation antigen (BCMA) has become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already received regulatory approval in the United States. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34461271"
        },
        {
          "offsetInBeginSection": 1113,
          "offsetInEndSection": 1321,
          "text": "These include isatuximab (also anti-CD38) and, in the past year, the antibody-drug conjugate (ADC) belantamab mafodotin and the chimeric antigen receptor (CAR) T-cell product idecabtagene vicleucel (ide-cel).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34527606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 406,
          "text": "Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253"
        },
        {
          "offsetInBeginSection": 1917,
          "offsetInEndSection": 2100,
          "text": "CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253"
        },
        {
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1822,
          "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1632,
          "text": "After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "text": "BACKGROUND AND OBJECTIVE: Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33598857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 325,
          "text": "Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two ther",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33896344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34104374"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316,
          "text": "Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33896344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 341,
          "text": "Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34854741"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34854741"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 392,
          "text": "BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626253"
        },
        {
          "offsetInBeginSection": 499,
          "offsetInEndSection": 886,
          "text": "The bulk of CAR T-cell constructs currently in clinical development target the B-cell maturation antigen (BCMA) and to date only idecabtagene vicleucel (ide-cel) is approved by the Food and Drug Administration (FDA) for commercial use in adult patients with relapsed or refractory MM based on the promising clinical responses and positive safety record shown in the pivotal KarMMa study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34625232"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 405,
          "text": "Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34145225"
        }
      ],
      "body": "Idecabtagene vicleucel can be used for treatment of which disease?",
      "type": "factoid",
      "id": "61f7ce26882a024a1000002d",
      "ideal_answer": [
        "Idecabtagene vicleucel was shown to be effective for Relapsed and Refractory Multiple Myeloma."
      ],
      "exact_answer": [
        [
          "Multiple Myeloma"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34105151",
        "http://www.ncbi.nlm.nih.gov/pubmed/34741346",
        "http://www.ncbi.nlm.nih.gov/pubmed/30618083",
        "http://www.ncbi.nlm.nih.gov/pubmed/29499931",
        "http://www.ncbi.nlm.nih.gov/pubmed/31128030",
        "http://www.ncbi.nlm.nih.gov/pubmed/29906749",
        "http://www.ncbi.nlm.nih.gov/pubmed/31239716",
        "http://www.ncbi.nlm.nih.gov/pubmed/33235461",
        "http://www.ncbi.nlm.nih.gov/pubmed/28171565",
        "http://www.ncbi.nlm.nih.gov/pubmed/31081143",
        "http://www.ncbi.nlm.nih.gov/pubmed/32991297",
        "http://www.ncbi.nlm.nih.gov/pubmed/31269584",
        "http://www.ncbi.nlm.nih.gov/pubmed/32308105",
        "http://www.ncbi.nlm.nih.gov/pubmed/31188482",
        "http://www.ncbi.nlm.nih.gov/pubmed/30485513",
        "http://www.ncbi.nlm.nih.gov/pubmed/31781497"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 204,
          "text": "Through microarray data, Linc00339 was identified as a candidate oncogenic lncRNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "PURPOSE: To investigate the role and mechanism of long non-coding (lnc) RNA LINC00339 in pancreatic cancer (PANC), and provided a potential target for its biological diagnosis and trea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31128030"
        },
        {
          "offsetInBeginSection": 276,
          "offsetInEndSection": 417,
          "text": " showed that LINC00339 was significantly up-regulated in NSCLC tissue and cells, which indicated the poor prognosis of NSCLC patients. Loss-o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29906749"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 232,
          "text": "(HCC). The lncRNA LINC00339 was reported to regulate the development of lung cancer or breast",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31239716"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 372,
          "text": "we demonstrated that LINC00339 was upregulated in glioma tissue as well as in glioma cell lines. The e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499931"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "LINC00339 promotes cell proliferation and metastasis in pancreatic cancer via miR-497-5p/IGF1R axis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31128030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Introduction: Accumulating evidence has indicated that long noncoding RNAs (lncRNAs) are pivotal regulators involved in the pathogenesis of cancer; however, the molecular mechanism of LINC00339 in colorectal cancer (CRC) remain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33235461"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 805,
          "text": "vasion. Xenograft experiment was used to test tumor growth in vivo. Results: LINC00339 overexpression was correlated with an advanced stage, metastasis, and bad prognosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31239716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Endometriosis risk alleles at 1p36.12 act through inverse regulation of CDC42 and LINC00339",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28171565"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "LINC00339 regulates ROCK1 by miR-152 to promote cell proliferation and migration in hepatocellular carcinoma",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31081143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 208,
          "text": "ugh microarray data, Linc00339 was identified as a candidate oncogenic lncRNA. We ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 1063,
          "offsetInEndSection": 1249,
          "text": " in vivo experiments, Linc00339 overexpression promoted triple-negative breast cancer (TNBC) proliferation, inhibited cell cycle arrest, and suppressed apoptosis. Silencing of Linc00339 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 339,
          "text": "pared the expression levels of Linc00339 in several breast cancer cell lines and normal mammary gland epithelial cell line. The ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 541,
          "offsetInEndSection": 700,
          "text": "work identified a 5-lncRNA signature (ENSG00000206567, PCAT29, ENSG00000257989, LOC388282, and LINC00339) from TCGA training studies (n \u003d 1,878). The identifie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32991297"
        },
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 426,
          "text": "fects of Linc00339 on tumor progression were examined both in vitro and in vivo. 3-(4",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 348,
          "offsetInEndSection": 459,
          "text": "LINC00339 expression in colorectal cancer tissues and adjacent colorectal sampleswas detected by Real-time PCR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31269584"
        },
        {
          "offsetInBeginSection": 541,
          "offsetInEndSection": 628,
          "text": "Linc00339 was then found to play a critical role in Huaier-mediated cancer suppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781497"
        },
        {
          "offsetInBeginSection": 2169,
          "offsetInEndSection": 2306,
          "text": "Conclusions: LINC00339 expression is upregulated in colorectal cancer tissues and correlated with patients\u0027 clinicopathological features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31269584"
        },
        {
          "offsetInBeginSection": 839,
          "offsetInEndSection": 937,
          "text": "tween miR-152 and ROCK1. The role of LINC00339 in tumor formation and metastasis were explored thr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31081143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "PURPOSE: To investigate the role and mechanism of long non-coding (lnc) RNA LINC00339 in pancreatic cancer (PANC), and provided a potential target for its biological diagnosis and treatment.METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of LINC00339 in PANC tissue specime",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31128030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "LINC00339 promotes gastric cancer progression by elevating DCP1A expression via inhibiting miR-377-3p.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31188482"
        },
        {
          "offsetInBeginSection": 1486,
          "offsetInEndSection": 1689,
          "text": "Our findings highlight the importance of the LINC00339-miR-539-SOX9 pathway in gastric cancer pathogenesis and may point to novel targets for the diagnosis, prognosis, and/or treatment of gastric cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "LINC00339 promotes cell proliferation and metastasis in pancreatic cancer via miR-497-5p/IGF1R axis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31128030"
        },
        {
          "offsetInBeginSection": 783,
          "offsetInEndSection": 900,
          "text": "In conclusion, LINC00339 promotes gastric cancer progression by elevating DCP1A expression via inhibiting miR-377-3p.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31188482"
        },
        {
          "offsetInBeginSection": 1276,
          "offsetInEndSection": 1514,
          "text": "r transfected with miR-152 mimics. LINC00339 exerted oncogenesis effect on HCC progression by targeting miR-152/ROCK1, and the expression of LINC00339 was negatively correlated with miR-152 expression and positively correlated with ROCK1 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31081143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Long noncoding RNA LINC00339 promotes laryngeal squamous cell carcinoma cell proliferation and invasion via sponging miR-145.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30485513"
        },
        {
          "offsetInBeginSection": 1762,
          "offsetInEndSection": 1954,
          "text": "In conclusion, our results illuminated that the novel Linc00339/miR-377-3p/HOXC6 axis played a critical role in TNBC progression and might be a promising therapeutic target for TNBC treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1225,
          "text": "Through in vitro and in vivo experiments, Linc00339 overexpression promoted triple-negative breast cancer (TNBC) proliferation, inhibited cell cycle arrest, and suppressed apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 949,
          "offsetInEndSection": 1042,
          "text": "Linc00339 was increased in breast cancer cell lines compared with the normal epithelial cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1714,
          "text": "And miR-377-3p was involved in Linc00339-mediated TNBC proliferation through regulating HOXC6 expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The SP1-Induced Long Noncoding RNA, LINC00339, Promotes Tumorigenesis in Colorectal Cancer via the miR-378a-3p/MED19 Axis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33235461"
        },
        {
          "offsetInBeginSection": 205,
          "offsetInEndSection": 334,
          "text": "We compared the expression levels of Linc00339 in several breast cancer cell lines and normal mammary gland epithelial cell line.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30618083"
        }
      ],
      "body": "LINC00339 is a diagnostic, prognostic and treatment efficacy biomarker for what disease?",
      "type": "factoid",
      "id": "623345bf3a8413c6530000ab",
      "ideal_answer": [
        "LINC00339 as a cancer diagnostic, prognostic and treatment efficacy biomarker."
      ],
      "exact_answer": [
        [
          "cancer"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34885209"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 164,
          "text": "LncRNA PCAT6 was involved in the progression of multiple human cancers. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31676070"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 814,
          "text": "Emerging evidence has shown that PCAT6, a newly discovered carcinogenic lncRNA, is abnormally elevated in various human malignant tumors. Until now, PCAT6 has been found to sponge various miRNAs to activate the signaling pathways, which further affects tumor cell proliferation, migration, invasion, cycle, apoptosis, radioresistance, and chemoresistance. Moreover, PCAT6 has been shown to exert biological functions beyond ceRNAs. In this review, we summarize the biological characteristics of PCAT6 in a variety of human malignancies and describe the biological mechanisms by which PCAT6 can facilitate tumor progression. Finally, we discuss its diagnostic and prognostic values and clinical applications in various human malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34885209"
        }
      ],
      "body": "What is the role of PCAT6 in human cancers?",
      "type": "summary",
      "id": "622669363a8413c653000089",
      "ideal_answer": [
        "PCAT6, is a carcinogenic lncRNA. It is abnormally elevated in various human malignant tumors. PCAT6 has been found to sponge various miRNAs to activate the signaling pathways, which further affects tumor cell proliferation, migration, invasion, cycle, apoptosis, radioresistance, and chemoresistance. It is believed to have diagnostic and prognostic value and clinical applications in various human malignancies."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34732400"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1410,
          "offsetInEndSection": 1893,
          "text": "Whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31% after exclusion of common causes. Most diagnoses were non-mitochondrial disorders and included developmental disorders with intellectual disability, epileptic encephalopathies, other metabolic disorders, cardiomyopathies, and leukodystrophies. These would have been missed if a targeted approach was taken, and some have specific treatments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34732400"
        }
      ],
      "body": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?",
      "type": "yesno",
      "id": "62068e67c9dfcb9c09000038",
      "ideal_answer": [
        "Yes. Whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31% after exclusion of common causes. Most diagnoses were non-mitochondrial disorders and included developmental disorders with intellectual disability, epileptic encephalopathies, other metabolic disorders, cardiomyopathies, and leukodystrophies. These would have been missed if a targeted approach was taken, and some have specific treatments."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34552008",
        "http://www.ncbi.nlm.nih.gov/pubmed/34580817",
        "http://www.ncbi.nlm.nih.gov/pubmed/32972961",
        "http://www.ncbi.nlm.nih.gov/pubmed/33307872",
        "http://www.ncbi.nlm.nih.gov/pubmed/33453089",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465704",
        "http://www.ncbi.nlm.nih.gov/pubmed/33301227",
        "http://www.ncbi.nlm.nih.gov/pubmed/32100250",
        "http://www.ncbi.nlm.nih.gov/pubmed/29233825",
        "http://www.ncbi.nlm.nih.gov/pubmed/34023541",
        "http://www.ncbi.nlm.nih.gov/pubmed/31117741",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025950",
        "http://www.ncbi.nlm.nih.gov/pubmed/33876372",
        "http://www.ncbi.nlm.nih.gov/pubmed/32615108",
        "http://www.ncbi.nlm.nih.gov/pubmed/34343033",
        "http://www.ncbi.nlm.nih.gov/pubmed/30274985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32821296"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 807,
          "text": "In vitro studies tested the efficacy of MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, and avapritinib) in sarcoma cell lines. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34552008"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 649,
          "text": "In this review, we briefly outline the history of treatment for systemic mastocytosis and subsequently focus on the clinical development and potential applications of avapritinib (previously known as BLU-285), a potent and selective oral inhibitor of the tyrosine kinase most commonly mutated in this condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34580817"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 401,
          "text": "Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32972961"
        },
        {
          "offsetInBeginSection": 1095,
          "offsetInEndSection": 1382,
          "text": "Clearly, better knowledge of the molecular mechanisms underlying the resistance to imatinib as well as the development of a new class of broad-spectrum tyrosine kinase inhibitors such as avapritinib and ripretinib will provide new individualized therapeutic strategies for GIST patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33307872"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 453,
          "text": "NAVIGATOR is a two-part, single-arm, dose escalation and expansion study designed to evaluate safety and antineoplastic activity of avapritinib, a selective, potent inhibitor of KIT and PDGFRA, in patients with unresectable or metastatic GIST.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33453089"
        },
        {
          "offsetInBeginSection": 1624,
          "offsetInEndSection": 1778,
          "text": "CONCLUSION: Targeting PDGFRA D842V-mutant GIST with avapritinib resulted in an unprecedented, durable clinical benefit, with a manageable safety profile. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465704"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32100250"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Avapritinib is a protein kinase inhibitor designed to selectively inhibit oncogenic KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34023541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233825"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 840,
          "text": "In this study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741"
        },
        {
          "offsetInBeginSection": 314,
          "offsetInEndSection": 482,
          "text": "Avapritinib is approved in the USA for PDGFRA exon 18 (including D842V) mutant GIST and is undergoing regulatory assessment in the USA as a 4th-line treatment for GIST.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32100250"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "Avapritinib is a tyrosine kinase inhibitor (TKI) that has recently received Food and Drug Administration (FDA) approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025950"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 911,
          "text": "y, United States Federal and Drug Administration (FDA) approved two new tyrosine kinase inhibitors for the treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGFRA). In this ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33876372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233825"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 547,
          "text": "ibitors. We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA D842V-mutant gastrointestinal stromal tumours (NAVIGA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32615108"
        },
        {
          "offsetInBeginSection": 574,
          "offsetInEndSection": 854,
          "text": "study, we discovered that avapritinib (BLU-285), a potent, selective, and orally bioavailable tyrosine kinase inhibitor against mutant forms of KIT and platelet-derived growth factor receptor alpha (PDGFRA), attenuates the transport function of both ABCB1 and ABCG2. Moreover, ava",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31117741"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 284,
          "text": "V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genoty",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32972961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 289,
          "text": "Avapritinib is a tyrosine kinase inhibitor (TKI) that has recently received Food and Drug Administration (FDA) approval for the treatment of metastatic or unresectable gastrointestinal stromal tumors harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Muta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025950"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 254,
          "text": "(GISTs). Avapritinib selectively and potently inhibits KIT- and PDGFRA-mutant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34343033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301227"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 793,
          "text": "Herein, we report a clinical case of a patient with metastatic vulvar melanoma, harboring an exon 17 c-KIT mutation, treated with avapritinib (BLU-285) - a highly potent and selective oral kinase inhibitor designed to treat imatinib-resistant gastro-intestinal stromal tumors (GIST) by targeting KIT/PDGFRα activation loop mutants (exons 17/18).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32821296"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 756,
          "text": "utation. We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n \u003d 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 ), exon 11 (UZLX-GIST3 KIT 11 ), or exon 9 (UZLX-GIST2B KIT9 ) mutations, resp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30274985"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 755,
          "text": "inhibitors. We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA D842V-mutant gastrointestinal stromal tumours (NAVIGATOR).METHODS: NAVIGATOR is a two-part, open-label, dose-escalation and dose-expansion, phase 1 study done at 17 sites across nine countries (Belgium, France, Germany, Poland, Netherlands, South Korea, Spain, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32615108"
        }
      ],
      "body": "What are the targets of avapritinib?",
      "type": "list",
      "id": "61f7d535882a024a10000034",
      "ideal_answer": [
        "Avapritinib is a novel inhibitor of KIT/PDGFRA. It is approved in the U.S. for the treatment of adults with PDGFRA exon 18-mutant unresectable or metastatic gastrointestinal stromal tumors."
      ],
      "exact_answer": [
        [
          "KIT"
        ],
        [
          "PDGFRA"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33337637",
        "http://www.ncbi.nlm.nih.gov/pubmed/33043556",
        "http://www.ncbi.nlm.nih.gov/pubmed/32510747",
        "http://www.ncbi.nlm.nih.gov/pubmed/30543463",
        "http://www.ncbi.nlm.nih.gov/pubmed/29967357",
        "http://www.ncbi.nlm.nih.gov/pubmed/25961439",
        "http://www.ncbi.nlm.nih.gov/pubmed/29667413",
        "http://www.ncbi.nlm.nih.gov/pubmed/34001027",
        "http://www.ncbi.nlm.nih.gov/pubmed/23452629",
        "http://www.ncbi.nlm.nih.gov/pubmed/27458179",
        "http://www.ncbi.nlm.nih.gov/pubmed/32601779",
        "http://www.ncbi.nlm.nih.gov/pubmed/30941328",
        "http://www.ncbi.nlm.nih.gov/pubmed/34642274",
        "http://www.ncbi.nlm.nih.gov/pubmed/27274539",
        "http://www.ncbi.nlm.nih.gov/pubmed/26927491",
        "http://www.ncbi.nlm.nih.gov/pubmed/29521727",
        "http://www.ncbi.nlm.nih.gov/pubmed/27660053"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Jackhammer esophagus (JE) is a recently recognized esophageal motility disorder that is characterized by hypercontractile peristalsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33337637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Hypercontractile esophagus (HE), also known as jackhammer esophagus, is an esophageal motility disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33043556"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 221,
          "text": " Jackhammer esophagus (JE) is a hypercontractile esophageal motor disorder defined by at least two swallows with a distal contractile integral (DCI) \u003e8000 mm Hg.s.cm during high-resolution manometry (HRM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Jackhammer esophagus (JE) is a hypercontractile disorder, the pathogenesis of which is incompletely understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30543463"
        },
        {
          "offsetInBeginSection": 72,
          "offsetInEndSection": 325,
          "text": "Jackhammer esophagus (JE), a novel hypercontractile disorder associated with progression to achalasia and limited outcomes following anti-reflux surgery in patients with typical symptoms of GERD and responsiveness to proton pump inhibitor (PPI) therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29967357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Nutcracker esophagus and jackhammer esophagus are largely unknown motility disorders, also sometimes called hypertensive and hypercontractile peristalsis, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "BACKGROUND: Jackhammer esophagus is a rare esophageal motility disorder that can result in dysphagia, chest pain, and gastro-esophageal reflux symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Two Distinct Types of Hypercontractile Esophagus: Classic and Spastic Jackhammer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458179"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 630,
          "text": "The diagnosis of jackhammer esophagus as a primary motility disorder is based on the characteristic manometric findings after ruling out mechanical obstruction and eosinophilic esophagitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "The jackhammer esophagus is a rare hypercontractile disorder and diagnosis is based on high-resolution manometry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29667413"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 248,
          "text": "Jackhammer esophagus is also rare, is characterized by esophageal hypercontraction, and comprises 4.1% of esophageal motility disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32601779"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Hypercontractile esophagus (nicknamed jackhammer esophagus) is a recently defined disease within the esophageal motility disorders classification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458179"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Background: Jackhammer esophagus is a hypercontractile esophageal disorder recently brought to light with the advent of high resolution manometry (HRM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30941328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "BACKGROUND AND STUDY AIMS: With the success of peroral endoscopic myotomy (POEM) in treatment of achalasia, its successful application to other spastic esophageal motility disorders such as Jackhammer es",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27274539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Hypercontractile esophagus (nicknamed jackhammer esophagus) is a recently defined disease within the esophageal motility disorders classification. Res",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27458179"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BACKGROUND: Jackhammer esophagus is a rare esophageal motility disorder that can result in dysphagia, chest pain, and gastro-esophageal reflux s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Background: Jackhammer esophagus is a hypercontractile esophageal disorder recently brought to light with the advent of high resolution manomet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30941328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Background/Aims: Jackhammer esophagus is an uncommon heterogeneous motility disorder associated with a distal contractile integral \u003e 80",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34642274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Hypercontractile esophagus (HE), also known as jackhammer esophagus, is an esophageal motility disorder. Nowa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33043556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND: Jackhammer Esophagus is defined as intact esophageal peristaltic contractions with extremely elevate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Background: Jackhammer esophagus is a hypercontractile esophageal disorder recently brought to light with the advent of high resolution mano",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30941328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "BACKGROUND: Jackhammer Esophagus is defined as intact esophageal peristaltic contractions with extremely elevated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "BACKGROUND/AIMS: Jackhammer esophagus (JE) is a hypercontractile esophageal motor disorder defined by at least two swallows with a distal contractile integral (DCI) \u003e8000 mm Hg.s.cm during high-resolution",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "BACKGROUND: Jackhammer esophagus (JE) is a rare esophageal motility disorder defined in the Chicago Classification of Esophageal Motility by presence of excessively high distal contractile integral (DCI) on high-resolution manometry (HRM), with unknown natural manome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660053"
        },
        {
          "offsetInBeginSection": 1431,
          "offsetInEndSection": 1579,
          "text": "y and a high relapse rate.CONCLUSION: Jackhammer esophagus is a rare motility disorder. Diagnostic workup is heterogeneous and should be standardize",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510747"
        },
        {
          "offsetInBeginSection": 569,
          "offsetInEndSection": 866,
          "text": "dies with a diagnosis of jackhammer esophagus, hypercontractile esophagus, nutcracker, esophagogastric junction outflow obstruction, or hypertensive lower esophageal sphincter were reread using Chicago Classification version 3.0, and were included if they met criteria for jackhammer esophagus. Un",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29521727"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Frequency of Jackhammer Esophagus as the Extreme Phenotypes of Esophageal Hypercontractility Based on the New Chicago Classification.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "BACKGROUND: Jackhammer Esophagus is defined as intact esophageal peristaltic contractions with extremely elevated amplitudes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "BACKGROUND: Jackhammer esophagus is a rare esophageal motility disorder that can result in dysphagia, chest pain, and gastro-esophageal reflux symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Background/Aims: Jackhammer esophagus is an uncommon heterogeneous motility disorder associated with a distal contractile integral \u003e ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34642274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "BACKGROUND: Jackhammer esophagus is a rare esophageal motility disorder that can result in dysphagia, chest pain, and gastro-esophageal refl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001027"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 368,
          "text": "amplitudes. We conducted a retrospective study to identify the frequency of esophageal hypercontractility and the clinical characteristics of Jackhammer Esophagus.METHODS: Charts for the patients referred for manometric study at a tertiary-care motility ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927491"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 328,
          "text": "whereas jackhammer esophagus is associated with hypercontractility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452629"
        }
      ],
      "body": "What is Jackhammer esophagus?",
      "type": "summary",
      "id": "622cbec13a8413c65300009b",
      "ideal_answer": [
        "Jackhammer esophagus (JE) is a recently recognized esophageal motility disorder that is characterized by hypercontractile peristalsis.",
        "Jackhammer esophagus (JE) is a hypercontractile esophageal motor disorder defined by at least two swallows with a distal contractile integral (DCI) \u003e8000 mm Hg.s.cm during high-resolution manometry (HRM)."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34505967"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "METTL3-Mediated lncRNA m6A Modification in the Osteogenic Differentiation of Human Adipose-Derived Stem Cells Induced by NEL-Like 1 Protein.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34505967"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 290,
          "text": "This study aimed to explore the regulatory mechanism of methyltransferase3 (METTL3) -mediated long non-coding RNA (lncRNA) N6-methyladenosine (m6A) modification in the osteogenic differentiation of human adipose-derived stem cells (hASCs) induced by NEL-like 1 protein (NELL-1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34505967"
        },
        {
          "offsetInBeginSection": 1918,
          "offsetInEndSection": 2129,
          "text": "This study shows, for the first time, that METTL3 can activate the MAPK signaling pathway by regulating the m6A modification and expression of a lncRNA, thereby enhancing the osteogenic differentiation of hASCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34505967"
        }
      ],
      "body": "Can METTL3 methylate long noncoding RNAs?",
      "type": "yesno",
      "id": "622662e13a8413c653000085",
      "ideal_answer": [
        "Yes, METTL3 can modulate methylation and expression of lncRNA."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33559681"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33559681"
        },
        {
          "offsetInBeginSection": 2510,
          "offsetInEndSection": 3068,
          "text": "In summary, we estimate that biallelic variants in VWA1 may be responsible for up to 1% of unexplained hereditary motor neuropathy cases in Europeans. The detailed clinical characterization provided here will facilitate targeted testing on suitable patient cohorts. This novel disease gene may have previously evaded detection because of high GC content, consequential low coverage and computational difficulties associated with robustly detecting repeat-expansions. Reviewing previously unsolved exomes using lower QC filters may generate further diagnoses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33559681"
        }
      ],
      "body": "Which disease is caused by repeat expansion in VWA1?",
      "type": "factoid",
      "id": "61f86c03882a024a10000044",
      "ideal_answer": [
        "An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy."
      ],
      "exact_answer": [
        [
          "Recessive hereditary motor neuropathy"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33250474",
        "http://www.ncbi.nlm.nih.gov/pubmed/33721198",
        "http://www.ncbi.nlm.nih.gov/pubmed/33683710",
        "http://www.ncbi.nlm.nih.gov/pubmed/34067551",
        "http://www.ncbi.nlm.nih.gov/pubmed/34041090",
        "http://www.ncbi.nlm.nih.gov/pubmed/27902493",
        "http://www.ncbi.nlm.nih.gov/pubmed/17236637",
        "http://www.ncbi.nlm.nih.gov/pubmed/32415631",
        "http://www.ncbi.nlm.nih.gov/pubmed/33832577",
        "http://www.ncbi.nlm.nih.gov/pubmed/34782501",
        "http://www.ncbi.nlm.nih.gov/pubmed/11861340",
        "http://www.ncbi.nlm.nih.gov/pubmed/31230771"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 525,
          "offsetInEndSection": 1003,
          "text": "For PONV, anesthesia duration and Apfel score were independent risk factors.CONCLUSIONS: Our results indicate that desflurane was the main cause of ePONV. However, during the delayed phase, a higher Apfel score was the strongest predictor. In the early and delayed phases, long anesthesia duration was associated with high risk of PONV. Thus, prolonged anesthesia and desflurane use should be avoided for patients at high risk of PONV, particularly those with high Apfel scores.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33250474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Interpretation of the four risk factors for postoperative nausea and vomiting in the Apfel simplified risk score: an analysis of published studies.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "PURPOSE: The Apfel simplified risk score, developed in 1999, is the most widely used tool for risk stratification of postoperative nausea and vomiting (PONV). I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        },
        {
          "offsetInBeginSection": 1297,
          "offsetInEndSection": 1465,
          "text": "CONCLUSIONS: Significant variation exists in how the Apfel risk factors are defined and applied in PONV research, particularly with respect to postoperative opioid use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 449,
          "text": "METHODS: One hundred and twenty patients undergoing laparoscopic surgeries having 2 or more risk factors for PONV (simplified Apfel score) were randomised into 2 groups of 60 each. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33683710"
        },
        {
          "offsetInBeginSection": 650,
          "offsetInEndSection": 762,
          "text": "In univariate analysis, female sex and Apfel scores of 2, 3, and 4 were associated with a higher POV incidence. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34067551"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1004,
          "text": "In multivariate logistic regression, sex, age, Apfel score, and intraoperative crystalloid infusion rate were POV predictive factors. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34067551"
        },
        {
          "offsetInBeginSection": 594,
          "offsetInEndSection": 716,
          "text": "We used the Apfel scoring system for evaluation of risk of post-operative nausea and vomiting (PONV) for each participant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34041090"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 501,
          "text": "THODS: Adult inpatients undergoing elective surgery during general anesthesia and having at least two of the four Apfel risk factors for postoperative nausea and vomiting were enrolled at 9 U.S. and 10 European sites. A",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27902493"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 241,
          "text": "The Apfel Simplified Score is an evidence-based instrument for determining individual risk of PONV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33832577"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 236,
          "text": "The simplified Apfel score is an attractive and frequently used tool to assess PONV risk in the general surgical population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32415631"
        },
        {
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1178,
          "text": "The Apfel score is an evidence-based tool that providers can use to reduce the risk of PONV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33832577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "PURPOSE: The Apfel simplified risk score, developed in 1999, is the most widely used tool for risk stratification of postoperative nausea and vomiting (PONV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Preventing Nausea and Vomiting After Bariatric Surgery: Is the Apfel Risk Prediction Score Enough to Guide Prophylaxis?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32415631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "PURPOSE: The Apfel simplified risk score, developed in 1999, is the most widely used tool for risk stratification of postoperative nausea and vomiting",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Background: Simplified risk models, such as the Apfel score, have been developed to calculate the risk of postoperative nausea-vomiting (PONV) for adult ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782501"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 238,
          "text": " simplified Apfel score is an attractive and frequently used tool to assess PONV risk in the general surgical population. D",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32415631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Apfel\u0027s simplified score may favourably predict the risk of postoperative nausea and vomiting.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11861340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Postoperative nausea and vomiting (PONV) : usefulness of the Apfel-score for identification of high risk patients for PONV.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17236637"
        },
        {
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1216,
          "text": "dansetron returned. The Apfel score is an evidence-based tool that providers can use to reduce the risk of PONV. This electronic tool and the reminder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33832577"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 160,
          "text": ": Simplified risk models, such as the Apfel score, have been developed to calculate the risk of postoperative nausea-vomiting (PONV) for adult patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782501"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 340,
          "text": " The simplified Apfel-score includes the four factors female gender, no smoking, postoperative use of opioides and previous PONV or motion-sickness in patients\u0027 history",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17236637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "A common predictive measure of postoperative nausea and vomiting (PONV) is the Apfel score.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31230771"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "PURPOSE: The Apfel simplified risk score, developed in 1999, is the most widely used tool for risk stratification of postoperative nausea and vomitin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33721198"
        }
      ],
      "body": "What is the use of the Apfel Score?",
      "type": "summary",
      "id": "6200839bc9dfcb9c0900001d",
      "ideal_answer": [
        "The Apfel simplified risk score, developed in 1999, is the most widely used tool for risk stratification of postoperative nausea and vomiting."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30957602",
        "http://www.ncbi.nlm.nih.gov/pubmed/31018725",
        "http://www.ncbi.nlm.nih.gov/pubmed/31272257",
        "http://www.ncbi.nlm.nih.gov/pubmed/31402735",
        "http://www.ncbi.nlm.nih.gov/pubmed/21749283",
        "http://www.ncbi.nlm.nih.gov/pubmed/31372118",
        "http://www.ncbi.nlm.nih.gov/pubmed/24304137",
        "http://www.ncbi.nlm.nih.gov/pubmed/23599878",
        "http://www.ncbi.nlm.nih.gov/pubmed/24840939",
        "http://www.ncbi.nlm.nih.gov/pubmed/23573382",
        "http://www.ncbi.nlm.nih.gov/pubmed/10838338",
        "http://www.ncbi.nlm.nih.gov/pubmed/18301713",
        "http://www.ncbi.nlm.nih.gov/pubmed/15703979",
        "http://www.ncbi.nlm.nih.gov/pubmed/29727785",
        "http://www.ncbi.nlm.nih.gov/pubmed/22506729",
        "http://www.ncbi.nlm.nih.gov/pubmed/16118716",
        "http://www.ncbi.nlm.nih.gov/pubmed/29373884",
        "http://www.ncbi.nlm.nih.gov/pubmed/22706240",
        "http://www.ncbi.nlm.nih.gov/pubmed/23179796",
        "http://www.ncbi.nlm.nih.gov/pubmed/24175963",
        "http://www.ncbi.nlm.nih.gov/pubmed/15329560"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 156,
          "text": "preterm premature rupture of fetal membranes (PPROM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30957602"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 301,
          "text": "To examine the effect of aspirin, an anti-inflammatory agent, on the prevalence of preterm prelabor rupture of membranes (PPRoMs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31018725"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 276,
          "text": " preterm prelabor rupture of membranes (PPROM). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31272257"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 215,
          "text": "preterm premature rupture of membranes (PPROM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31402735"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 440,
          "text": " focused on TTTS, preterm premature rupture of membranes (PPROM), pregnancy-induced hypertension (PIH), and fetal sex as possible causes of PTB.RE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21749283"
        },
        {
          "offsetInBeginSection": 910,
          "offsetInEndSection": 1397,
          "text": "lts: Patients with the pregnancy complicated by OHSS, had a considerably higher rate of preterm labor, whether this was labor before gestation week 37 (56.0% vs. 30.5%) or before gestation week 34 (34.0% vs. 6.8%); significantly lower weight of newborns, as in the newborns with low body weight \u003c2500g (45.6% vs. 25.0%) and specially in the newborn with very low body weight \u003c1500 grams (19.1% vs. 3.8%), as well as preterm premature rupture of membranes (PPROM), (11.76% vs. 1.59%).Conc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31372118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as a rupture of the amniotic membranes occurring before 37 weeks of gestation and before the onse",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Preterm premature rupture of membranes (PPROM) occurs in 1% to 2% of births. Im",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Preterm premature rupture of membranes (PPROM) is defined as rupture of membrane that happens before the onset of labor and 37 weeks. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24304137"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as the rupture of fetal membranes befor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23573382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Objective: To show that infants delivered prematurely because of preterm premature rupture of the membranes (PPROM) show a tendency for asymmetric intrauterine growth retardation (IUGR). A",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10838338"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 746,
          "text": "ported among preterm prelabor rupture of membranes (PPROM). Educating the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18301713"
        },
        {
          "offsetInBeginSection": 682,
          "offsetInEndSection": 936,
          "text": "ates with PC were significantly different from controls with regard to male prevalence ( P \u003d0.002), rates of preterm premature rupture of membranes (PPROM) ( P \u003d0.02), longer duration of antibiotic therapy ( P \u003d0.01) and of ventilation ( P \u003d0.02). The di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15703979"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 162,
          "text": "premature rupture of membranes (PPROM) is a common condition in pregnant women and is associated with significant maternal and perinatal morbidity. Mo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22706240"
        },
        {
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1137,
          "text": "tory response to lipopolysaccharide (LPS). This heightened response could be a critical pathway in promoting premature rupture of membranes (PPROM) and may be associated with life long",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22506729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as a rupture of the amniotic membranes occurring before 37 weeks of gestation and before the ons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Objective: To show that infants delivered prematurely because of preterm premature rupture of the membranes (PPROM) show a tendency for asymmetric intrauterine growth retardation (IUGR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10838338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 281,
          "text": "AIM: To determine whether preterm premature rupture of membranes (PPROM) before 24 weeks is an independent risk factor for poor outcome in preterm neonates.METHODS: A retrospective comparative cohort study was conducted, including viable premature infants born between 25 and 34-we",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24175963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 383,
          "text": "PURPOSE: To assess prevalence and risk factors for posttraumatic stress disorder (PTSD) and depression in fathers after early preeclampsia (PE) or preterm premature rupture of membranes (PPROM).METHODS: Partners of patients hospitalized for PE or PPROM and partners of healthy controls completed PTSD (PSS-SR) and depression (BDI-II) questionnaires during pregnancy (t 1) and 6 weeks",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179796"
        },
        {
          "offsetInBeginSection": 1712,
          "offsetInEndSection": 2081,
          "text": "s and iatrogenic preterm delivery. In our high-risk cohort there was no gender difference for preeclampsia (RR 0.93, 95% CI 0.61 to 1.41, p \u003d 0.725) or preterm premature rupture of membranes (PPROM) (RR 1.14, 95% CI 0.86 to 1.50, p \u003d 0.384) CONCLUSIONS: In a high-risk cohort there was no significant increased risk of miscarriage, spontaneous or iatrogenic PTB, preecl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29727785"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Preterm premature rupture of membranes (PPROM) is a condition leading to an increased risk of maternal and neonatal morbidity and mortality in pregnant women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29373884"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "UNLABELLED: Preterm premature rupture of membranes (PPROM) occurs in 3% of pregnancies and is responsible for one third of all pre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329560"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Preterm premature rupture of the membranes (PPROM) occurs in approximately 3% of all pregnancies, and accounts for one third of all preterm births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16118716"
        }
      ],
      "body": "Is PPROM a condition that occurs in males or females?",
      "type": "factoid",
      "id": "622a5a7c3a8413c653000090",
      "ideal_answer": [
        "Preterm premature rupture of fetal membranes (PPROM) occurs in pregnant females."
      ],
      "exact_answer": [
        [
          "Females"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31752933"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752933"
        },
        {
          "offsetInBeginSection": 279,
          "offsetInEndSection": 686,
          "text": "We developed a fast, low-input, low sequencing depth method, EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion, to simultaneously examine accessibility/TF binding and methylation on the same DNA. Here we demonstrate that EpiMethylTag can be used to study the functional interplay between chromatin accessibility and TF binding (CTCF and KLF4) at methylated sites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31752933"
        }
      ],
      "body": "What is EpiMethylTag?",
      "type": "summary",
      "id": "6201a20cc9dfcb9c09000027",
      "ideal_answer": [
        "EpiMethylTag is a fast, low-input, low sequencing depth method, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion, to simultaneously examine accessibility/TF binding and methylation on the same DNA."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
        "http://www.ncbi.nlm.nih.gov/pubmed/33512410",
        "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
        "http://www.ncbi.nlm.nih.gov/pubmed/32176765",
        "http://www.ncbi.nlm.nih.gov/pubmed/30559259",
        "http://www.ncbi.nlm.nih.gov/pubmed/29737533",
        "http://www.ncbi.nlm.nih.gov/pubmed/30635392",
        "http://www.ncbi.nlm.nih.gov/pubmed/31229501",
        "http://www.ncbi.nlm.nih.gov/pubmed/31114413",
        "http://www.ncbi.nlm.nih.gov/pubmed/31523413",
        "http://www.ncbi.nlm.nih.gov/pubmed/33261023"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 805,
          "offsetInEndSection": 1018,
          "text": "Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease (CAD), primarily with the C1s inhibitor of the classical complement pathway, sutimlimab, but also with pegcetacoplan.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482398"
        },
        {
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1369,
          "text": " The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512410"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 316,
          "text": "Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 223,
          "text": "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32176765"
        },
        {
          "offsetInBeginSection": 257,
          "offsetInEndSection": 494,
          "text": "Therapeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 222,
          "text": "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32176765"
        },
        {
          "offsetInBeginSection": 1975,
          "offsetInEndSection": 2205,
          "text": "SIONS: In patients with cold agglutinin disease who received sutimlimab, selective upstream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue. (Fund",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
        },
        {
          "offsetInBeginSection": 1219,
          "offsetInEndSection": 1369,
          "text": "The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 730,
          "text": "In this study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392"
        },
        {
          "offsetInBeginSection": 567,
          "offsetInEndSection": 790,
          "text": "Novel treatment options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31114413"
        },
        {
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1323,
          "text": "Of these, the anti-C1s monoclonal antibody sutimlimab has shown favorable activity in CAD, while the anti-C3 cyclic peptide pegcetacoplan appears to be promising in PNH as well as CAD, and may also have a therapeutic potential in wAIHA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523413"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 307,
          "text": "t pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
        },
        {
          "offsetInBeginSection": 579,
          "offsetInEndSection": 802,
          "text": "ent options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials. These achie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31114413"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 499,
          "text": "apeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway. A ph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 312,
          "text": "is trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259"
        },
        {
          "offsetInBeginSection": 477,
          "offsetInEndSection": 739,
          "text": "s study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. We repor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 526,
          "text": "In this phase 1 trial, we evaluated the safety and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229501"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 524,
          "text": " and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229501"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 479,
          "text": "and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical comp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "text": ". Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathw",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 354,
          "text": ". This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. Ten patients with cold agglutinin disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259"
        },
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1407,
          "text": "cted therapies (ibrutinib, venetoclax, parsaclisib) and inhibitors of complement (sutimlimab, pegcetacoplan), spleen tyrosine kinases (fostamatinib), ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33261023"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 508,
          "text": "nt pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.METHODS: We conducted a 26-week multicenter, open-label, single-group study to assess the efficacy and safety of intravenous sutimlimab in patients with cold agglutinin disease and a recent hi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 311,
          "text": "This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259"
        }
      ],
      "body": "What is the target of Sutimlimab?",
      "type": "factoid",
      "id": "61f7cc0c882a024a1000002a",
      "ideal_answer": [
        "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s."
      ],
      "exact_answer": [
        [
          "C1s"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31496071",
        "http://www.ncbi.nlm.nih.gov/pubmed/28614408",
        "http://www.ncbi.nlm.nih.gov/pubmed/26840774",
        "http://www.ncbi.nlm.nih.gov/pubmed/34703270",
        "http://www.ncbi.nlm.nih.gov/pubmed/18654798",
        "http://www.ncbi.nlm.nih.gov/pubmed/34358648",
        "http://www.ncbi.nlm.nih.gov/pubmed/34169075",
        "http://www.ncbi.nlm.nih.gov/pubmed/17042799",
        "http://www.ncbi.nlm.nih.gov/pubmed/18824533"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Helminths and their products can shape immune responses by modulating immune cells, which are dysfunctional in inflammatory diseases such as asthm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31496071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Schistosoma japonicum peptide SJMHE1 suppresses airway inflammation of allergic asthma in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31496071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Schistosoma japonicum infection downregulates house dust mite-induced allergic airway inflammation in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 1091,
          "offsetInEndSection": 1294,
          "text": "To our knowledge, it is the first study to reveal the impact of S. japonicum infection on house dust mite induced severe asthma. More in depth investigation is need to elucidate the underlying mechanisms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Novel T-cell epitopes on Schistosoma japonicum SjP40 protein and their preventive effect on allergic asthma in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840774"
        },
        {
          "offsetInBeginSection": 845,
          "offsetInEndSection": 1022,
          "text": "hese results reveal a novel form of immune protective mechanism, which may play an important role in the modulating effect of helminth infection on allergic asthmatic reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840774"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 843,
          "text": "Using a panel of overlapping peptides, we identified T-cell epitopes on SjP40 protein of Schistosoma japonicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840774"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 148,
          "text": "Helminths and their products can regulate immune response and offer new strategies to control and alleviate inflammation, including asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34703270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "SJMHE1 Peptide from Schistosoma japonicum Inhibits Asthma in Mice by Regulating Th17/Treg Cell Balance via miR-155.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34703270"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 254,
          "text": "We previously found that a peptide named as SJMHE1 from Schistosoma japonicum can suppress asthma in mice",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34703270"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 855,
          "text": "el of overlapping peptides, we identified T-cell epitopes on SjP40 protein of Schistosoma japonicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. These resul",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840774"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 268,
          "text": "has been shown that helminth infections including Schistosoma mansoni may modulate atopic diseases including asthma. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18654798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Schistosoma japonicum infection downregulates house dust mite-induced allergic airway inflammation in mice",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 1109,
          "offsetInEndSection": 1237,
          "text": "it is the first study to reveal the impact of S. japonicum infection on house dust mite induced severe asthma. More in depth inv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 402,
          "offsetInEndSection": 675,
          "text": "s study, we investigated the impact of Schistosoma japonicum infection on the allergic airway inflammation induced by repeated intracheal inoculations of house dust mites (HDM), which is a Th17 and neutrophils dominant murine asthma model, mimicking severe asthma. We found",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Schistosoma japonicum infection showed protective effects against allergic airway inflammation (AAI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34169075"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 384,
          "text": "Therefore, we hypothesize that Schistosoma japonicum egg antigens, a type of native antigen, can induce production of CD4(+) CD25(+) T cells with regulatory activity, modulating airway inflammation and inhibiting asthma development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042799"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Schistosoma japonicum infection modulates the development of allergen-induced airway inflammation in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18654798"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 266,
          "text": "It has been shown that helminth infections including Schistosoma mansoni may modulate atopic diseases including asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18654798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Schistosoma japonicum egg antigens stimulate CD4 CD25 T cells and modulate airway inflammation in a murine model of asthma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042799"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 511,
          "text": "Most previous studies focused on understanding the preventive effect of S. japonicum infection on asthma (infection before allergen sensitization), whereas the protective effects of S. japonicum infection (allergen sensitization before infection) on asthma were rarely investigated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34169075"
        },
        {
          "offsetInBeginSection": 1619,
          "offsetInEndSection": 1739,
          "text": "In conclusion, our data showed that lung-stage S. japonicum infection could relieve OVA-induced asthma in a mouse model.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34169075"
        },
        {
          "offsetInBeginSection": 512,
          "offsetInEndSection": 641,
          "text": "In this study, we investigated the protective effects of S. japonicum infection on AAI using a mouse model of OVA-induced asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34169075"
        },
        {
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1122,
          "text": " prior to OVA immunization. These results suggest that both bisexual and male S. japonicum infections may modulate the development of allergic asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18654798"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 849,
          "text": "aponicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. These",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840774"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 605,
          "text": "ve found that Schistosoma infection or Schistosoma related products can improve or prevent some immune and inflammatory diseases, such as severe asthm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34358648"
        },
        {
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1090,
          "text": "Our findings indicated that S. japonicum infection was able to effectively inhibit host\u0027s allergic airway inflammation, which may be related to the upregulated Treg cells upon infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1122,
          "text": "These results suggest that both bisexual and male S. japonicum infections may modulate the development of allergic asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18654798"
        },
        {
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1069,
          "text": "We found that lung-stage S. japonicum infection significantly ameliorated OVA-induced AAI, whereas post-lung-stage infection did not.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34169075"
        },
        {
          "offsetInBeginSection": 1201,
          "offsetInEndSection": 1378,
          "text": "In a murine model of asthma, S. japonicum egg antigens decreased the expression of Th2 cytokines, relieved antigen-induced airway inflammation, and inhibited asthma development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17042799"
        },
        {
          "offsetInBeginSection": 667,
          "offsetInEndSection": 745,
          "text": "We found that S. japonicum infection downregulated airway hyperresponsiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28614408"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 655,
          "text": "However, in recent years, studies have found that Schistosoma infection or Schistosoma related products can improve or prevent some immune and inflammatory diseases, such as severe asthma, inflammatory bowel disease, diabetes and so on.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34358648"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "In areas where schistosomiasis is endemic, a negative correlation is observed between atopy and helminth infection, associated with a low prevalence of asthma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824533"
        }
      ],
      "body": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?",
      "type": "yesno",
      "id": "622f6ad13a8413c6530000aa",
      "ideal_answer": [
        "A peptide named as SJMHE1 from Schistosoma japonicum can suppress asthma in mice."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30580288"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 354,
          "text": "Genetic testing of hereditary cancer using comprehensive gene panels can identify patients with more than one pathogenic mutation in high and/or moderate-risk-associated cancer genes. This phenomenon is known as multilocus inherited neoplasia alleles syndrome (MINAS), which has been potentially linked to more severe clinical manifestations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30580288"
        }
      ],
      "body": "Describe Multilocus Inherited Neoplasia Allele Syndrome (MINAS)",
      "type": "summary",
      "id": "62059190c9dfcb9c09000034",
      "ideal_answer": [
        "Genetic testing of hereditary cancer using comprehensive gene panels can identify patients with more than one pathogenic mutation in high and/or moderate-risk-associated cancer genes. This phenomenon is known as multilocus inherited neoplasia alleles syndrome (MINAS), which has been potentially linked to more severe clinical manifestations."
      ]
    }
  ]
}